TWI581775B - Absorbent items - Google Patents
Absorbent items Download PDFInfo
- Publication number
- TWI581775B TWI581775B TW102111515A TW102111515A TWI581775B TW I581775 B TWI581775 B TW I581775B TW 102111515 A TW102111515 A TW 102111515A TW 102111515 A TW102111515 A TW 102111515A TW I581775 B TWI581775 B TW I581775B
- Authority
- TW
- Taiwan
- Prior art keywords
- chain hydrocarbon
- acid
- top sheet
- ester
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/47—Sanitary towels, incontinence pads or napkins
- A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
- A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
- A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
- A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
- A61F13/512—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Description
本發明係關於生理用衛生棉、衛生護墊、失禁墊、失禁護墊等之吸收性物品。 The present invention relates to absorbent articles for sanitary napkins, sanitary pads, incontinence pads, incontinence pads and the like.
在主體部分的頂部薄片添加護膚組成物的吸收性物品為習知技術(例如專利文獻1)。在該吸收性物品的頂部薄片使用經開孔的成形薄膜。又,在該吸收性物品設置使頂部薄片向寬方向延長而形成的翼部。 The absorbent article in which the skin care composition is added to the top sheet of the main body portion is a conventional technique (for example, Patent Document 1). An apertured formed film is used on the top sheet of the absorbent article. Further, in the absorbent article, a wing portion formed by extending the top sheet in the width direction is provided.
[專利文獻1]日本特表2003-510164號公報 [Patent Document 1] Japanese Patent Publication No. 2003-510164
為了使專利文獻1所記載的吸收性物品包裝化而將翼部折疊時,有賦予本體部之頂部薄片的護膚組成物通過折疊的翼部之頂部薄片的開孔部分浸透至翼部之情 形。該場合,因浸透的護膚組成物而翼部之頂部薄片與背部薄片間的接合變弱,吸收性物品長時間使用時,有頂部薄片從背部薄片剝離之情形。 In order to package the absorbent article described in Patent Document 1 and fold the wing portion, the skin care composition applied to the top sheet of the body portion is saturated with the opening portion of the top sheet of the folded wing portion to the wing portion. shape. In this case, the joint between the top sheet of the wing portion and the back sheet is weakened by the infiltrated skin care composition, and when the absorbent article is used for a long period of time, the top sheet is peeled off from the back sheet.
本發明以提供抑制因塗佈於本體部之頂部薄片的組成物浸透至翼部而構成翼部的薄片剝離的吸收性物品為目的。 The present invention has an object of providing an absorbent article which suppresses peeling of a sheet which constitutes a wing portion by a composition which is applied to a top sheet of a main body portion so as to penetrate into a wing portion.
本發明為了解決上述課題,採用以下的構成。 In order to solve the above problems, the present invention adopts the following configuration.
亦即本發明為具有長度方向及寬方向,包含具備肌膚側所設置的液透過性的頂部薄片、著衣側所設置的液不透過性的背部薄片及頂部薄片與背部薄片間所設置的液保留性的吸收體的本體部、與從本體部之兩側緣向寬方向延伸出的具備頂部薄片及背部薄片的一對翼部之吸收性物品,本體部之頂部薄片在肌膚側之面的至少接觸著用者的***口的***口接觸區域具備塗佈有特定組成物的組成物塗佈層,頂部薄片為樹脂薄膜,頂部薄片在至少***口接觸區域中具有開口部,翼部中不具有開口部,頂部薄片在翼部中具備突部。 In other words, the present invention has a longitudinal direction and a width direction, and includes a top sheet having liquid permeability provided on the skin side, a liquid impervious back sheet provided on the garment side, and a liquid provided between the top sheet and the back sheet. The main body of the retaining body and the absorbent article of the pair of wings having the top sheet and the back sheet extending from the both side edges of the body portion in the width direction, and the top sheet of the body portion on the skin side The excretory opening contact area contacting at least the user's excretory opening has a composition coating layer coated with a specific composition, the top sheet being a resin film, and the top sheet having an opening in at least the discharge port contact area, and not in the wing portion There is an opening, and the top sheet has a projection in the wing.
其他本發明為具有長度方向及寬方向,且包含具備肌膚側所設置的液透過性的頂部薄片、著衣側所設置的液不透過性的背部薄片、頂部薄片與背部薄片間所設置的液保留性的吸收體及頂部薄片的兩側所配置的一對側邊薄片的 本體部、與從本體部之兩側緣向寬方向延伸出的具備側邊薄片及背部薄片的一對翼部之吸收性物品,且頂部薄片在肌膚側之面的至少接觸著用者的***口的***口接觸區域具備塗佈有特定組成物的組成物塗佈層,側邊薄片為樹脂薄膜,側邊薄片在翼部中不具有開口部但具備突部。 Others of the present invention include a top sheet having a liquid permeability provided on the skin side, a liquid-impermeable back sheet provided on the garment side, and a liquid provided between the top sheet and the back sheet. Retaining absorbent body and a pair of side sheets disposed on both sides of the top sheet An absorbent article having a pair of wing portions including a side sheet and a back sheet extending from the both side edges of the main body portion in a width direction, and the top sheet on the skin side at least contacts the user's excretion The excretory opening contact region of the mouth is provided with a composition coating layer coated with a specific composition, and the side sheet is a resin film, and the side sheet does not have an opening in the wing portion but has a projection.
根據本發明,藉由塗佈於本體部之頂部薄片的組成物浸透至翼部,可抑制構成翼部的薄片剝離。 According to the invention, it is possible to suppress the peeling of the sheet constituting the wing portion by the composition of the top sheet applied to the main body portion soaking into the wing portion.
1‧‧‧吸收性物品 1‧‧‧Absorbables
2,2A‧‧‧頂部薄片 2,2A‧‧‧Top sheet
3‧‧‧背部薄片 3‧‧‧ Back sheet
4,4A‧‧‧吸收體 4,4A‧‧‧ absorber
6‧‧‧翼部 6‧‧‧ wing
7‧‧‧黏著部 7‧‧‧Adhesive
8‧‧‧壓縮溝 8‧‧‧Compression groove
9‧‧‧密封部 9‧‧‧ Sealing Department
10‧‧‧本體部 10‧‧‧ Body Department
18A‧‧‧側邊薄片 18A‧‧‧Side sheet
21‧‧‧第1山摺部 21‧‧‧1st Mountain Fold
22‧‧‧第2山摺部 22‧‧‧2nd mountain fold
23‧‧‧谷摺部 23‧‧‧ Valley Folding
24‧‧‧血液改質劑層 24‧‧‧ Blood modifier layer
25‧‧‧開口部 25‧‧‧ openings
26‧‧‧第1山摺部及谷摺部之側面 26‧‧‧1st side of the mountain fold and valley fold
100‧‧‧不織布製造裝置 100‧‧‧Nonwoven manufacturing equipment
120‧‧‧圖案滾筒 120‧‧‧pattern roller
130‧‧‧壓紋加工裝置 130‧‧‧embossing processing device
140‧‧‧背部薄片用輥 140‧‧‧Back roll for back sheet
150‧‧‧裁切器 150‧‧‧Cut
160‧‧‧改質劑塗佈噴霧器 160‧‧‧Modifier coating sprayer
210‧‧‧樹脂薄膜薄片的輥 210‧‧‧Roll of resin film sheet
212,214,216‧‧‧樹脂薄膜薄片 212,214,216‧‧‧Resin film sheet
220‧‧‧凹部形成輥 220‧‧‧ recess forming roller
230‧‧‧延伸齒輥 230‧‧‧Extended tooth roll
231‧‧‧上段輥 231‧‧‧Upper roll
232‧‧‧下段輥 232‧‧‧lower roller
233,235‧‧‧齒輪齒 233,235‧‧‧ gear teeth
234‧‧‧齒輪齒中途被切斷處 234‧‧‧ Gear teeth are cut in the middle
[圖1]圖1為本發明之吸收性物品的一實施形態的部分破斷平面圖。 Fig. 1 is a partially broken plan view showing an embodiment of an absorbent article of the present invention.
[圖2]圖2為圖1的A-A線斷面的概略斷面圖。 Fig. 2 is a schematic cross-sectional view showing a cross section taken along line A-A of Fig. 1;
[圖3]圖3為用以說明本發明之一實施形態的吸收性物品中本體部之頂部薄片中吸收體的寬方向的兩側面之外側區域及翼部之頂部薄片上形成的第1山摺部、第2山摺部及谷摺部之圖。 [Fig. 3] Fig. 3 is a view showing an outer side surface of the outer side in the width direction of the absorbent body and a first mountain formed on the top sheet of the wing portion in the top sheet of the main body portion of the absorbent article according to the embodiment of the present invention. Figure of the fold, the second mountain fold and the valley fold.
[圖4]圖4為用以說明本發明之一實施形態的吸收性物品中形成於***口接觸區域的第1山摺部、第2山摺部及谷摺部之圖。 [ Fig. 4] Fig. 4 is a view for explaining a first mountain fold portion, a second mountain fold portion, and a valley fold portion formed in the excretory opening contact region in the absorbent article according to the embodiment of the present invention.
[圖5]圖5為用以說明為了包裝而翼部被折疊的本發明之一實施形態的吸收性物品之圖。 Fig. 5 is a view for explaining an absorbent article according to an embodiment of the present invention in which a wing portion is folded for packaging.
[圖6]圖6為用以說明包含本發明之一實施形態的吸收性物品的包裝品的斜視圖。 Fig. 6 is a perspective view for explaining a package including an absorbent article according to an embodiment of the present invention.
[圖7]圖7為圖5之D-D線斷面之概略斷面圖。 Fig. 7 is a schematic cross-sectional view showing a cross section taken along line D-D of Fig. 5.
[圖8]圖8為用以說明本發明之一實施形態的吸收性物品的製造方法之圖。 Fig. 8 is a view for explaining a method of manufacturing an absorbent article according to an embodiment of the present invention.
[圖9]圖9為用以說明本發明之一實施形態的吸收性物品的製造所使用的凹部形成輥之圖。 [ Fig. 9] Fig. 9 is a view for explaining a concave portion forming roller used for the production of an absorbent article according to an embodiment of the present invention.
[圖10]圖10為用以說明頂部薄片用薄片中藉由凹部形成輥形成有凹部的區域之圖。 Fig. 10 is a view for explaining a region in which a concave portion is formed by a concave portion forming roller in a sheet for a top sheet.
[圖11]圖11為用以說明本發明之一實施形態的吸收性物品的製造所使用的延伸齒輥的上段輥之圖。 Fig. 11 is a view for explaining an upper roll of an extended tooth roll used for the production of an absorbent article according to an embodiment of the present invention.
[圖12]圖12為用以說明本發明之一實施形態的吸收性物品的製造所使用的延伸齒輥的下段輥之圖。 Fig. 12 is a view for explaining a lower roll of an extended tooth roll used for the production of an absorbent article according to an embodiment of the present invention.
[圖13]圖13為用以說明以延伸齒輥延伸的頂部薄片用薄片之圖。 Fig. 13 is a view for explaining a sheet for a top sheet extending with an extending tooth roll.
[圖14]圖14為本發明之吸收性物品的一實施形態的變形例的平面圖。 Fig. 14 is a plan view showing a modification of an embodiment of the absorbent article of the present invention.
[圖15]圖15為頂部薄片含有三C2L油脂肪酸甘油酯的生理用衛生棉中頂部薄片的肌膚接觸面之電子顯微鏡照片。 Fig. 15 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin of the top sheet containing the three C2L oil fatty acid glycerides.
[圖16]圖16為含有或不含血液改質劑的經血之顯微鏡照片。 Fig. 16 is a photomicrograph of menstrual blood with or without a blood modifying agent.
[圖17]圖17為用以說明表面張力之測定方法之圖。 Fig. 17 is a view for explaining a method of measuring surface tension.
以下,參考圖式,說明本發明,但本發明不被圖式所記載者限定。 Hereinafter, the present invention will be described with reference to the drawings, but the present invention is not limited by the description.
圖1為本發明之一實施形態的吸收性物品的部分破斷平面圖,圖2為圖1的A-A線斷面之概略斷面圖。吸收性物品1包含具備肌膚側(肌膚接觸側)所設置的液透過性的頂部薄片2、著衣側(非肌膚接觸側)所設置的液不透過性的背部薄片3及頂部薄片2與背部薄片3間所設置的液保留性的吸收體4的本體部10、與從本體部10之兩側緣向寬方向延伸出的具備頂部薄片2及背部薄片3的一對翼部6。符號61為翼部6之根部(本體部10與翼部6間的界線)。例如翼部6之長度方向兩側中,連結吸收性物品1的寬急遽變大的2個點之直線可視作翼部6之根部61。翼部6中著衣側之面之反對側之面係以頂部薄片2所構成。本體部10及翼部6之著衣側之面分別設置黏著部7。又,圖1中,吸收性物品1的寬方向為X方向、長度方向為Y方向。又,吸收性物品1之平面方向為XY方向。 Fig. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention, and Fig. 2 is a schematic cross-sectional view taken along line A-A of Fig. 1. The absorbent article 1 includes a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 and a top sheet 2 and a back provided on the garment side (non-skin contact side). The main body portion 10 of the liquid-retaining absorbent body 4 provided between the sheets 3 and the pair of wing portions 6 including the top sheet 2 and the back sheet 3 extending in the width direction from both side edges of the main body portion 10. Reference numeral 61 is the root of the wing portion 6 (the boundary between the body portion 10 and the wing portion 6). For example, in the longitudinal direction of both sides of the wing portion 6, a straight line connecting the two points of the wide and rapid increase of the absorbent article 1 can be regarded as the root portion 61 of the wing portion 6. The opposite side of the face of the dressing side of the wing portion 6 is constituted by the top sheet 2. Adhesive portions 7 are provided on the garment-side surfaces of the main body portion 10 and the wing portion 6, respectively. Moreover, in FIG. 1, the width direction of the absorbent article 1 is the X direction, and the longitudinal direction is the Y direction. Further, the plane direction of the absorbent article 1 is the XY direction.
本體部10之形狀為長方形、橢圓型、沙漏型等適合女性的身體及內褲形狀的形狀,則不特別限定。本體部10之外形中,長度方向的延伸尺寸,較佳為100~500mm,更佳為150~350mm。又,本體部10之外形中,寬方向的延伸尺寸,較佳為30~200mm,更佳為40~ 180mm。 The shape of the main body portion 10 is a shape suitable for a female body and a panty shape such as a rectangular shape, an elliptical shape, or an hourglass type, and is not particularly limited. In the outer shape of the main body portion 10, the extension in the longitudinal direction is preferably 100 to 500 mm, more preferably 150 to 350 mm. Further, in the outer shape of the main body portion 10, the extension in the width direction is preferably 30 to 200 mm, more preferably 40 to 180mm.
頂部薄片2,在本體部10,使自著用者排出的尿、經血等之體液移動至吸收體4。又,在本體部10,頂部薄片2的至少一部份具有液透過性,具有使體液透過用的多數的開口部。另一方面,在翼部6,頂部薄片2適於著用者折曲翼部6,同時與後述背部薄片3一起賦予翼部6即使裝設於內褲後亦不賦予著用者不適的適度的剛性。 The top sheet 2 moves the body fluid such as urine or menstrual blood discharged from the user to the absorber 4 in the main body portion 10. Further, in the main body portion 10, at least a portion of the top sheet 2 has liquid permeability, and has a plurality of openings for allowing body fluid to permeate. On the other hand, in the wing portion 6, the top sheet 2 is adapted to be used by the user to bend the wing portion 6, and the wing portion 6 is provided with the back sheet 3, which will be described later, even if it is attached to the undergarment, and does not give the user an appropriate degree of discomfort. rigidity.
頂部薄片2較佳為由樹脂薄膜製作。作為頂部薄片2使用的樹脂薄膜,可由烯烴與丙烯酸酯、乙酸乙烯酯等之其他單體的共聚合物、聚烯烴、聚酯、聚丙烯、聚乙烯、聚乙烯對苯二甲酸酯、聚醯胺、乙酸纖維素等來製作。由柔軟性高且對肌膚的刺激少觀點,作為頂部薄片2使用的樹脂薄膜,較佳為烯烴與其他單體的共聚合物、或聚烯烴。 The top sheet 2 is preferably made of a resin film. As the resin film used for the top sheet 2, a copolymer of an olefin and another monomer such as acrylate or vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, and poly Made from guanamine, cellulose acetate, etc. From the viewpoint of high flexibility and little irritation to the skin, the resin film used as the top sheet 2 is preferably a copolymer of an olefin and another monomer, or a polyolefin.
頂部薄片2的基重,較佳為1 g/m2以上、40 g/m2以下,更佳為10 g/m2以上、35 g/m2以下。又,構成頂部薄片2的樹脂薄膜的厚度,較佳為0.01mm以上、0.4mm以下,更佳為0.1mm以上、0.35mm以下。構成頂部薄片2的樹脂薄膜的厚度未達0.01mm之場合,有頂部薄片2的後述隱蔽性變得過小之場合,構成頂部薄片2的樹脂薄膜的厚度超過0.4mm之場合,有頂部薄片2的剛性變高,頂部薄片2對著用者的肌膚之刺激變得過強之情形。因頂部薄片2具有後述第1山摺部、第2山摺部及谷 摺部,故頂部薄片2的表觀上的厚度比構成頂部薄片2的樹脂薄膜的厚度大。頂部薄片2的表觀上的厚度,較佳為0.01mm以上、1mm以下,更佳為0.1mm以上、0.5mm以下。 The basis weight of the top sheet 2 is preferably 1 g/m 2 or more and 40 g/m 2 or less, more preferably 10 g/m 2 or more and 35 g/m 2 or less. Moreover, the thickness of the resin film constituting the top sheet 2 is preferably 0.01 mm or more and 0.4 mm or less, more preferably 0.1 mm or more and 0.35 mm or less. When the thickness of the resin film constituting the top sheet 2 is less than 0.01 mm, the concealability of the top sheet 2 described later becomes too small, and when the thickness of the resin film constituting the top sheet 2 exceeds 0.4 mm, the top sheet 2 is provided. The rigidity becomes high, and the stimulation of the top sheet 2 against the user's skin becomes too strong. Since the top sheet 2 has the first mountain fold portion, the second mountain fold portion, and the valley fold portion to be described later, the apparent thickness of the top sheet 2 is larger than the thickness of the resin film constituting the top sheet 2. The apparent thickness of the top sheet 2 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.1 mm or more and 0.5 mm or less.
頂部薄片2為了使吸收體4所吸收的體液從外部看不見,具有隱蔽性。頂部薄片2之隱蔽性係藉由在樹脂混合氧化鈦等之填料而產生。填料為氧化鈦之場合,氧化鈦的含有量,相對樹脂薄膜之重量,較佳為1%以上、50%以下,更佳為3%以上、15%以下。氧化鈦的含有量相對樹脂薄膜之重量,未達1%,則有隱蔽頂部薄片2中吸收體4所吸收的體液效果過小之情形。氧化鈦的含有量相對樹脂薄膜之重量,超過50%,則有含有氧化鈦的樹脂之薄片成形變得困難之情形。 The top sheet 2 has concealability in order to prevent the body fluid absorbed by the absorber 4 from being invisible from the outside. The concealability of the top sheet 2 is produced by mixing a filler such as titanium oxide in a resin. When the filler is titanium oxide, the content of the titanium oxide is preferably 1% or more and 50% or less, more preferably 3% or more and 15% or less, based on the weight of the resin film. When the content of the titanium oxide is less than 1% by weight of the resin film, the effect of the body fluid absorbed by the absorber 4 in the concealed top sheet 2 is too small. When the content of the titanium oxide exceeds 50% by weight based on the weight of the resin film, it may be difficult to form a sheet of a resin containing titanium oxide.
頂部薄片2具有在長度方向延伸存在且在寬方向交互排列的第1山摺部21及谷摺部、與在與第1山摺部21交叉方向延伸存在的第2山摺部22。本體部10之設置有吸收體4的區域12的頂部薄片2,進而形成有後述開口部。又,在設置有吸收體4的區域12中的***口接觸區域16,於頂部薄片2的表面,設置後述血液改質劑層。在此,***口接觸區域16係指以接觸著用者的體液之***口位置作為中心的長度方向之長度較佳為50~200mm、更佳為70~150mm,寬方向之長度較佳為10~80mm、更佳為20~50mm的吸收性物品1的區域。為了包裝吸收性物品1,一對翼部6之寬方向外側之緣62 互為相接之方式使一對翼部6向寬方向內側折疊,***口接觸區域16之大部分或全部藉由折疊的翼部6而被遮蔽(圖5及圖7作為參考)。 The top sheet 2 has a first mountain fold portion 21 and a valley fold portion that extend in the longitudinal direction and are alternately arranged in the width direction, and a second mountain fold portion 22 that extends in a direction intersecting the first mountain fold portion 21 . The top sheet 2 of the region 12 of the absorber 4 is provided in the main body portion 10, and an opening portion to be described later is formed. Further, in the excretory port contact region 16 in the region 12 in which the absorber 4 is provided, a blood modifying agent layer to be described later is provided on the surface of the top sheet 2. Here, the excretory opening contact region 16 means that the length in the longitudinal direction centering on the position of the excretory opening contacting the user's body fluid is preferably 50 to 200 mm, more preferably 70 to 150 mm, and the length in the width direction is preferably 10 An area of the absorbent article 1 of ~80 mm, more preferably 20 to 50 mm. In order to package the absorbent article 1, the outer edge 62 of the pair of wings 6 in the width direction The pair of wings 6 are folded inwardly in the widthwise direction, and most or all of the drain contact area 16 is shielded by the folded wings 6 (see Figs. 5 and 7 for reference).
參考圖3及圖4,詳細說明頂部薄片2所設置的第1山摺部21、第2山摺部22及谷摺部23。圖3為用以說明本體部10之頂部薄片2中吸收體4的寬方向的兩側面41的外側之區域14及翼部6之頂部薄片2上形成的(圖1作為參考)第1山摺部21、第2山摺部22及谷摺部23的圖。 The first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 provided in the top sheet 2 will be described in detail with reference to Figs. 3 and 4 . 3 is a view showing a region 14 on the outer side of the side faces 41 in the width direction of the absorbent body 4 of the main body portion 10 and a first mountain fold formed on the top sheet 2 of the wing portion 6 (FIG. 1 as a reference). A view of the portion 21, the second mountain fold portion 22, and the valley fold portion 23.
圖3所示般,吸收體4的寬方向的兩側面41的外側之區域14及翼部6中,頂部薄片2包含在長度方向(Y方向)延伸存在且於寬方向(X方向)交互排列的第1山摺部21及谷摺部23。第1山摺部21及谷摺部23的斷面之形狀為例如略U字形狀。在略U字形狀中,除U字形狀外,亦包含施加使角圓滑、直線變為曲線等之變形而成為U字形狀的形狀。例如在略U字形狀中,亦包含V字形狀、M字形狀、梯形及Ω形狀。 As shown in Fig. 3, in the region 14 and the wing portion 6 on the outer side of the both side faces 41 in the width direction of the absorbent body 4, the top sheet 2 is extended in the longitudinal direction (Y direction) and alternately arranged in the width direction (X direction). The first mountain fold portion 21 and the valley fold portion 23. The shape of the cross section of the first mountain fold portion 21 and the valley fold portion 23 is, for example, a substantially U-shape. In the U-shaped shape, in addition to the U-shape, a shape in which a corner is smoothly formed, a straight line is curved, or the like is applied to form a U-shape. For example, in a slightly U shape, a V shape, an M shape, a trapezoidal shape, and an Ω shape are also included.
第2山摺部22以在相對於長度方向(Y方向)延伸的第1山摺部21的交叉方向延伸為佳。例如第1山摺部21延伸的方向與第2山摺部22延伸的方向間所成角度,較佳為10°以上、170°以下。在相對第2山摺部22延伸方向的垂直方向,切斷第2山摺部22時的第2山摺部22的斷面之形狀為例如略U字形狀。又,雖可不設置第2山摺部22於頂部薄片2,但因為藉由形成第2山 摺部22而第1山摺部21變得不易崩散,以設置第2山摺部22於頂部薄片2為佳。 It is preferable that the second mountain fold portion 22 extends in the intersecting direction of the first mountain fold portion 21 that extends in the longitudinal direction (Y direction). For example, the angle between the direction in which the first mountain fold portion 21 extends and the direction in which the second mountain fold portion 22 extends is preferably 10° or more and 170° or less. The shape of the cross section of the second mountain fold portion 22 when the second mountain fold portion 22 is cut in the vertical direction with respect to the direction in which the second mountain fold portion 22 extends is, for example, a substantially U-shaped shape. Further, although the second mountain fold portion 22 may not be provided on the top sheet 2, since the second mountain is formed In the folded portion 22, the first mountain fold portion 21 is less likely to collapse, and it is preferable to provide the second mountain fold portion 22 to the top sheet 2.
寬方向中每1cm的第1山摺部21的數,較佳為3以上、更佳為5以上。寬方向中每1cm的第1山摺部21的數若在2以下,則有翼部6中谷摺部23的底接觸***口接觸區域16之後述血液改質劑層之情形。 The number of the first mountain fold portions 21 per 1 cm in the width direction is preferably 3 or more, and more preferably 5 or more. When the number of the first mountain fold portions 21 per 1 cm in the width direction is 2 or less, the bottom portion of the valley portion 23 in the wing portion 6 contacts the drain opening contact region 16 and the blood modifying agent layer will be described later.
第2山摺部22之長度方向(Y方向)的長度較佳為0.3mm以上、5mm以下、更佳為0.5mm以上、3mm以下。第2山摺部22之長度方向(Y方向)的長度比為0.3mm小時,有無法呈現使第1山摺部21不易崩散效果之情形。又,第2山摺部22之長度方向(Y方向)的長度比5mm大的場合,有翼部6中頂部薄片2與***口接觸區域16的後述血液改質劑層間的接觸面積不太變小之情形。 The length of the second mountain fold portion 22 in the longitudinal direction (Y direction) is preferably 0.3 mm or more and 5 mm or less, more preferably 0.5 mm or more and 3 mm or less. When the length ratio of the second mountain fold portion 22 in the longitudinal direction (Y direction) is 0.3 mm, there is a case where the first mountain fold portion 21 is not easily disintegrated. Further, when the length of the second mountain fold portion 22 in the longitudinal direction (Y direction) is larger than 5 mm, the contact area between the top sheet 2 and the excretion port contact region 16 in the wing portion 6 which is described later is not changed. Small situation.
翼部5中,頂部薄片2不含後述開口部。 In the wing portion 5, the top sheet 2 does not include an opening portion to be described later.
圖4為用以說明本發明之一實施形態的吸收性物品1的頂部薄片2中,在***口接觸區域16形成的第1山摺部21、第2山摺部22及谷摺部23的圖。圖4所示般,***口接觸區域16之頂部薄片2與本體部10之吸收體4的寬方向的兩側面41的外側之區域14及翼部5的頂部薄片2同樣地,包含第1山摺部21、第2山摺部22及谷摺部23。但,***口接觸區域16之頂部薄片2的第1山摺部21、第2山摺部22及谷摺部23,於肌膚側之表面再含有後述血液改質劑層24。又,***口接觸區域 16之頂部薄片2的第1山摺部21及谷摺部23於側面26進而含有開口部25。 4 is a view showing the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 formed in the drain opening contact region 16 in the top sheet 2 of the absorbent article 1 according to the embodiment of the present invention. Figure. As shown in Fig. 4, the top sheet 2 of the excretory opening contact region 16 is the same as the outer sheet region 14 of the side surface 41 of the absorbent body 4 in the width direction of the main body portion 10 and the top sheet 2 of the wing portion 5, and includes the first mountain. The folded portion 21, the second mountain fold portion 22, and the valley fold portion 23. However, the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 of the top sheet 2 of the excretory opening contact region 16 further include a blood modifying agent layer 24 to be described later on the skin side surface. Also, the drain contact area The first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 of 16 further include an opening portion 25 on the side surface 26.
***口接觸區域16之頂部薄片2的第1山摺部21及谷摺部23,於其兩側面26,具有於長度方向(Y方向)排列的複數的開口部25。***口接觸區域16之頂部薄片2所排出的著用者的體液,通過開口部25移動至吸收體4。又,藉由谷摺部23所形成的寬方向(X方向)的略U字形狀,頂部薄片2所排出的著用者的體液快速向谷摺部23之底部聚集。開口部25因設置於第1山摺部21及谷摺部23的側面26,所以向谷摺部23之底部流動的體液在到達谷摺部23之底前,通過第1山摺部21及谷摺部23之側面26所設置的開口部25,流至吸收體4。又,滯留谷摺部23的體液亦通過第1山摺部21及谷摺部23之側面26所設置的開口部25,流至吸收體4。因此,藉由第1山摺部21及谷摺部23的側面26所設置的開口部25,著用者的體液快速被吸收體4吸收。又,藉由第1山摺部21及谷摺部23的側面26所設置的開口部25,可使頂部薄片2殘留的體液之量減少。 The first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 of the drain opening contact region 16 have a plurality of openings 25 arranged in the longitudinal direction (Y direction) on both side faces 26 thereof. The body fluid of the user discharged from the top sheet 2 of the excretory opening contact region 16 is moved to the absorber 4 through the opening portion 25. Further, the body liquid of the user discharged from the top sheet 2 is rapidly gathered toward the bottom of the valley portion 23 by the substantially U-shape in the width direction (X direction) formed by the valley fold portion 23. Since the opening portion 25 is provided on the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23, the body fluid flowing to the bottom of the valley fold portion 23 passes through the first mountain fold portion 21 and the valley before reaching the bottom of the valley fold portion 23. The opening 25 provided in the side surface 26 of the folded portion 23 flows to the absorber 4. Further, the body fluid of the retention valley portion 23 also flows through the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23 to the absorber 4. Therefore, the body fluid of the user is quickly absorbed by the absorber 4 by the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23. Moreover, the amount of the body fluid remaining in the top sheet 2 can be reduced by the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23.
在***口接觸區域16之頂部薄片2的肌膚側之表面塗佈血液改質劑。於頂部薄片2的肌膚接觸側之表面設置血液改質劑層24。血液改質劑層24,以設置於一對翼部6之寬方向外側之緣62互為相接之方式使一對翼部6向寬方向內側折疊,藉由折疊的翼部6而被遮蔽範圍內為佳。藉此,包裝吸收性物品1時,藉由折疊的翼部6 血液改質劑層24被保護。藉由該血液改質劑層24,可抑制著用者的體液、尤其黏度高的體液(例如黏度高的經血)殘留於於頂部薄片2的表面。又,血液改質劑層24若設置於頂部薄片2的至少***口接觸區域16,則***口接觸區域16以外的區域可設置或不設置血液改質劑層24。該血液改質劑層24在之後詳細說明。 A blood modifying agent is applied to the surface of the skin side of the top sheet 2 of the excretory opening contact area 16. A blood modifying agent layer 24 is provided on the surface of the top sheet 2 on the skin contact side. The blood modifying agent layer 24 is folded so that the pair of wing portions 6 are folded inward in the width direction so that the edges 62 on the outer side in the width direction of the pair of wing portions 6 are in contact with each other, and are shielded by the folded wing portions 6. The range is better. Thereby, when the absorbent article 1 is packaged, the folded wing portion 6 is The blood modifying agent layer 24 is protected. By the blood modifying agent layer 24, it is possible to suppress the body fluid of the user, in particular, a body fluid having a high viscosity (for example, menstrual blood having a high viscosity) remaining on the surface of the top sheet 2. Further, if the blood modifying agent layer 24 is provided in at least the drain opening contact region 16 of the top sheet 2, the blood modifying agent layer 24 may or may not be provided in a region other than the drain opening contact region 16. This blood modifying agent layer 24 will be described in detail later.
因為藉由***口接觸區域16之頂部薄片2所設置的第1山摺部21而著用者的肌膚與頂部薄片2間的接觸面積變小,頂部薄片2的膚觸變得良好。又,可在***口接觸區域16之頂部薄片2僅形成第1山摺部及谷摺部,而不形成第2山摺部。該場合亦因為著用者的肌膚與頂部薄片2間的接觸面積變小,頂部薄片2的膚觸變得良好。但,藉由設置第2山摺部,第1山摺部變得不易崩散,故以在***口接觸區域16之頂部薄片2設置第1山摺部、第2山摺部及谷摺部為佳。 The contact area between the skin of the user and the top sheet 2 is reduced by the first mountain fold portion 21 provided in the top sheet 2 of the excretory opening contact region 16, and the skin contact of the top sheet 2 is good. Further, only the first mountain fold portion and the valley fold portion can be formed on the top sheet 2 of the drain opening contact region 16, and the second mountain fold portion can be formed. Also in this case, the contact area between the user's skin and the top sheet 2 is small, and the skin contact of the top sheet 2 is good. However, since the first mountain fold portion is not easily broken by the provision of the second mountain fold portion, the first mountain fold portion, the second mountain fold portion, and the valley fold portion are provided in the top sheet 2 of the drain opening contact region 16. It is better.
本體部10之設置有吸收體4的區域12中***口接觸區域16以外的區域亦與***口接觸區域16同樣地,於頂部薄片2設置有側面形成有開口部的第1山摺部21及谷摺部23以及第2山摺部22。但,本體部10之設置有吸收體4的區域12中,在***口接觸區域16以外的區域,於頂部薄片2的表面未設置血液改質劑層24。 Similarly to the drain port contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided, the first sheet portion 21 in which the opening portion is formed on the side surface is provided in the top sheet 2, and The valley fold portion 23 and the second mountain fold portion 22. However, in the region 12 of the main body portion 10 in which the absorbent body 4 is provided, in the region other than the excretory opening contact region 16, the blood modifying agent layer 24 is not provided on the surface of the top sheet 2.
又,本體部10之設置有吸收體4的區域12中,可於***口接觸區域16以外的區域的一部份或全部的頂部薄片2的表面,設置血液改質劑層24。藉此,可 抑制***口接觸區域16所流出的著用者的體液殘留於設置有吸收體4的區域12中***口接觸區域16以外的區域。 Further, in the region 12 of the main body portion 10 in which the absorbent body 4 is provided, the blood modifying agent layer 24 may be provided on the surface of a part or all of the top sheet 2 of the region other than the excretory opening contact region 16. By this, The bodily fluid of the user who has flowed out of the excretory opening contact region 16 is left in a region other than the excretory opening contact region 16 in the region 12 in which the absorber 4 is provided.
因為藉由本體部10之設置有吸收體4的區域12中***口接觸區域16以外的區域所設置的第1山摺部21而著用者的肌膚與頂部薄片2間的接觸面積變小,所以頂部薄片2的膚觸變得良好。又,在本體部10之設置有吸收體4的區域12中***口接觸區域16以外的區域的頂部薄片2可僅形成第1山摺部及谷摺部23而不形成第2山摺部。該場合亦因著用者的肌膚與頂部薄片2間的接觸面積變小,所以頂部薄片2的膚觸變得良好。但,因為藉由設置第2山摺部,第1山摺部變得不易崩散,故以本體部10之設置有吸收體4的區域12中***口接觸區域16以外的區域的頂部薄片2設置第1山摺部、第2山摺部及谷摺部23為佳。 The contact area between the skin of the user and the top sheet 2 is reduced by the first mountain fold portion 21 provided in the region other than the excretory opening contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided. Therefore, the skin contact of the top sheet 2 becomes good. Further, in the region 12 of the main body portion 10 in which the absorber 4 is provided, the top sheet 2 of the region other than the drain contact region 16 can form only the first mountain fold portion and the valley fold portion 23 without forming the second mountain fold portion. Also in this case, since the contact area between the user's skin and the top sheet 2 is small, the skin contact of the top sheet 2 is good. However, since the first mountain fold portion is not easily broken by the provision of the second mountain fold portion, the top sheet 2 of the region other than the drain port contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided It is preferable to provide the first mountain fold portion, the second mountain fold portion, and the valley fold portion 23.
頂部薄片2的至少***口接觸區域16若設置開口部25,設置有吸收體4的區域12中***口接觸區域16以外的區域的一部份或全部可不設置開口部25。因為在頂部薄片2的表面,自著用者排出的體液若不由***口接觸區域16流出,則有***口接觸區域16以外的區域不需形成開口部25之情形。又,本體部10之頂部薄片2之吸收體4的寬方向的兩緣41的外側之區域14的一部份可設置開口部25。藉此,因為在頂部薄片2的表面,本體部10之設置有吸收體4的區域12所流出的體液通過吸收 體4的寬方向的兩緣41的外側之區域14所設置的開口部被吸收體4吸收,可更抑制自著用者排出的體液從吸收性物品1的緣向外滲漏。 At least the discharge port contact region 16 of the top sheet 2 is provided with the opening portion 25, and a part or all of the region other than the drain port contact region 16 in the region 12 in which the absorber 4 is provided may not be provided with the opening portion 25. Since the body fluid discharged from the user does not flow out of the drain port contact region 16 on the surface of the top sheet 2, the region other than the drain port contact region 16 does not need to form the opening portion 25. Further, an opening portion 25 may be provided in a portion of the outer region 14 of the outer edge 41 of the absorbent body 4 of the top sheet 2 of the main body portion 10. Thereby, since the body liquid flowing out from the region 12 of the main body portion 10 where the absorber 4 is provided is absorbed on the surface of the top sheet 2 The opening provided in the region 14 on the outer side of the both edges 41 in the width direction of the body 4 is absorbed by the absorber 4, and it is possible to further prevent the body fluid discharged from the user from leaking outward from the edge of the absorbent article 1.
如圖1及圖2所示之背部薄片3,防止吸收體4所吸收的體液滲漏至外部。在背部薄片3,使用不透過體液的材料。例如背部薄片3,使用疏水性之不織布、聚乙烯及聚丙烯等之不透水性的塑膠薄膜或不織布與不透水性塑膠薄膜之層合薄片等。又,亦可使用將耐水性高的熔噴不織布以強度強的紡黏不織布挾持的紡黏‧熔噴‧紡黏(SMS)纖維不織布作為背部薄片3。藉由使用體液不通過的具有通氣性之材料作為背部薄片3,可降低著用時的悶熱。背部薄片3使用熱熔接著劑等之接著劑,與頂部薄片2的谷摺部23之底接合。 The back sheet 3 shown in Figs. 1 and 2 prevents the body fluid absorbed by the absorbent body 4 from leaking to the outside. In the back sheet 3, a material that does not penetrate body fluid is used. For example, the back sheet 3 is made of a hydrophobic non-woven fabric, a water-impermeable plastic film such as polyethylene or polypropylene, or a laminated sheet of a non-woven fabric and a water-impermeable plastic film. Further, as the back sheet 3, a spunbond, melt-blown/spun-spun (SMS) fiber nonwoven fabric in which a melt-resistant nonwoven fabric having high water resistance is held by a spunbonded nonwoven fabric having high strength can be used. By using the air permeable material that does not pass the body fluid as the back sheet 3, the sultry heat during use can be reduced. The back sheet 3 is bonded to the bottom of the valley portion 23 of the top sheet 2 by using an adhesive such as a hot melt adhesive.
吸收體4吸收體液而保留。吸收體4為體積大、型狀不易崩散、化學刺激性少者為佳。例如作為吸收體4,使用起毛狀紙漿或者氣流成網不織布與高吸收性聚合物(SAP)所構成的複合吸收體。該複合吸收體亦可以織物等之液透過性的材料被覆。 The absorbent body 4 absorbs body fluid and remains. The absorber 4 is preferably bulky, has a shape that is not easily broken, and is less chemically irritating. For example, as the absorber 4, a composite absorbent composed of a fluffy pulp or an airlaid nonwoven fabric and a superabsorbent polymer (SAP) is used. The composite absorbent body can also be coated with a liquid permeable material such as a woven fabric.
又,取代上述複合吸收體的起毛狀紙漿,亦可使用例如化學紙漿、纖維素纖維、人造絲及乙酸酯等之人工纖維素纖維。上述複合吸收體中紙漿等之吸收性纖維的基重,較佳為100 g/m2以上、800 g/m2以下,上述複合吸收體中高吸收性聚合物的質量比,以吸收性纖維作為100%,較佳為10%以上、65%以下。被覆上述複合吸收體 的織物等液透過性的材料的基重,較佳為12 g/m2以上、30 g/m2以下。 Further, artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon, and acetate may be used instead of the raised pulp of the composite absorbent. The basis weight of the absorbent fibers such as pulp in the composite absorbent body is preferably 100 g/m 2 or more and 800 g/m 2 or less, and the mass ratio of the superabsorbent polymer in the composite absorbent body is based on absorbent fibers. 100%, preferably 10% or more and 65% or less. The basis weight of the liquid-permeable material such as the woven fabric covering the composite absorbent body is preferably 12 g/m 2 or more and 30 g/m 2 or less.
作為上述複合吸收體的氣流成網不織布,可使用例如使紙漿與合成纖維熱熔著的不織布或使紙漿與合成纖維以黏著劑固著的不織布。 As the air-laid nonwoven fabric of the composite absorbent body, for example, a nonwoven fabric which thermally fuses pulp and synthetic fibers or a nonwoven fabric which fixes pulp and synthetic fibers with an adhesive can be used.
上述複合吸收體的高吸收性聚合物,具有水溶性高分子適度交聯的三維網狀構造。該吸收性聚合物相對吸收水前的吸收性聚合物的體積,吸收30~60倍的水。但,該吸收性聚合物本質上為水不溶性。又,該吸收性聚合物即使施加些許壓力,一旦經吸收的水亦不離水。作為該吸收性聚合物,使用例如澱粉系、丙烯酸系或胺基酸系的粒子狀或纖維狀的聚合物。 The superabsorbent polymer of the above composite absorbent has a three-dimensional network structure in which a water-soluble polymer is moderately crosslinked. The absorbent polymer absorbs 30 to 60 times of water relative to the volume of the absorbent polymer before absorption of water. However, the absorbent polymer is essentially water insoluble. Further, even if the absorbent polymer is applied with a slight pressure, the absorbed water does not leave the water. As the absorbent polymer, for example, a starch-based or acrylic-based particulate or fibrous polymer is used.
吸收體4的形狀及構造雖可因應必要而改變,但吸收體4的全吸收量,必需對應作為吸收性物品1的設計***量及所期望之用途。又,吸收體4的尺寸或吸收能力等因應用途而改變。 The shape and structure of the absorber 4 may be changed as necessary, but the total absorption amount of the absorber 4 must correspond to the design insertion amount of the absorbent article 1 and the intended use. Further, the size of the absorbent body 4, the absorbing ability, and the like are changed depending on the application.
使用熱熔接著劑,吸收體4與頂部薄片2接著。藉此可抑制頂部薄片2由吸收體4剝離。 The absorbent body 4 is followed by the top sheet 2 using a hot melt adhesive. Thereby, the top sheet 2 can be suppressed from being peeled off by the absorber 4.
如上述般,翼部6係為了使吸收性物品1安定固定於內褲而設置於吸收性物品1。藉由使翼部6在內褲外面側折曲後,透過黏著部7黏貼於內褲之褲檔區域,可使吸收性物品1安定固定於內褲。又,本體部10亦設置有黏著部7,防止內褲之褲檔區域中本體部10滑動。 As described above, the wing portion 6 is provided in the absorbent article 1 in order to securely fix the absorbent article 1 to the undergarment. After the wing portion 6 is bent on the outer side of the undergarment, the adhesive portion 7 is adhered to the pant region of the underwear through the adhesive portion 7, so that the absorbent article 1 can be stably fixed to the undergarment. Further, the body portion 10 is also provided with an adhesive portion 7 for preventing the body portion 10 from sliding in the pants region of the undergarment.
圖2所示之吸收性物品1的黏著部7將吸收 性物品1固定於內褲之褲檔區域。形成黏著部7的黏著劑,宜使用例如苯乙烯系聚合物、黏著賦予劑、可塑劑的任一為主成分者。作為前述苯乙烯系聚合物,可舉例如苯乙烯-乙烯-丁烯-苯乙烯嵌段共聚合物、苯乙烯-丁烯聚合物、苯乙烯-丁烯-苯乙烯嵌段共聚合物、苯乙烯-異丁烯-苯乙烯共聚合物等,但亦可僅使用此等之中的1種、或二種以上的聚合物混合物。其中,由熱安定性良好觀點,苯乙烯-乙烯-丁烯-苯乙烯嵌段共聚合物為佳。 The adhesive portion 7 of the absorbent article 1 shown in Fig. 2 will absorb The sexual item 1 is fixed to the pant area of the underwear. As the adhesive for forming the adhesive portion 7, it is preferable to use, for example, any of a styrene-based polymer, an adhesion-imparting agent, and a plasticizer. Examples of the styrene-based polymer include a styrene-ethylene-butylene-styrene block copolymer, a styrene-butene polymer, a styrene-butene-styrene block copolymer, and benzene. An ethylene-isobutylene-styrene copolymer or the like may be used, but one or a mixture of two or more of these may be used. Among them, a styrene-ethylene-butylene-styrene block copolymer is preferred from the viewpoint of good thermal stability.
又,作為前述黏著賦予劑及可塑劑,宜使用常溫下為固體者,在黏著賦予劑,可舉例如C5系石油樹脂、C9系石油樹脂、二環戊二烯系石油樹脂、松香系石油樹脂、聚萜烯樹脂、萜烯酚樹脂等,在前述可塑劑,可舉例如磷酸三甲苯酯、苯二甲酸二丁酯、苯二甲酸二辛基酯等之單體可塑劑外,可舉如乙烯基聚合物或聚酯般聚合物可塑劑。 In addition, as the adhesion-imparting agent and the plasticizer, it is preferable to use a solid at room temperature, and examples of the adhesion-imparting agent include a C5-based petroleum resin, a C9-based petroleum resin, a dicyclopentadiene-based petroleum resin, and a rosin-based petroleum resin. The polydecene resin, the terpene phenol resin, and the like, and the plasticizer may, for example, be a monomer plasticizer such as tricresyl phosphate, dibutyl phthalate or dioctyl phthalate. Vinyl polymer or polyester polymer plasticizer.
圖1及圖2所示般,頂部薄片2及吸收體4具有藉由壓紋加工而在厚度方向壓縮所形成的從頂部薄片2至吸收體4的內部的壓縮溝8。壓縮溝8抑制吸收性物品1之中心部分(接觸著用者的體液之***口的部分)所排出的體液向寬方向(X方向)擴散。又,藉此可抑制頂部薄片2從吸收體4剝離。壓縮溝8包圍吸收性物品1之中心部分,且具有連續的略環狀之形狀。又,包圍吸收性物品1之中央部的壓縮溝8可部分被中斷。亦即壓縮溝8亦可具有非連續的略環狀之形狀。 As shown in Fig. 1 and Fig. 2, the top sheet 2 and the absorbent body 4 have compression grooves 8 formed from the top sheet 2 to the inside of the absorbent body 4 which are formed by compression in the thickness direction by embossing. The compression groove 8 suppresses the body fluid discharged from the central portion of the absorbent article 1 (portion that contacts the user's body fluid discharge port) from diffusing in the width direction (X direction). Moreover, the peeling of the top sheet 2 from the absorber 4 can be suppressed. The compression groove 8 surrounds the central portion of the absorbent article 1 and has a continuous substantially annular shape. Further, the compression groove 8 surrounding the central portion of the absorbent article 1 can be partially interrupted. That is, the compression groove 8 may also have a discontinuous, slightly annular shape.
又,藉由以熱壓紋加工使頂部薄片2與背部薄片3壓縮接合,在本體部10之長度方向兩側之緣部分及翼部6之寬方向外側之緣部分形成密封部9。藉此,頂部薄片2變得可不由背部薄片3剝離。 Moreover, the top sheet 2 and the back sheet 3 are compression-bonded by heat embossing, and the sealing portion 9 is formed at the edge portion on both sides in the longitudinal direction of the main body portion 10 and the outer edge portion of the wing portion 6 in the width direction. Thereby, the top sheet 2 becomes undetachable by the back sheet 3.
接著,詳細說明上述血液改質劑層24。血液改質劑層24的血液改質劑,具有約0.00~約0.60之IOB、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g之水溶解度。 Next, the above-described blood modifying agent layer 24 will be described in detail. The blood modifying agent of the blood modifying agent layer 24 has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C.
IOB(Inorganic Organic Balance)為表示親水性及親油性的平衡之指標,在本說明書,係指以小田氏們之下式:IOB=無機性值/有機性值所算出之值。 IOB (Inorganic Organic Balance) is an index indicating the balance between hydrophilicity and lipophilicity, and in the present specification, the value calculated by the formula: IOB = inorganic value / organic value.
上述無機性值與有機性值係基於藤田穆「有機化合物的預測與有機概念圖」化學區域Vol.11,No.10(1957)p.719-725)記載的有機概念圖。藤田氏之主要基的有機性值及無機性值如下述表1。 The inorganic value and the organic value are based on the organic concept map described in Fujita Mu's "Predicting and Organic Concepts of Organic Compounds" Chemical Region Vol. 11, No. 10 (1957) p. 719-725). The organic value and inorganic value of the main base of Fujita are as shown in Table 1 below.
例如碳數14的十四烷酸與碳數12的十二基醇之酯之場合,因有機性值成為520(CH2,20×26個)、無機性值成為60(-COOR,60×1個),故IOB=0.12。 For example, in the case of an ester of tetradecanoic acid having a carbon number of 14 and a dodecyl alcohol having a carbon number of 12, the organic value is 520 (CH 2 , 20 × 26), and the inorganic value is 60 (-COOR, 60 ×). 1), so IOB=0.12.
上述血液改質劑中,IOB為約0.00~約0.60,以約0.00~約0.50為佳、約0.00~約0.40更佳、而約0~約0.30又更佳。因認為IOB愈低,有機性高,與血球之親和性變高。 The above blood modifying agent has an IOB of from about 0.00 to about 0.60, preferably from about 0.00 to about 0.50, more preferably from about 0.00 to about 0.40, and still more preferably from about 0 to about 0.30. Because of the lower IOB, the organicity is high, and the affinity with blood cells is high.
本說明書中,「熔點」係指示差掃瞄熱量分析計中,以昇溫速度10℃/分鐘測定場合的由固狀變為液狀時之吸熱峰的峰頂溫度。上述熔點可使用例如島津製作所公司製之DSC-60型DSC測定裝置進行測定。 In the present specification, the "melting point" indicates the peak top temperature of the endothermic peak when the solid state is changed to a liquid state at a temperature increase rate of 10 ° C / min in the differential scanning calorimeter. The melting point can be measured by, for example, a DSC-60 DSC measuring apparatus manufactured by Shimadzu Corporation.
上述血液改質劑,若具有約45℃以下之熔點,則在室溫可為液體或固體,亦即熔點可在約25℃以上或未達約25℃,而例如可具有約-5℃、約-20℃等之熔點。 上述血液改質劑之熔點在約45℃以下的根據如後述。 The above blood modifying agent, if it has a melting point of about 45 ° C or less, may be liquid or solid at room temperature, that is, the melting point may be above about 25 ° C or less than about 25 ° C, and for example, may have about -5 ° C, The melting point of about -20 ° C. The melting point of the above blood modifying agent is about 45 ° C or less, as will be described later.
上述血液改質劑,其熔點雖無下限,但以其蒸氣壓低者為佳。上述血液改質劑的蒸氣壓在1氣壓及25℃約0.00~約0.01Pa為佳、約0.000~約0.001Pa更佳、而約0.0000~約0.0001Pa又更佳。本發明之吸收性物品若考量與人體接觸使用,上述蒸氣壓在1氣壓及40℃以約0.00~約0.01Pa為佳、約0.000~約0.001Pa更佳、而約0.0000~約0.0001Pa又更佳。因蒸氣壓高,則有產生保存中氣化、血液改質劑的量減少、著用時之臭氣等之問題之情形。 Although the above-mentioned blood modifying agent has no lower limit of the melting point, it is preferred that the blood pressure is low. The vapor pressure of the above blood modifying agent is preferably from about 0.00 to about 0.01 Pa at 1 atm and 25 ° C, more preferably from about 0.000 to about 0.001 Pa, and still more preferably from about 0.0000 to about 0.0001 Pa. When the absorbent article of the present invention is used in contact with a human body, the vapor pressure is preferably from about 0.00 to about 0.01 Pa at 1 atm and 40 ° C, more preferably from about 0.000 to about 0.001 Pa, and more preferably from about 0.0000 to about 0.0001 Pa. good. When the vapor pressure is high, there is a problem that gasification during storage, a decrease in the amount of the blood modifying agent, and an odor during use are caused.
又,血液改質劑之熔點可因應氣候、著用時間之長度等,適當選擇使用。認為例如平均氣溫在約10℃以下的地區,藉由採用具有約10℃以下之熔點的血液改質劑,經血被***後,即使在因周圍溫度而被冷卻的場合,血液改質劑可安定地將血液改質。又,在吸收性物品長時間使用的場合,血液改質劑之熔點以45℃以下的範圍的高者為佳。因不易受到汗、著用時之摩擦等之影響,即使在長時間著用的場合,血液改質劑不易移動。 Further, the melting point of the blood modifying agent can be appropriately selected depending on the weather, the length of time of use, and the like. It is considered that, for example, in a region where the average temperature is below about 10 ° C, the blood modifying agent can be stabilized even after being cooled by the ambient temperature by using a blood modifying agent having a melting point of about 10 ° C or lower. The blood is modified. Further, when the absorbent article is used for a long period of time, the melting point of the blood modifying agent is preferably in the range of 45 ° C or lower. The blood modifying agent does not easily move even when it is used for a long period of time due to the influence of the sweat and the friction during use.
0.00~0.05g的水溶解度為25℃中,在100g的脫離子水中加入0.05g的試料,靜置24小時,24小時後,因應必要輕輕攪拌,接著,可藉由以目視評估試料溶解與否來測定。又,在本說明書,關於水溶解度,「溶解」包含試料完全溶解於去離子水,形成均勻混合物之情形、與試料完全乳化之情形。又,「完全」係指去離子水 中無試料之團塊。 0.00 to 0.05 g of water solubility is 25 ° C, 0.05 g of sample is added to 100 g of deionized water, and allowed to stand for 24 hours. After 24 hours, gently stir as necessary, and then visually evaluate the dissolution of the sample by No to determine. Further, in the present specification, the "solubility" of the water solubility includes a case where the sample is completely dissolved in deionized water to form a homogeneous mixture, and the sample is completely emulsified. Also, "completely" means deionized water There is no briquette in the sample.
在該技術區域,以改變血液的表面張力等、使血液迅速吸收為目的,將頂部薄片的表面以界面活性劑塗佈。但,因界面活性劑一般水溶解度高,經塗佈界面活性劑的頂部薄片與血液中親水性成分(血漿等)親和性佳,甚至有使血液殘留在頂部薄片作用之傾向。認為上述血液改質劑因水溶解度低,與習知界面活性劑不同,不使血液殘留於頂部薄片,可迅速移動至吸收體。 In this technical area, the surface of the top sheet is coated with a surfactant for the purpose of changing the surface tension of blood or the like to rapidly absorb blood. However, since the surfactant generally has high water solubility, the top sheet of the coated surfactant has a good affinity with hydrophilic components (plasma, etc.) in the blood, and even has a tendency to leave blood in the top sheet. The blood modifying agent is considered to have a low water solubility, and unlike the conventional surfactant, the blood is not allowed to remain on the top sheet, and can be quickly moved to the absorber.
本說明書中,25℃中,對100g之水的溶解度有單稱「水溶解度」之情形。 In the present specification, the solubility in 100 g of water at 25 ° C is referred to as "water solubility".
本說明書中,「重量平均分子量」為包含多分散系的化合物(例如逐次聚合所製造的化合物、複數的脂肪酸與複數的脂肪族1元醇所生成的酯)與單一化合物(例如1種脂肪酸與1種脂肪族1元醇所生成的酯)之概念,係指Ni個之分子量Mi之分子(i=1、或i=1,2‧‧‧)所構成的系中,以下式:Mw=ΣNiMi 2/ΣNiMi所求得的Mw。 In the present specification, the "weight average molecular weight" is a compound containing a polydisperse system (for example, a compound produced by sequential polymerization, an ester of a plurality of fatty acids and a plurality of aliphatic monohydric alcohols), and a single compound (for example, a fatty acid and 1 the concept of aliphatic monohydric alcohol esters generated), the number N i refers to molecules with a molecular weight of M i (i = 1, or i = 1,2‧‧‧) system consisting of the following formula: M w = Σ N i M i 2 / Σ N i M i obtained M w .
本說明書中,重量平均分子量意指經膠體滲透層析(GPC)求得的聚苯乙烯換算之值。GPC之測定條件,可舉例如以下。 In the present specification, the weight average molecular weight means a value in terms of polystyrene obtained by colloidal permeation chromatography (GPC). The measurement conditions of GPC are as follows, for example.
機種:(股)Hitachi High-Technologies製 高速液體層析儀Lachrom Elite Model: (share) Hitachi High-Technologies high-speed liquid chromatography Lachrom Elite
管柱:昭和電工(股)製SHODEX KF-801、KF-803 及KF-804 Pipe column: SHODEX KF-801, KF-803 made by Showa Denko Electric Co., Ltd. And KF-804
溶離液:THF Dissolution: THF
流量:1.0mL/分 Flow rate: 1.0mL/min
注入量:100μL Injection volume: 100μL
檢測:RI(示差折射計) Detection: RI (differential refractometer)
又,本說明書的實施例記載的重量平均分子量為以上述條件測定者。 Moreover, the weight average molecular weight described in the examples of the present specification is measured under the above conditions.
上述血液改質劑,較佳為由下述(i)~(iii)、(i)烴、(ii)具有(ii-1)烴部分、與(ii-2)上述烴部分之C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中選出的一個或複數的相同或相異的基的化合物、及(iii)具有(iii-1)烴部分、與(iii-2)上述烴部分之C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中選出的一個或複數的相同或相異的基、與(iii-3)取代上述烴部分之氫原子的羧基(-COOH)及羥基(-OH)所成群中選出的一個或複數的相同或相異的基的化合物、以及彼等之任意組合所成群中選出。 The above blood modifying agent is preferably a CC single bond of the following (i) to (iii), (i) hydrocarbon, (ii) having (ii-1) a hydrocarbon moiety, and (ii-2) the above hydrocarbon moiety. An intervening compound of one or more of the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) having a hydrocarbon moiety of (iii-1), (iii-2) one or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between the CC single bonds of the above hydrocarbon moiety, and (iii- 3) a compound in which one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) of a hydrogen atom of the above hydrocarbon moiety, and any combination thereof are grouped Elected.
本說明書中,「烴」為碳與氫所構成的化合物,鏈狀烴,可舉例如石蠟系烴(亦稱不含雙鍵及三鍵的烷烴)、烯烴系烴(亦稱含1個雙鍵之烯類)、乙炔系烴(亦稱含1個三鍵之炔)、及含2個以上雙鍵及三鍵所成之群所選出的鍵結之烴、以及環狀烴,可舉例如芳香族 烴、脂環式烴。 In the present specification, the "hydrocarbon" is a compound composed of carbon and hydrogen, and the chain hydrocarbon may, for example, be a paraffinic hydrocarbon (also referred to as an alkane having no double bond or triple bond) or an olefin hydrocarbon (also referred to as a double). Alkene of a bond, an acetylene hydrocarbon (also referred to as an alkyne having one triple bond), and a bonded hydrocarbon selected from the group consisting of two or more double bonds and triple bonds, and a cyclic hydrocarbon can be exemplified. Aromatic Hydrocarbon, alicyclic hydrocarbon.
上述烴,以鏈狀烴及脂環式烴為佳、鏈狀烴更佳、石蠟系烴、烯烴系烴、及含2個以上雙鍵之烴(不含三鍵)又更佳、而石蠟系烴最佳。上述鏈狀烴中,包含直鏈狀烴及分枝鏈狀烴。 The above hydrocarbons are preferably a chain hydrocarbon or an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffinic hydrocarbon, an olefin hydrocarbon, and a hydrocarbon having two or more double bonds (excluding a triple bond) and more preferably a paraffin wax. The hydrocarbons are the best. The chain hydrocarbons include linear hydrocarbons and branched chain hydrocarbons.
上述(ii)及(iii)之化合物中,在***2個以上氧基(-O-)的場合,各氧基(-O-)不相鄰。因此,上述(ii)及(iii)之化合物中,不包含氧基連續的化合物(所謂的過氧化物)。 In the compounds of the above (ii) and (iii), when two or more oxy groups (-O-) are inserted, each of the oxy groups (-O-) is not adjacent. Therefore, among the compounds of the above (ii) and (iii), a compound having a continuous oxy group (so-called peroxide) is not contained.
又,在上述(iii)的化合物,相較於烴部分的至少1個氫原子被羧基(-COOH)所取代的化合物,以烴部分的至少1個氫原子被羥基(-OH)所取代的化合物者為佳。如表1所示般,因羧基與經血中之金屬等鍵結,而無機性值由150大幅上升至400以上,故具有羧基的血液改質劑,使用時IOB之值超過約0.60,有與血球親和性降低之可能性。 Further, in the compound of the above (iii), the compound substituted with at least one hydrogen atom of the hydrocarbon moiety by the carboxyl group (-COOH) is substituted with at least one hydrogen atom of the hydrocarbon moiety by a hydroxyl group (-OH). Compounds are preferred. As shown in Table 1, since the carboxyl group is bonded to the metal in the menstrual blood, and the inorganic value is greatly increased from 150 to 400 or more, the blood modifying agent having a carboxyl group has a value of IOB of more than about 0.60 when used. The possibility of a decrease in blood cell affinity.
上述血液改質劑,更佳為由下述(i’)~(iii’)、(i’)烴、(ii’)具有(ii’-1)烴部分、與(ii’-2)上述烴部分的C-C單鍵間***的由羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結之化合物、及 (iii’)具有(iii’-1)烴部分、與(iii’-2)上述烴部分的C-C單鍵間***的由羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結、與(iii’-3)取代上述烴部分的氫原子的由羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物、以及彼等之任意組合所成群中所選出。 More preferably, the above blood modifying agent is composed of (i') to (iii'), (i') hydrocarbon, (ii') having (ii'-1) hydrocarbon moiety, and (ii'-2) The CC bond between the hydrocarbon moiety is interposed by a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-). One or more of the same or different bonded compounds selected, and (iii') a carbonyl bond (-CO-) or an ester bond (-COO-) having a (iii'-1) hydrocarbon moiety and a CC single bond interposed between (iii'-2) and the above hydrocarbon moiety One or a plurality of identical or different bonds selected from the group consisting of carbonate linkages (-OCOO-) and ether linkages (-O-), and (iii'-3) hydrogen substituted for the above hydrocarbon moiety The atom is selected from the group consisting of one or more of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH), and any combination thereof.
上述(ii’)及(iii’)之化合物中,在***2個以上的相同或相異的鍵結之場合,亦即,在***2個以上選自羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)及醚鍵(-O-)的相同或相異的鍵結之場合,各鍵結不相鄰,在各鍵結間至少有1個碳原子。 In the above compounds (ii') and (iii'), when two or more identical or different linkages are inserted, that is, two or more carbonyl linkages (-CO-) and esters are inserted. Where the bond (-COO-), carbonate bond (-OCOO-), and ether bond (-O-) are the same or different bonds, the bonds are not adjacent, and there is at least a bond between the bonds. 1 carbon atom.
上述血液改質劑,又更佳可為烴部分中,每10個碳原子,具有羰基鍵結(-CO-)約1.8個以下、酯鍵結(-COO-)2個以下、碳酸酯鍵結(-OCOO-)約1.5個以下、醚鍵(-O-)約6個以下、羧基(-COOH)約0.8個以下、及/或羥基(-OH)約1.2個以下之化合物。 More preferably, the above-mentioned blood modifying agent may have a carbonyl bond (-CO-) of about 1.8 or less, an ester bond (-COO-) of 2 or less, and a carbonate bond per 10 carbon atoms in the hydrocarbon moiety. The compound (-OCOO-) is about 1.5 or less, the ether bond (-O-) is about 6 or less, the carboxyl group (-COOH) is about 0.8 or less, and/or the hydroxyl group (-OH) is about 1.2 or less.
本發明之血液改質劑,又更佳為由下述(A)~(F)、(A)(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物之酯、 (B)(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之醚、(C)(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之酯、(D)具有鏈狀烴部分、與上述鏈狀烴部分的C-C單鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結之化合物、(E)聚氧化C2~C6烷二醇、或其烷基酯或者烷基醚、及(F)鏈狀烴、以及彼等之任意組合所成群中所選出。 More preferably, the blood modifying agent of the present invention has a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety described below by (A) to (F) and (A) (A1). And (A) a compound having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (B) (B1) having a chain hydrocarbon moiety and a hydrogen replacing the above chain hydrocarbon moiety; a compound having 2 to 4 hydroxyl groups of an atom and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety; (C) (C1) containing a chain hydrocarbon moiety and a substitution a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having 2 to 4 carboxyl groups of a hydrogen atom of the above-mentioned chain hydrocarbon moiety and (C2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety An ester of a hydroxyl group compound, (D) having a chain hydrocarbon moiety, an ether bond (-O-), a carbonyl bond (-CO-), an ester bond interposed between a CC single bond of the above chain hydrocarbon moiety ( -COO-), and a compound selected from the group consisting of carbonate linkages (-OCOO-), (E) polyoxy C 2 -C 6 alkanediol, or an alkyl ester or alkyl group thereof Ether, and (F) chain hydrocarbons, and In any combination of the selected groups.
以下、詳細說明(A)~(F)之血液改質劑。 Hereinafter, the blood modifying agents of (A) to (F) will be described in detail.
(A)(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部 分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物之酯(以下、有亦稱「化合物(A)」之場合)在具有上述之IOB、熔點及水溶解度下,羥基可不全被酯化。 (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety An ester of a compound which is substituted with one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter, also referred to as "compound (A)") may have a hydroxyl group which is not fully formed by having the above-mentioned IOB, melting point and water solubility. Esterification.
(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物(以下、有亦稱「化合物(A1)」之場合),可舉例如鏈狀烴四醇,例如烷烴四醇,例如季戊四醇、鏈狀烴三醇,例如烷烴三醇,例如甘油、及鏈狀烴二醇,例如烷烴二醇,例如二醇。 (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety (hereinafter also referred to as "compound (A1)"), for example, a chain hydrocarbon tetraol For example, alkanol tetraols such as pentaerythritol, chain hydrocarbon triols such as alkane triols such as glycerol, and chain hydrocarbon diols such as alkane diols such as diols.
(A2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物(以下、有亦稱「化合物(A2)」之情形),可舉例如烴上的1個氫原子以1個羧基(-COOH)所取代的化合物,例如脂肪酸。 (A2) A compound having a chain hydrocarbon moiety and one carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (A2)"), for example, one hydrogen atom on a hydrocarbon A compound substituted with one carboxy group (-COOH), such as a fatty acid.
化合物(A),可舉例如(a1)鏈狀烴四醇與至少1個脂肪酸之酯、(a2)鏈狀烴三醇與至少1個脂肪酸之酯、及(a3)鏈狀烴二醇與至少1個脂肪酸之酯。 The compound (A) may, for example, be an ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid, (a 2 ) a chain hydrocarbon triol with at least one fatty acid ester, and (a 3 ) a chain hydrocarbon. An ester of a diol with at least one fatty acid.
上述鏈狀烴四醇與至少1個脂肪酸之酯,可舉例如下式(1):
構成上述季戊四醇與脂肪酸之酯的脂肪酸(R1COOH、R2COOH,R3COOH,及R4COOH),若季戊四醇與脂肪酸之酯滿足上述IOB、熔點及水溶解度的要件,則不特別限制。例如飽和脂肪酸,例如C2~C30之飽和脂肪酸,例如乙酸(C2)、(C2表示碳數,相當R1C、R2C,R3C或R4C之碳數,以下相同)、丙烷酸(C3)、丁烷酸(C4)及其異構物,例如2-甲基丙烷酸(C4)、戊 烷酸(C5)及其異構物,例如2-甲基丁烷酸(C5)、2,2-二甲基丙烷酸(C5)、己烷酸(C6)、庚烷酸(C7)、辛烷酸(C8)及其異構物,例如2-乙基己烷酸(C8)、壬烷酸(C9)、癸烷酸(C10)、十二烷酸(C12)、十四烷酸(C14)、十六烷酸(C16)、十七烷酸(C17)、十八烷酸(C18)、二十烷酸(C20)、二十二烷酸(C22)、二十四烷酸(C24)、二十六烷酸(C26)、二十八烷酸(C28)、三十烷酸(C30)等、以及此等之異構物(除上述者外)。 The fatty acid (R 1 COOH, R 2 COOH, R 3 COOH, and R 4 COOH) constituting the ester of pentaerythritol and a fatty acid is not particularly limited as long as the ester of pentaerythritol and a fatty acid satisfies the above requirements of IOB, melting point, and water solubility. For example, a saturated fatty acid such as a C 2 - C 30 saturated fatty acid such as acetic acid (C 2 ) , (C 2 represents a carbon number, and a carbon number equivalent to R 1 C, R 2 C, R 3 C or R 4 C, the same below ), propane acid (C 3 ), butanoic acid (C 4 ) and isomers thereof, such as 2-methylpropanic acid (C 4 ), pentanoic acid (C 5 ) and isomers thereof, for example 2- Methyl butanoic acid (C 5 ), 2,2-dimethylpropane acid (C 5 ), hexane acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ) and the like a structure such as 2-ethylhexane acid (C 8 ), decanoic acid (C 9 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), myristic acid (C 14 ), Hexadecanic acid (C 16 ), heptadecanoic acid (C 17 ), octadecanoic acid (C 18 ), eicosanoic acid (C 20 ), behenic acid (C 22 ), tetracosane Acid (C 24 ), dihexadecanoic acid (C 26 ), octadecanoic acid (C 28 ), tridecanoic acid (C 30 ), and the like, and the isomers thereof (other than the above).
上述脂肪酸可為不飽和脂肪酸。上述不飽和脂肪酸,可舉例如C3~C20之不飽和脂肪酸,例如單不飽和脂肪酸,例如巴豆酸(C4)、十四碳烯酸(C14)、十六碳烯酸(C16)、油酸(C18)、反式十八碳烯酸(C18)、十八碳烯酸(C18)、二十碳烯酸(C20)、二十烯酸(C20)等,二不飽和脂肪酸,例如亞油酸(C18)、二十碳二烯酸(C20)等,三不飽和脂肪酸,例如亞麻油酸,例如α-亞麻油酸(C18)及γ-亞麻油酸(C18)、松子油酸(C18)、桐油酸,例如α-桐油酸(C18)及β-桐油酸(C18)、米德酸(C20)、二同-γ-亞麻油酸(C20)、二十碳三烯酸(C20)等,四不飽和脂肪酸,例如硬脂四烯酸(C20)、花生烯四酸(C20)、二十碳四烯酸(C20)等,五不飽和脂肪酸,例如波西爾番他安酸(bosseopentaenoic acid)(C18)、二十碳五烯酸(C20)等、以及此等之部分氫加成物。 The above fatty acid may be an unsaturated fatty acid. The above unsaturated fatty acid may, for example, be a C 3 - C 20 unsaturated fatty acid such as a monounsaturated fatty acid such as crotonic acid (C 4 ), tetradecenoic acid (C 14 ) or hexadecenoic acid (C 16). ), oleic acid (C 18 ), trans-octadecenoic acid (C 18 ), octadecenoic acid (C 18 ), eicosenoic acid (C 20 ), eicosenoic acid (C 20 ), etc. , diunsaturated fatty acids, such as linoleic acid (C 18 ), eicosadienoic acid (C 20 ), etc., triunsaturated fatty acids, such as linoleic acid, such as α-linolenic acid (C 18 ) and γ- Linoleic acid (C 18 ), pine nut oleic acid (C 18 ), tung oil, such as α-tricoleic acid (C 18 ) and β-tungonic acid (C 18 ), metic acid (C 20 ), di-γ-γ - linoleic acid (C 20 ), eicosatrienoic acid (C 20 ), etc., tetraunsaturated fatty acids, such as stearic acid (C 20 ), arachidonic acid (C 20 ), twenty carbon four Acetate (C 20 ), etc., penta-unsaturated fatty acids, such as bosseopentaenoic acid (C 18 ), eicosapentaenoic acid (C 20 ), etc., and some of these hydrogen additions Things.
作為上述季戊四醇與脂肪酸之酯,若考量因氧化等而變性的可能性,以來自飽和脂肪酸的季戊四醇與脂肪酸之酯,亦即,季戊四醇與飽和脂肪酸之酯為佳。又,作為上述季戊四醇與脂肪酸之酯,為了使IOB變小、且更為疏水性,以二酯、三酯或四酯為佳、三酯或四酯更佳、而四酯再佳。 As the ester of the pentaerythritol and the fatty acid, it is preferable to use an ester of pentaerythritol derived from a saturated fatty acid and a fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, in consideration of the possibility of denaturation by oxidation or the like. Further, as the ester of pentaerythritol and a fatty acid, in order to make IOB smaller and more hydrophobic, a diester, a triester or a tetraester is preferred, a triester or a tetraester is more preferable, and a tetraester is more preferable.
在上述季戊四醇與脂肪酸之四酯,構成季戊四醇與脂肪酸之四酯的脂肪酸之碳數合計,亦即,上述式(1)中,R1C、R2C、R3C及R4C部分的碳數合計為15之場合,IOB成為0.60。因此,在上述季戊四醇與脂肪酸之四酯,在上述碳數合計為約15以上的場合,IOB滿足約0.00~約0.60之要件。在上述季戊四醇與脂肪酸之四酯,可舉例如季戊四醇與己烷酸(C6)、庚烷酸(C7)、辛烷酸(C8),例如2-乙基己烷酸(C8)、壬烷酸(C9)、癸烷酸(C10)及/或十二烷酸(C12)之四酯。 In the above tetrakis pentaerythritol and a fatty acid tetraester, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and the fatty acid, that is, the R 1 C, R 2 C, R 3 C and R 4 C portions in the above formula (1) When the total carbon number is 15, the IOB becomes 0.60. Therefore, in the case where the above-mentioned pentaerythritol and the fatty acid tetraester have a total carbon number of about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Examples of the above tetraester of pentaerythritol and a fatty acid include pentaerythritol and hexane acid (C 6 ), heptanoic acid (C 7 ), and octanoic acid (C 8 ), for example, 2-ethylhexane acid (C 8 ). , nonanoic acid (C 9), capric acid (C 10) and / or lauric acid (C 12) of the tetraester.
在上述季戊四醇與脂肪酸之三酯,構成季戊四醇與脂肪酸之三酯之脂肪酸的碳數合計,亦即,上述式(2)中,R1C、R2C及R3C部分的碳數合計為19之場合,IOB成為0.58。因此,在上述季戊四醇與脂肪酸之三酯,脂肪酸的碳數合計為約19以上的場合,IOB滿足約0.00~約0.60之要件。 In the above-mentioned formula (2), the total number of carbon atoms of the R 1 C, R 2 C and R 3 C moieties is the total number of carbon atoms of the fatty acid triester of the pentaerythritol and the fatty acid. In the case of 19, the IOB became 0.58. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid triester and fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
在上述季戊四醇與脂肪酸之二酯,構成季戊四醇與脂肪酸之二酯之脂肪酸的碳數合計,亦即,上述式(3)中,R1C及R2C部分的碳數合計為22的場合,IOB 成為0.59。因此,在上述季戊四醇與脂肪酸之二酯,脂肪酸的碳數合計為約22以上之場合,IOB滿足約0.00~約0.60之要件。 In the above formula (3), the carbon number of the R 1 C and R 2 C moieties is 22 in total, in the case where the diester of the pentaerythritol and the fatty acid is a total of the carbon number of the fatty acid of the diester of the pentaerythritol and the fatty acid. IOB became 0.59. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid diester and fatty acid is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述季戊四醇與脂肪酸之單酯,構成季戊四醇與脂肪酸之單酯之脂肪酸的碳數,亦即,上述式(4)中,R1C部分的碳數為25之場合,IOB成為0.60。因此,在上述季戊四醇與脂肪酸之單酯,脂肪酸的碳數為約25以上之場合,IOB滿足約0.00~約0.60之要件。又,在上述計算,不考慮雙鍵、三鍵、iso分枝、及tert分枝的影響。 In the monoester of pentaerythritol and a fatty acid, the carbon number of the fatty acid constituting the monoester of pentaerythritol and a fatty acid, that is, in the above formula (4), when the carbon number of the R 1 C moiety is 25, the IOB is 0.60. Therefore, in the case where the above-mentioned pentaerythritol and a monoester of a fatty acid have a carbon number of about 25 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Also, in the above calculation, the effects of double bonds, triple bonds, iso branches, and tert branches are not considered.
上述季戊四醇與脂肪酸之酯的市售品,可舉例如UNISTAR H-408BRS、H-2408BRS-22(混合品)等(以上、日油股份公司製)。 The commercially available product of the ester of the pentaerythritol and the fatty acid may, for example, be UNISTAR H-408BRS or H-2408BRS-22 (mixed product) (above, manufactured by Nippon Oil Co., Ltd.).
上述鏈狀烴三醇與至少1個脂肪酸之酯,可舉例如下式(5):
作為構成上述甘油與脂肪酸之酯的脂肪酸(R6COOH、R6COOH及R7COOH),甘油與脂肪酸之酯為滿足上述IOB、熔點及水溶解度要件者,即不特別限制,例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中所列舉的脂肪酸,亦即,可舉例如飽和脂肪酸及不飽和脂肪酸,若考量因氧化等而變性的可能性,以來自飽和脂肪酸的甘油與脂肪酸之酯,亦即,甘油與飽和脂肪酸之酯為佳。 The fatty acid (R 6 COOH, R 6 COOH, and R 7 COOH) constituting the ester of the glycerin and the fatty acid, and the ester of the glycerin and the fatty acid are not particularly limited as long as the above-mentioned IOB, melting point, and water solubility are satisfied, for example, "(a 1 ) The fatty acid exemplified in the ester of a chain hydrocarbon tetraol and at least one fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, for example, may be denatured by oxidation or the like, and may be derived from a saturated fatty acid. An ester of glycerin with a fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferred.
又,上述甘油與脂肪酸的酯方面,為了使IOB變小、且更為疏水性,以二酯或三酯為佳、接著三酯更佳。 Further, in order to make the IOB smaller and more hydrophobic, the ester of the glycerin and the fatty acid is preferably a diester or a triester, and more preferably a triester.
上述甘油與脂肪酸之三酯,亦稱三甘油酯,例如甘油與辛烷酸(C8)之三酯、甘油與癸烷酸(C10) 之三酯、甘油與十二烷酸(C12)之三酯、及甘油與2種或3種之脂肪酸之三酯、以及此等之混合物。 The above triglyceride of glycerol and fatty acid, also known as triglyceride, such as triester of glycerol and octanoic acid (C 8 ), triester of glycerol and decanoic acid (C 10 ), glycerol and dodecanoic acid (C 12 a triester, and a triester of glycerin with two or three fatty acids, and mixtures thereof.
上述甘油與2種以上的脂肪酸之三酯,可舉例如甘油與辛烷酸(C8)及癸烷酸(C10)之三酯、甘油與辛烷酸(C8)、癸烷酸(C10)及十二烷酸(C12)之三酯、甘油與辛烷酸(C8)、癸烷酸(C10)、十二烷酸(C12)、十四烷酸(C14)、十六烷酸(C16)及十八烷酸(C18)之三酯等。 Examples of the glycerin and the triester of two or more kinds of fatty acids include triglycerides of glycerol and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin and octanoic acid (C 8 ), and decanoic acid ( C 10 ) and the triester of dodecanoic acid (C 12 ), glycerol and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), myristic acid (C 14 ), a triester of palmitic acid (C 16 ) and octadecanoic acid (C 18 ).
上述甘油與脂肪酸之三酯方面,為了使熔點在約45℃以下,構成甘油與脂肪酸之三酯的脂肪酸的碳數合計,亦即,式(5)中,R5C、R6C及R7C部分的碳數合計以約40以下為佳。 In the above-mentioned glycerin and fatty acid triester, in order to make the melting point be lower than about 45 ° C, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, in the formula (5), R 5 C, R 6 C and R The total carbon number of the 7 C portion is preferably about 40 or less.
又,在上述甘油與脂肪酸之三酯,構成甘油與脂肪酸之三酯的脂肪酸的碳數合計,亦即,式(5)中,R5C、R6C及R7C部分的碳數合計為12的場合,IOB成為0.60。因此,在上述甘油與脂肪酸之三酯,脂肪酸的碳數合計在約12以上之場合,IOB滿足約0.00~約0.60之要件。上述甘油與脂肪酸之三酯為所謂的脂肪,因為係可構成人體的成分,在安全性的觀點為佳。 Further, in the above-mentioned triglyceride of glycerin and fatty acid, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, the total carbon number of the R 5 C, R 6 C and R 7 C portions in the formula (5) In the case of 12, the IOB becomes 0.60. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid triester and the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. The above-mentioned triglyceride of glycerin and fatty acid is a so-called fat, and it is a component of a human body, and it is preferable from a viewpoint of safety.
上述甘油與脂肪酸之三酯之市售品,可舉例如三椰子油脂肪酸甘油酯、NA36、Panasate800、Panasate800B及Panasate810S、以及三C2L油脂肪酸甘油酯及三CL油脂肪酸甘油酯(以上、日油股份公司製)等。 The commercially available product of the above-mentioned glycerin and fatty acid triester may, for example, be tricocohol fatty acid glyceride, NA36, Panaseate 800, Panasete 800B, and Panaseate 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, Nippon Oil Co., Ltd.) Company system) and so on.
上述甘油與脂肪酸之二酯亦稱二甘油酯,例如甘油與癸烷酸(C10)之二酯、甘油與十二烷酸(C12)之二酯、甘油與十六烷酸(C16)之二酯、及甘油與2種之脂肪酸之二酯、以及此等之混合物。 The above diglycerides of glycerol and fatty acid are also called diglycerides, such as diesters of glycerol and decanoic acid (C 10 ), diesters of glycerol and dodecanoic acid (C 12 ), glycerol and palmitic acid (C 16 a diester, and a diester of glycerin and two fatty acids, and mixtures thereof.
在上述甘油與脂肪酸之二酯,構成甘油與脂肪酸之二酯的脂肪酸的碳數合計,亦即,式(6)中,R5C及R6C部分的碳數合計為16之場合,IOB成為0.58。因此,在上述甘油與脂肪酸之二酯,脂肪酸的碳數合計為約16以上之場合,IOB滿足約0.00~約0.60之要件。 In the case where the glycerin and the fatty acid diester are combined with the carbon number of the fatty acid constituting the diester of the glycerin and the fatty acid, that is, in the formula (6), when the total carbon number of the R 5 C and R 6 C moieties is 16, IOB Become 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid diester and the fatty acid is about 16 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
上述甘油與脂肪酸之單酯,亦稱單甘油酯,例如甘油之二十烷酸(C20)單酯、甘油之二十二烷酸(C22)單酯等。在上述甘油與脂肪酸之單酯,構成甘油與脂肪酸之單酯的脂肪酸的碳數,亦即,式(7)中,R5C部分的碳數為19之場合,IOB成為0.59。因此,在上述甘油與脂肪酸之單酯,脂肪酸的碳數為約19以上的場合,IOB滿足約0.00~約0.60之要件。 The monoester of the above glycerin and fatty acid is also called a monoglyceride, for example, a monoalcoholic acid (C 20 ) monoester of glycerin, a behenic acid (C 22 ) monoester of glycerin or the like. In the case where the monoester of glycerin and a fatty acid constitutes a carbon number of a fatty acid which constitutes a monoester of glycerin and a fatty acid, that is, in the formula (7), when the carbon number of the R 5 C moiety is 19, IOB is 0.59. Therefore, in the case where the carbon number of the glycerin and the fatty acid monoester and the fatty acid is about 19 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
上述鏈狀烴二醇與至少1個脂肪酸之酯,可舉例如C2~C6之鏈狀烴二醇,例如C2~C6之二醇,例如乙二醇、丙二醇、丁二醇、戊二醇或己二醇與脂肪酸之單酯或二酯。 The ester of the chain hydrocarbon diol and at least one fatty acid may, for example, be a C 2 -C 6 chain hydrocarbon diol, for example, a C 2 -C 6 diol such as ethylene glycol, propylene glycol or butylene glycol. a monoester or diester of pentanediol or hexanediol with a fatty acid.
具體上,上述鏈狀烴二醇與至少1個脂肪酸之酯,可舉例如下式(8): R8COOCkH2kOCOR9 (8)(式中,k為2~6之整數,而R8及R9各自為鏈狀烴)之C2~C6二醇與脂肪酸之二酯、及下式(9):R8COOCkH2kOH (9)(式中,k為2~6之整數,而R8為鏈狀烴)之C2~C6二醇與脂肪酸之單酯。 Specifically, the ester of the above chain hydrocarbon diol and at least one fatty acid can be exemplified by the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (wherein k is an integer of 2 to 6, and R 8 and R 9 are each a chain hydrocarbon; a diester of a C 2 -C 6 diol and a fatty acid, and a formula (9): R 8 COOC k H 2k OH (9) (wherein k is 2 to 6) An integer of the formula, and R 8 is a chain hydrocarbon) of a C 2 -C 6 diol and a monoester of a fatty acid.
上述C2~C6二醇與脂肪酸之酯中,欲酯化脂肪酸(式(8)及式(9)中,相當R8COOH及R9COOH)方面,C2~C6二醇與脂肪酸之酯為滿足上述IOB、熔點及水溶解度要件者,即不特別限制,例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中列舉的脂肪酸,亦即飽和脂肪酸及不飽和脂肪酸,若考量因氧化等變性之可能性,以飽和脂肪酸較佳。 Among the above-mentioned esters of C 2 -C 6 diols and fatty acids, it is desired to esterify fatty acids (in the formulas (8) and (9), which are equivalent to R 8 COOH and R 9 COOH), C 2 -C 6 diols and fatty acids. The ester is not particularly limited as long as it satisfies the above requirements for IOB, melting point and water solubility, for example, the fatty acid listed in "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, saturated fatty acid and unsaturated For fatty acids, it is preferred to use saturated fatty acids in consideration of the possibility of denaturation by oxidation or the like.
在式(8)所示之丁二醇(k=4)與脂肪酸之二酯,R8C及R9C部分的碳數合計為6之場合,IOB成為0.60。因此,在式(8)所示之丁二醇(k=4)與脂肪酸之二酯,上述碳數合計為約6以上的場合,IOB滿足約0.00~約0.60之要件。又,在式(9)所示之乙二醇(k=2)與脂肪酸之單酯,R8C部分的碳數為12的場合,IOB成為0.57。因此,在式(9)所示之乙二醇(k=2)與脂肪酸之單酯,脂肪酸的碳數在約12以上之場合,IOB滿足約0.00~約0.60之要件。 When the total number of carbon atoms of the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid and the R 8 C and R 9 C moieties is 6, the IOB becomes 0.60. Therefore, in the case where the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid have a total carbon number of about 6 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Further, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the R 8 C moiety is 12, the IOB is 0.57. Therefore, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
上述C2~C6二醇與脂肪酸之酯方面,若考量因氧化等而變性的可能性,以來自飽和脂肪酸的C2~C6 二醇與脂肪酸之酯,亦即C2~C6二醇與飽和脂肪酸之酯為佳。 In the case of the above-mentioned ester of a C 2 -C 6 diol and a fatty acid, considering the possibility of denaturation by oxidation or the like, an ester of a C 2 -C 6 diol derived from a saturated fatty acid and a fatty acid, that is, a C 2 -C 6 II Esters of alcohols and saturated fatty acids are preferred.
又,上述C2~C6二醇與脂肪酸之酯方面,為了使IOB變小、且更為疏水性,以來自大碳數的二醇的醇與脂肪酸之酯,例如來自丁二醇、戊二醇或己二醇的醇與脂肪酸之酯為佳。 Further, in order to make the IOB smaller and more hydrophobic, the ester of the C 2 -C 6 diol and the fatty acid is an ester of an alcohol and a fatty acid derived from a diol of a large carbon number, for example, from butanediol or pentane. Esters of alcohols and fatty acids of diol or hexanediol are preferred.
進而,上述C2~C6二醇與脂肪酸之酯方面,為了使IOB變小、且更為疏水性,以二酯為佳。上述C2~C6二醇與脂肪酸之酯的市售品,可舉例如科母波魯BL、科母波魯BS(以上、日油股份公司製)等。 Further, in terms of the ester of the C 2 -C 6 diol and the fatty acid, in order to make the IOB smaller and more hydrophobic, a diester is preferred. The commercially available product of the above-mentioned ester of a C 2 -C 6 diol and a fatty acid may, for example, be a Cobopol BL or a Cotomboru BS (above, manufactured by Nippon Oil Co., Ltd.).
(B)(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之醚(以下、有亦稱「化合物(B)」之情形)在具有上述之IOB、熔點及水溶解度下,羥基可不全被醚化。 (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) 1 having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ether of a hydroxy group compound (hereinafter also referred to as "compound (B)") may have an ether group which is not completely etherified by having the above-mentioned IOB, melting point and water solubility.
(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物方面,可舉例如「化合物(A)」中作為化合物(A1)所列舉者,例如季戊四醇、甘油、及二醇。 (B1) The compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, for example, "the compound (A)", as a compound (A1), for example, pentaerythritol, Glycerin, and diol.
(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原 子的1個羥基的化合物(以下、有亦稱「化合物(B2)」之情形),可舉例如烴之1個氫原子被1個羥基(-OH)所取代的化合物,例如脂肪族1元醇,例如飽和脂肪族1元醇及不飽和脂肪族1元醇。 (B2) a hydrogen atom having a chain hydrocarbon portion and a portion replacing the above chain hydrocarbon portion A compound having one hydroxyl group (hereinafter also referred to as "compound (B2)") may, for example, be a compound in which one hydrogen atom of a hydrocarbon is substituted with one hydroxyl group (-OH), for example, an aliphatic one. Alcohols such as saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols.
上述飽和脂肪族1元醇,可舉例如C1~C20之飽和脂肪族1元醇,例如甲基醇(C1)(C1表示碳數,以下相同)、乙基醇(C2)、丙基醇(C3)及其異構物,例如異丙基醇(C3)、丁基醇(C4)及其異構物,例如sec-丁基醇(C4)及tert-丁基醇(C4)、戊基醇(C5)、己基醇(C6)、庚基醇(C7)、辛基醇(C8)及其異構物,例如2-乙基己基醇(C8)、壬基醇(C9)、癸基醇(C10)、十二醇(C12)、十四基醇(C14)、十六基醇(C16)、十七基醇(C17)、十八基醇(C18)、及二十烷基醇(C20)、以及此等之未列舉的異構物。 The saturated aliphatic monohydric alcohol may, for example, be a C 1 to C 20 saturated aliphatic monohydric alcohol such as methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), and ethyl alcohol (C 2 ) , propyl alcohol (C 3 ) and isomers thereof, such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and isomers thereof, such as sec-butyl alcohol (C 4 ) and tert- Butanol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl Alcohol (C 8 ), mercapto alcohol (C 9 ), mercapto alcohol (C 10 ), dodecyl alcohol (C 12 ), tetradecyl alcohol (C 14 ), hexadecanol (C 16 ), seventeen alcohol (C 17), octadecyl alcohol (C 18), and eicosyl alcohol (C 20), and of these isomers thereof not enumerated.
上述不飽和脂肪族1元醇,可舉例如將上述飽和脂肪族1元醇之C-C單鍵之1個以C=C雙鍵取代者,例如油基醇,例如新日本理化股份公司以Rikacol系列及安捷可魯系列名稱販售。 The unsaturated aliphatic monohydric alcohol may, for example, be one in which one of the CC single bonds of the above saturated aliphatic monohydric alcohol is substituted with a C=C double bond, for example, an oleyl alcohol, for example, a new Japanese physicochemical company with a Rikacol series. And the Anjie Kelu series name is sold.
化合物(B),可舉例如(b1)鏈狀烴四醇與至少1個脂肪族1元醇之醚,例如單醚、二醚、三醚及四醚、較佳為二醚、三醚及四醚、更佳為三醚及四醚、再佳為四醚、(b2)鏈狀烴三醇與至少1個脂肪族1元醇之醚,例如單醚、二醚及三醚、較佳為二醚及三醚、而更佳為三醚、以及(b3)鏈狀烴二醇與至少1個脂肪族1元醇 之醚,例如單醚及二醚、而較佳為二醚。 The compound (B) may, for example, be an ether of a (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as a monoether, a diether, a triether and a tetraether, preferably a diether or a triether. And a tetraether, more preferably a triether and a tetraether, more preferably a tetraether, (b 2 ) a chain hydrocarbon triol and an ether of at least one aliphatic monohydric alcohol, such as a monoether, a diether and a triether, preferably diether ether and three, three and more preferably an ether, and (b 3) a chain hydrocarbon diol and at least one of an aliphatic monohydric alcohol ethers, monoethers and diethers, for example, and preferably two ether.
上述鏈狀烴四醇與至少1個脂肪族1元醇之醚,可舉例如下式(10)~(13):
上述鏈狀烴三醇與至少1個脂肪族1元醇之醚,可舉例如下式(14)~(16):
上述鏈狀烴二醇與至少1個脂肪族1元醇之醚,可舉例如下式(17):R17OCnH2nOR18 (17)(式中,n為2~6之整數,而R17及R18各自為鏈狀烴)之C2~C6二醇與脂肪族1元醇之二醚、及下式(18):R17OCnH2nOH (18)(式中,n為2~6之整數,而R17為鏈狀烴)之C2~C6二醇與脂肪族1元醇之單醚。 The ether of the above chain hydrocarbon diol and at least one aliphatic monohydric alcohol can be exemplified by the following formula (17): R 17 OC n H 2n OR 18 (17) (wherein n is an integer of 2 to 6, and R 17 and R 18 are each a chain hydrocarbon (C 2 -C 6 diol) and a diester of an aliphatic monohydric alcohol, and the following formula (18): R 17 OC n H 2n OH (18) (wherein n is an integer of 2 to 6, and R 17 is a chain hydrocarbon (C 2 -C 6 diol) and a monoether of an aliphatic monohydric alcohol.
在上述季戊四醇與脂肪族1元醇之四醚,構成季戊四醇與脂肪族1元醇之四醚的脂肪族1元醇的碳數合計,亦即,上述式(10)中,R10、R11、R12及R13部分的碳數合計為4之場合,IOB成為0.44。因此,在上述季戊四醇與脂肪族1元醇之四醚,脂肪族1元醇的碳數合計 為約4以上之場合,IOB滿足約0.00~約0.60之要件。 In the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R 10 and R 11 in the above formula (10) When the total carbon number of the R 12 and R 13 portions is 4, the IOB becomes 0.44. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 4 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述季戊四醇與脂肪族1元醇之三醚,構成季戊四醇與脂肪族1元醇之三醚的脂肪族1元醇的碳數合計,亦即,上述式(11)中,R10、R11及R12部分的碳數合計為9之場合,IOB成為0.57。因此,在上述季戊四醇與脂肪族1元醇之三醚,脂肪族1元醇的碳數合計在約9以上之場合,IOB滿足約0.00~約0.60之要件。 The total number of carbon atoms of the aliphatic monohydric alcohol forming the pentaerythritol and the triether of the aliphatic monohydric alcohol in the above-mentioned pentaerythritol and the aliphatic trihydric alcohol triol, that is, in the above formula (11), R 10 and R 11 When the total carbon number of the R 12 portion is 9, the IOB becomes 0.57. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述季戊四醇與脂肪族1元醇之二醚,構成季戊四醇與脂肪族1元醇之二醚的脂肪族1元醇的碳數合計,亦即,上述式(12)中,R10及R11部分的碳數合計為15之場合,IOB成為0.60。因此,在上述季戊四醇與脂肪族1元醇之二醚,脂肪族1元醇的碳數合計為約15以上之場合,IOB滿足約0.00~約0.60之要件。 In the diether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R 10 and R 11 in the above formula (12) When the total carbon number is 15 in total, the IOB becomes 0.60. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述季戊四醇與脂肪族1元醇之單醚,構成季戊四醇與脂肪族1元醇之單醚的脂肪族1元醇的碳數,亦即,上述式(13)中,R10部分的碳數為22的場合,IOB成為0.59。因此,在上述季戊四醇與脂肪族1元醇之單醚,脂肪族1元醇的碳數為約22以上之場合,IOB滿足約0.00~約0.60之要件。 The carbon number of the aliphatic monohydric alcohol which constitutes the monoether of pentaerythritol and the aliphatic monohydric alcohol in the monoether of the pentaerythritol and the aliphatic monohydric alcohol, that is, the carbon number of the R 10 moiety in the above formula (13) For the case of 22, the IOB becomes 0.59. Therefore, in the case where the carbon number of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
又,在上述甘油與脂肪族1元醇之三醚,構成甘油與脂肪族1元醇之三醚的脂肪族1元醇的碳數合計,亦即,式(14)中,R14、R15及R16部分的碳數合計為3之場合,IOB成為0.50。因此,在上述甘油與脂肪族1元醇之三醚,脂肪族1元醇的碳數合計為約3以上之場 合,IOB滿足約0.00~約0.60之要件。 Further, in the triether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of glycerin and the aliphatic monohydric alcohol, that is, R 14 and R in the formula (14) When the total carbon number of the 15 and R 16 portions is 3, the IOB becomes 0.50. Therefore, when the total number of carbon atoms of the glycerin and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 3 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述甘油與脂肪族1元醇之二醚,構成甘油與脂肪族1元醇之二醚的脂肪族1元醇的碳數合計,亦即,式(15)中,R14及R15部分的碳數合計為9之場合,IOB成為0.58。因此,在上述甘油與脂肪族1元醇之二醚,脂肪族1元醇的碳數合計在約9以上之場合,IOB滿足約0.00~約0.60之要件。 In the diether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the glycerin and the aliphatic monohydric alcohol, that is, the R 14 and R 15 portions in the formula (15) When the total carbon number is 9, the IOB becomes 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.
在上述甘油與脂肪族1元醇之單醚,構成甘油與脂肪族1元醇之單醚的脂肪族1元醇的碳數,亦即,式(16)中,R14部分的碳數為16之場合,IOB成為0.58。因此,在上述甘油與脂肪族1元醇之單醚,脂肪族1元醇的碳數為約16以上之場合,IOB滿足約0.00~約0.60之要件。 In the monoether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of the glycerin and the aliphatic monohydric alcohol, that is, in the formula (16), the carbon number of the R 14 moiety is On the 16th occasion, the IOB became 0.58. Therefore, in the case where the carbon number of the monoglyceride of the glycerin and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 16 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.
在式(17)所示之丁二醇(n=4)與脂肪族1元醇之二醚,R17及R18部分的碳數合計為2的場合,IOB成為0.33。因此,在式(17)所示之丁二醇(n=4)與脂肪族1元醇之二醚,脂肪族1元醇的碳數合計為2以上的場合,IOB滿足約0.00~約0.60之要件。又,在式(18)所示之乙二醇(n=2)與脂肪族1元醇之單醚,R17部分的碳數為8之場合,IOB成為0.60。因此,在式(18)所示之乙二醇(n=2)與脂肪族1元醇之單醚,脂肪族1元醇的碳數為約8以上之場合,IOB滿足約0.00~約0.60之要件。 When the total number of carbon atoms of the diphenyl diol (n = 4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the R 17 and R 18 portions is 2, the IOB is 0.33. Therefore, when the total number of carbon atoms of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is 2 or more, the IOB satisfies about 0.00 to about 0.60. The essentials. Further, in the case of the ethylene glycol (n = 2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol, when the carbon number of the R 17 moiety is 8, the IOB is 0.60. Therefore, in the case where the ethylene glycol (n=2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol have a carbon number of about 8 or more, the IOB satisfies about 0.00 to about 0.60. The essentials.
化合物(B),可藉由使化合物(B1)與化合 物(B2)在酸觸媒存在下進行脫水縮合而生成。 Compound (B) by combining compound (B1) with compound The substance (B2) is produced by dehydration condensation in the presence of an acid catalyst.
(C)(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之酯(以下、有亦稱「化合物(C)」之情形)在具有上述之IOB、熔點及水溶解度下,羧基可不全被酯化。 (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) having a chain hydrocarbon An ester of a compound partially substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (C)") may have a carboxyl group which may have a carboxyl group having a melting point and a water solubility as described above. Esterification.
(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸(以下、有亦稱「化合物(C1)」之情形),可舉例如具有2~4個羧基的鏈狀烴羧酸,例如鏈狀烴二羧酸,例如烷烴二羧酸,例如乙烷二酸、丙烷二酸、丁烷二酸、戊烷二酸、己烷二酸、庚烷二酸、辛烷二酸、壬烷二酸及癸烷二酸、鏈狀烴三羧酸,例如烷烴三羧酸,例如丙烷三酸、丁烷三酸、戊烷三酸、己烷三酸、庚烷三酸、辛烷三酸、壬烷三酸及癸烷三酸、以及鏈狀烴四羧酸,例如烷烴四羧酸,例如丁烷四酸、戊烷四酸、己烷四酸、庚烷四酸、辛烷四酸、壬烷四酸及癸烷四酸。 (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a side oxyacid containing a chain hydrocarbon moiety and a 2-4 carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter, also referred to as "compound (C1)" In the case of the above, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, for example, a chain hydrocarbon dicarboxylic acid such as an alkanedicarboxylic acid such as ethanedioic acid, propane diacid or butanedioic acid, Pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, such as an alkane tricarboxylic acid, such as propane triacid, butane Triacid, pentanetricarboxylic acid, hexanetricarboxylic acid, heptanetricarboxylic acid, octanetricarboxylic acid, decanetricarboxylic acid and decanetricarboxylic acid, and chain hydrocarbon tetracarboxylic acid, such as an alkanetetracarboxylic acid, such as butane Tetraacid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, decanetetracarboxylic acid, and decanetetracarboxylic acid.
又,化合物(C1)中,包含具有2~4個羧基 的鏈狀烴羥基酸,例如蘋果酸、酒石酸、檸檬酸、異檸檬酸等、具有2~4個羧基的鏈狀烴烷氧基酸,例如O-乙醯基檸檬酸、及具有2~4個羧基的鏈狀烴側氧酸。 Further, the compound (C1) contains 2 to 4 carboxyl groups. Chain hydrocarbon hydroxy acid, such as malic acid, tartaric acid, citric acid, isocitric acid, etc., a chain hydrocarbon alkoxy acid having 2 to 4 carboxyl groups, such as O-ethyl citrate, and having 2 to 4 a carboxyl group-like hydrocarbon side acid.
(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物方面,可舉例如在「化合物(B)」之中所列舉者,例如脂肪族1元醇。 (C2) The compound having a chain hydrocarbon moiety and a hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety, for example, those listed in "Compound (B)", for example, an aliphatic monohydric alcohol.
化合物(C),可舉例如(c1)具有4個羧基的鏈狀烴四羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯,例如單酯、二酯、三酯及四酯、較佳為二酯、三酯及四酯、更佳為三酯及四酯、再佳為四酯、(c2)具有3個羧基的鏈狀烴三羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯,例如單酯、二酯及三酯、較佳為二酯及三酯、而更佳為三酯、以及(c3)具有2個羧基的鏈狀烴二羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯,例如單酯及二酯、較佳為二酯。 The compound (C) may, for example, be (c 1 ) an ester of a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol, for example, a monoester. , diester, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and triesters, more preferably tetraesters, (c 2 ) chain hydrocarbons having 3 carboxyl groups An ester of a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant acid with at least one aliphatic monohydric alcohol, such as a monoester, a diester and a triester, preferably a diester and a triester, and more preferably three. And an ester of (c 3 ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a oxo acid with at least one aliphatic monohydric alcohol, such as a monoester or a diester, Jia is a diester.
化合物(C)的例子方面,如己二酸二辛基酯、O-乙醯基檸檬酸三丁酯等、市售品。 Examples of the compound (C) include commercially available products such as dioctyl adipate, tributyl butyl ethoxide and the like.
(D)具有鏈狀烴部分、與上述鏈狀烴部分的C-C單 鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結之化合物(以下、有亦稱「化合物(D)」之情形),可舉例如(d1)脂肪族1元醇與脂肪族1元醇之醚、(d2)二烷基酮、(d3)脂肪酸與脂肪族1元醇之酯、及(d4)二烷基碳酸酯。 (D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonic acid having a chain hydrocarbon moiety and a CC single bond intercalated with the above chain hydrocarbon moiety Any of the compounds selected in the group in which the ester bond (-OCOO-) is selected (hereinafter, also referred to as "compound (D)"), for example, (d 1 ) aliphatic monohydric alcohol and fat An ether of a monohydric alcohol, a (d 2 ) dialkyl ketone, an ester of a (d 3 ) fatty acid and an aliphatic monohydric alcohol, and (d 4 ) a dialkyl carbonate.
上述脂肪族1元醇與脂肪族1元醇之醚,可舉例如具有下式(19):R19OR20 (19)(式中,R19及R20各自為鏈狀烴)之化合物。 The ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (19): R 19 OR 20 (19) (wherein each of R 19 and R 20 is a chain hydrocarbon).
構成上述醚的脂肪族1元醇(式(19)中,相當R19OH及R20OH)方面,上述醚為滿足上述IOB、熔點及水溶解度要件者,即不特別限制,可舉例如「化合物(B)」之中所列舉的脂肪族1元醇。 In the case of the aliphatic monohydric alcohol (equivalent to R 19 OH and R 20 OH in the formula (19)), the ether is not particularly limited as long as it satisfies the above-mentioned requirements for IOB, melting point and water solubility, and for example, The aliphatic monohydric alcohol exemplified in the compound (B).
在脂肪族1元醇與脂肪族1元醇之醚,構成該醚的脂肪族1元醇的碳數合計,亦即,上述式(19)中,R19及R20部分的碳數合計為2的場合,IOB成為0.50,所以該碳數合計為約2以上,則滿足上述IOB的要件。但,上述碳數合計在6左右,水溶解度為高約2g、在蒸氣壓的觀點上亦有問題。為了滿足水溶解度為約0.00~約0.05g的要件,上述碳數合計以約8以上為佳。 In the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether, that is, in the above formula (19), the total carbon number of the R 19 and R 20 moieties is In the case of 2, since the IOB is 0.50, the total number of carbon atoms is about 2 or more, and the requirements of the above IOB are satisfied. However, the total carbon number is about 6, and the water solubility is about 2 g higher, which is also problematic from the viewpoint of vapor pressure. In order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.
上述二烷基酮,可舉例如具有下式(20):R21COR22 (20)(式中,R21及R22各自為烷基)之化合物。 The dialkyl ketone may, for example, be a compound having the following formula (20): R 21 COR 22 (20) (wherein each of R 21 and R 22 is an alkyl group).
在上述二烷基酮,R21及R22的碳數合計為5之場合,IOB成為0.54,因此若該碳數合計為約5以上,則滿足上述IOB的要件。但是,在上述碳數合計為5左右,水溶解度為高至約2g。因此,為了滿足水溶解度為約0.00~約0.05g之要件,以上述碳數合計為約8以上為佳。又,若考量蒸氣壓,則上述碳數以約10以上為佳、而約12以上為佳。 In the case where the total number of carbon atoms of R 21 and R 22 is 5, the IOB is 0.54. Therefore, if the total number of carbon atoms is about 5 or more, the requirements of the above IOB are satisfied. However, the total carbon number is about 5, and the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, it is preferred that the total carbon number is about 8 or more. Further, when the vapor pressure is considered, the carbon number is preferably about 10 or more, and more preferably about 12 or more.
又,上述碳數合計為約8之場合,例如在5-壬酮,熔點為約-50℃、蒸氣壓在20℃約為230Pa。 Further, when the total carbon number is about 8, for example, 5-nonanone has a melting point of about -50 ° C and a vapor pressure of about 230 Pa at 20 ° C.
上述二烷基酮除市售者外,可藉由習知方法,例如將第二級醇以鉻酸等氧化而得到。 The above dialkyl ketone can be obtained by a conventional method, for example, by oxidizing a second-stage alcohol with chromic acid or the like, in addition to a commercially available one.
上述脂肪酸與脂肪族1元醇之酯,可舉例如具有下式(21):R23COOR24 (21)(式中,R23及R24各自為鏈狀烴)之化合物。 The ester of the fatty acid and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (21): R 23 COOR 24 (21) (wherein each of R 23 and R 24 is a chain hydrocarbon).
構成上述酯的脂肪酸(式(21)中,相當R23COOH),可舉例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中所列舉的脂肪酸,亦即,飽和脂肪酸或不飽和脂肪酸,若考量因氧化等而變性的可能性,以飽和脂肪酸為佳。構成上述酯的脂肪族1元醇(式(21)中,相當R24OH),可舉例如「化合物(B)」之中所列舉的脂肪族1元醇。 The fatty acid constituting the above-mentioned ester (corresponding to R 23 COOH in the formula (21)) may, for example, be a fatty acid as exemplified in the "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, a saturated fatty acid. Or unsaturated fatty acids, if considering the possibility of denaturation by oxidation, etc., it is preferable to use a saturated fatty acid. The aliphatic monohydric alcohol (e.g., R 24 OH in the formula (21)) constituting the above-mentioned ester may, for example, be an aliphatic monohydric alcohol as exemplified in the "compound (B)".
又,在上述脂肪酸與脂肪族1元醇之酯,脂肪酸及脂肪族1元醇的碳數合計,亦即,式(21)中,R23C及R24部分的碳數合計為5之場合,IOB成為0.60,故R23C及R24部分的碳數合計為約5以上之場合,滿足上述IOB的要件。但是,例如在上述碳數合計為6之乙酸丁酯,蒸氣壓高至超過2,000Pa。因此,若考量蒸氣壓,以上述碳數合計為約12以上為佳。又,若上述碳數合計為約11以上,可滿足水溶解度為約0.00~約0.05g之要件。 In addition, in the case where the carbon number of the fatty acid and the aliphatic monohydric alcohol, the fatty acid and the aliphatic monohydric alcohol are in total, that is, in the formula (21), the total carbon number of the R 23 C and R 24 moieties is 5 When the IOB is 0.60, the total number of carbon atoms in the R 23 C and R 24 portions is about 5 or more, and the requirements of the above IOB are satisfied. However, for example, in the case of the above-mentioned butyl acetate having a total carbon number of 6, the vapor pressure is as high as more than 2,000 Pa. Therefore, in consideration of the vapor pressure, it is preferred that the total carbon number is about 12 or more. Moreover, when the total carbon number is about 11 or more, the water solubility is about 0.00 to about 0.05 g.
上述脂肪酸與脂肪族1元醇之酯之例,可舉例如十二烷酸(C12)與十二醇(C12)之酯、十四烷酸(C14)與十二醇(C12)之酯等,上述脂肪酸與脂肪族1元醇之酯的市售品,可舉例如愛雷特魯WE20、及愛雷特魯WE40(以上、日油股份公司製)。 Examples of the ester of the above fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), myristic acid (C 14 ) and dodecyl alcohol (C 12 ). For example, the ester of the above-mentioned fatty acid and the ester of the aliphatic monohydric alcohol may, for example, be an Aurelu WE20 or an Ailelu WE40 (above, manufactured by Nippon Oil Co., Ltd.).
上述二烷基碳酸酯方面,可舉例如具有下式(22): R25OC(=O)OR26 (22)(式中,R25及R26各自為烷基)之化合物。 The dialkyl carbonate may, for example, be a compound having the following formula (22): R 25 OC(=O)OR 26 (22) (wherein each of R 25 and R 26 is an alkyl group).
在上述二烷基碳酸酯,R25及R26的碳數合計為6之場合,IOB成為0.57,故R25及R26的碳數合計在約6以上則滿足IOB的要件。 In the case where the total number of carbon atoms of R 25 and R 26 is 6 in the above dialkyl carbonate, the IOB is 0.57. Therefore, the total carbon number of R 25 and R 26 is about 6 or more to satisfy the requirements of IOB.
若考量水溶解度,則R25及R26的碳數合計為約7以上為佳、而約9以上更佳。 When the water solubility is considered, the total carbon number of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
上述二烷基碳酸酯除市售者外,可藉由光氣與醇之反應、氯化甲酸酯與醇或醇鹽之反應、及碳酸銀與碘化烷基酯之反應來合成。 The above dialkyl carbonates can be synthesized by the reaction of phosgene with an alcohol, the reaction of a chlorinated formate with an alcohol or an alkoxide, and the reaction of silver carbonate with an alkyl iodide, in addition to those commercially available.
上述聚氧化C2~C6烷二醇、或其酯或者醚(以下、化合物(E)之情形),可舉例如(e1)聚氧化C2~C6烷二醇、(e2)聚氧化C2~C6烷二醇與至少1個脂肪酸之酯、(e3)聚氧化C2~C6烷二醇與至少1個脂肪族1元醇之醚、(e4)聚氧化C2~C6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯、及(e5)聚氧化C2~C6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚。以下,進行說明。 The polyoxy C 2 -C 6 alkanediol, or an ester or ether thereof (hereinafter, in the case of the compound (E)), for example, (e 1 ) a polyoxygenated C 2 -C 6 alkanediol, (e 2 ) Polyoxy-C 2 -C 6 alkanediol with at least one fatty acid ester, (e 3 ) polyoxygenated C 2 -C 6 alkanediol and at least one aliphatic monohydric alcohol ether, (e 4 ) polyoxidation An ester of a C 2 -C 6 alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid, and (e 5 ) a polyoxygenated C 2 -C 6 alkanediol and a chain An ether of a hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol. The following description will be made.
上述聚氧化C2~C6烷二醇係指i)具有氧化C2~C6 烷烯骨架,亦即,由氧化乙烯骨架、氧化丙烯骨架、氧化丁烯骨架、氧化戊烯骨架、及氧化己烯骨架所成群中所選出的任1種之骨架且兩末端具有羥基的同聚物、ii)具有由上述群所選出的2種以上的骨架且兩末端具有羥基的嵌段共聚物、或iii)具有由上述群所選出的2種以上的骨架且兩末端具有羥基的無規共聚物。 The above polyoxygenated C 2 -C 6 alkanediol refers to i) having an oxidized C 2 -C 6 alkene skeleton, that is, an oxyethylene skeleton, an oxypropylene skeleton, a butylene oxide skeleton, a pentene oxide skeleton, and oxidation. a homopolymer having a skeleton selected from the group consisting of a hexene skeleton and having a hydroxyl group at both terminals, ii) a block copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals, Or iii) a random copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals.
上述氧化C2~C6烷烯骨架由使聚氧化C2~C6烷二醇的IOB降低觀點,以氧化丙烯骨架,氧化丁烯骨架、氧化戊烯骨架、或氧化己烯骨架為佳,氧化丁烯骨架、氧化戊烯骨架或氧化己烯骨架更佳。 The oxidized C 2 -C 6 alkene skeleton preferably has an oxypropylene skeleton, a oxidized butene skeleton, a pentylene skeleton, or a hexene oxide skeleton from the viewpoint of lowering the IOB of the polyoxygen C 2 -C 6 alkanediol. The butylene oxide skeleton, the pentene oxide skeleton or the oxyhexene skeleton is more preferable.
上述聚氧化C2~C6烷二醇可以下式(23):HO-(CmH2mO)n-H (23)(式中,m為2~6之整數)來表示。 The polyoxygenated C 2 -C 6 alkanediol can be represented by the following formula (23): HO-(C m H 2m O) n -H (23) (wherein m is an integer of 2 to 6).
又,本發明者進行確認後,得知聚乙二醇(式(23)中,相當m=2之同聚物)在n≧45(重量平均分子量為超過約2,000)之場合,雖滿足約0.00~約0.60之IOB的要件,但即使在重量平均分子量超過約4,000的場合,不滿足水溶解度之要件。因此,(e1)聚氧化C2~C6烷二醇中,不包含乙二醇的同聚物,乙二醇係作為與其他二醇之嵌段共聚物或無規共聚物,包含在(e1)聚氧化C2~C6烷二醇。 Moreover, the inventors of the present invention confirmed that polyethylene glycol (a homopolymer equivalent to m=2 in the formula (23)) satisfies about n:45 (weight average molecular weight is more than about 2,000). 0.00 to about 0.60 of the requirements of the IOB, but even in the case where the weight average molecular weight exceeds about 4,000, the water solubility requirement is not satisfied. Therefore, the (e 1 ) polyoxygenated C 2 -C 6 alkanediol does not contain a homopolymer of ethylene glycol, and the ethylene glycol is used as a block copolymer or a random copolymer with other diols, and is contained in (e 1 ) a polyoxygenated C 2 ~C 6 alkanediol.
因此,式(23)的同聚物中,可包含丙二醇、丁二醇、戊二醇或己二醇的同聚物。 Therefore, the homopolymer of the formula (23) may contain a homopolymer of propylene glycol, butylene glycol, pentanediol or hexanediol.
由以上,式(23)中,m為約3~約6,而以約4~約6更佳、再佳係n為2以上。 From the above, in the formula (23), m is from about 3 to about 6, more preferably from about 4 to about 6, and further preferably n is 2 or more.
上述式(23)中,n之值為聚氧化C2~C6烷二醇具有約0.00~約0.60之IOB、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g的水溶解度的值。 In the above formula (23), the value of n is a polyoxygenated C 2 -C 6 alkanediol having an IOB of from about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water content of from about 0.00 to about 0.05 g per 100 g of water at 25 ° C. The value of the water solubility.
例如式(23)為聚丙二醇(m=3的同聚物)的場合,n=12之場合,IOB成為0.58。因此,式(23)為聚丙二醇(m=3的同聚物)的場合,m≧約12之場合,滿足上述IOB的要件。 For example, when the formula (23) is polypropylene glycol (m=3 homopolymer), when n=12, IOB is 0.58. Therefore, when the formula (23) is a polypropylene glycol (m=3 homopolymer), when m≧ is about 12, the requirements of the above IOB are satisfied.
又,式(21)為聚丁二醇(m=4的同聚物)的場合,n=7之場合,IOB成為0.57。因此,式(23)為聚丁二醇(m=4的同聚物)的場合,n≧約7之場合,滿足上述IOB的要件。 Further, when the formula (21) is polytetramethylene glycol (m=4 homopolymer), when n=7, IOB is 0.57. Therefore, when the formula (23) is polytetramethylene glycol (m=4 homopolymer), when n≧ is about 7, the requirements of the above IOB are satisfied.
由IOB、熔點及水溶解度的觀點,聚氧化C2~C6烷二醇的重量平均分子量,較佳為在約200~約10,000、更佳為約250~約8,000、又更佳為約250~約5,000之範圍。 The weight average molecular weight of the polyoxygenated C 2 -C 6 alkanediol is preferably from about 200 to about 10,000, more preferably from about 250 to about 8,000, still more preferably from about 250, from the viewpoints of IOB, melting point and water solubility. ~ A range of about 5,000.
又,由IOB、熔點及水溶解度的觀點,聚氧化C3烷二醇,亦即聚丙二醇的重量平均分子量,較佳為在約1,000~約10,000、更佳為約3,000~約8,000、又更佳為約4,000~約5,000之範圍。因上述重量平均分子量未達約1,000,則水溶解度不滿足要件,且有重量平均分子量愈大,尤其吸收體移動速度及頂部薄片的潔白度提升傾向。 Further, from the viewpoints of IOB, melting point and water solubility, the weight average molecular weight of the polyoxygenated C 3 alkanediol, i.e., polypropylene glycol, is preferably from about 1,000 to about 10,000, more preferably from about 3,000 to about 8,000, still more. Good is in the range of about 4,000 to about 5,000. Since the above weight average molecular weight is less than about 1,000, the water solubility is not satisfactory, and the weight average molecular weight is larger, in particular, the moving speed of the absorbent and the whiteness of the top sheet tend to increase.
上述聚氧化C2~C6烷二醇的市售品,可舉例如Uniol(商標)D-1000,D-1200,D-2000,D-3000,D-4000,PB-500,PB-700,PB-1000及PB-2000(以上、日油股份公司製)。 Commercial products of the above polyoxidized C 2 -C 6 alkanediol include, for example, Uniol (trademark) D-1000, D-1200, D-2000, D-3000, D-4000, PB-500, PB-700. , PB-1000 and PB-2000 (above, manufactured by Nippon Oil Co., Ltd.).
上述聚氧化C2~C6烷二醇與至少1個脂肪酸之酯,可舉例如「(e1)聚氧化C2~C6烷二醇」部分所說明的聚氧化C2~C6烷二醇的OH末端之一者或兩者經脂肪酸而被酯化者,亦即單酯及二酯。 The above-described polyoxyalkylene C 2 ~ C 6 alkylene glycol and at least one ester of a fatty acid includes, for example, "(e 1) polyoxy C 2 ~ C 6 alkanediol" section described polyoxyalkylene C 2 ~ C 6 alkyl One or both of the OH ends of the diol are esterified with fatty acids, i.e., monoesters and diesters.
聚氧化C2~C6烷二醇與至少1個脂肪酸之酯中,欲酯化脂肪酸,可舉例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中,所列舉的脂肪酸,亦即飽和脂肪酸或不飽和脂肪酸,若考量因氧化等而改性的可能性,以飽和脂肪酸為佳。 In the ester of a polyoxygenated C 2 -C 6 alkanediol and at least one fatty acid, the fatty acid is to be esterified, and examples thereof include "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester". A fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, is preferably a saturated fatty acid if it is considered to be modified by oxidation or the like.
上述聚氧化C2~C6烷二醇與脂肪酸之酯的市售品,可舉例如WILBRIDEcp9(日油股份公司製)。 A commercially available product of the above-mentioned ester of a polyoxygenated C 2 -C 6 alkanediol and a fatty acid is, for example, WILBRIDE cp9 (manufactured by Nippon Oil Co., Ltd.).
上述聚氧化C2~C6烷二醇與至少1個脂肪族1元醇之醚,可舉例如「(e1)聚氧化C2~C6烷二醇」部分所說明的聚氧化C2~C6烷二醇的OH末端之一者或兩者經脂肪族1元醇所醚化者,亦即單醚及二醚。 The above-described polyoxyalkylene C 2 ~ C 6 alkylene glycol and at least one aliphatic ethers of monohydric alcohol includes, for example, "(e 1) polyoxy C 2 ~ C 6 alkanediol" section described polyoxyalkylene C 2 ~ OH terminus of one or both C 6 alkanediol by aliphatic monohydric alcohol etherified by, i.e., monoethers and diethers.
聚氧化C2~C6烷二醇與至少1個脂肪族1元醇之醚中,欲醚化的脂肪族1元醇,可舉例如「化合物(B)」的部分所列舉的脂肪族1元醇。 In the ether of the polyoxygenated C 2 -C 6 alkanediol and the at least one aliphatic monohydric alcohol, the aliphatic monohydric alcohol to be etherified may, for example, be an aliphatic 1 as exemplified in the "compound (B)". Alcohol.
上述聚氧化C2~C6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯中,欲酯化聚氧化C2~C6烷二醇,可舉例如「(e1)聚氧化C2~C6烷二醇」部分所說明的聚氧化C2~C6烷二醇。又,欲酯化鏈狀烴四羧酸、鏈狀烴三羧酸、及鏈狀烴二羧酸,可舉例如「(化合物(C)」的部分所說明者。 The above-mentioned ester of a polyoxygenated C 2 -C 6 alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid, to esterify a polyoxygenated C 2 -C 6 alkanediol includes, for example, "(e 1) polyoxy C 2 ~ C 6 alkanediol" section described polyoxyalkylene C 2 ~ C 6 alkanediol. Further, the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, and the chain hydrocarbon dicarboxylic acid are preferably esterified, and examples thereof include those described in "(Compound (C)".
上述聚氧化C2~C6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯除市售品外,可使鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸與氧化C2~C6烷二醇在習知條件下進行聚縮合而製造。 The polyoxy C 2 -C 6 alkanediol and the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, or the chain hydrocarbon dicarboxylic acid ester may be a chain hydrocarbon tetracarboxylic acid, in addition to a commercial product. The chain hydrocarbon tricarboxylic acid or the chain hydrocarbon dicarboxylic acid is produced by polycondensation of an oxidized C 2 -C 6 alkanediol under a known condition.
上述聚氧化C2~C6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚中,欲醚化的聚氧化C2~C6烷二醇,可舉例如「(e1)聚氧化C2~C6烷二醇」部分所說明的聚氧化C2~C6烷二醇。又,欲醚化的鏈狀烴四醇、鏈狀烴三醇、及鏈狀烴二醇,可舉例如「(化合物 (A)」的部分所說明者,例如季戊四醇、甘油、及二醇。 The above-described polyoxyalkylene C 2 ~ C 6 alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol of the ether to be etherified polyoxyalkylene C 2 ~ C 6 alkylene glycol, may be Examples such as "(e 1) polyoxy C 2 ~ C 6 alkanediol" section described polyoxyalkylene C 2 ~ C 6 alkanediol. Further, examples of the chain hydrocarbon tetraol, the chain hydrocarbon triol, and the chain hydrocarbon diol to be etherified include those described in the section "(Compound (A)", such as pentaerythritol, glycerin, and diol.
上述聚氧化C2~C6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚的市售品,可舉例如UNILUBE(商標)5TP-300KB,以及Uniol(商標)TG-3000及TG-4000(日油股份公司製)。 Commercial products of the above-mentioned polyoxy C 2 -C 6 alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol are exemplified by UNILUBE (trademark) 5TP-300KB, and Uniol. (Trademark) TG-3000 and TG-4000 (made by Nippon Oil Co., Ltd.).
UNILUBE(商標)5TP-300KB為使季戊四醇1莫耳與丙二醇65莫耳與乙二醇5莫耳進行聚縮合的化合物,其IOB為0.39、熔點未達45℃、而水溶解度未達0.05g。 UNILUBE (Trade Mark) 5TP-300KB is a compound which polycondenses pentaerythritol 1 molar with propylene glycol 65 mole and ethylene glycol 5 mole, and has an IOB of 0.39, a melting point of less than 45 ° C, and a water solubility of less than 0.05 g.
Uniol(商標)TG-3000為甘油1莫耳與丙二醇50莫耳聚縮合之化合物,其IOB為0.42、熔點為未達45℃、水溶解度為未達0.05g、而重量平均分子量約3,000。 Uniol (trademark) TG-3000 is a compound in which 50 mer of glycerol 1 molar and propylene glycol 50 is condensed, and has an IOB of 0.42, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 3,000.
Uniol(商標)TG-4000為甘油1莫耳與丙二醇70莫耳聚縮合之化合物、其IOB為0.40、熔點為未達45℃、水溶解度為未達0.05g、而重量平均分子量約4,000。 Uniol (trademark) TG-4000 is a compound in which glycerol 1 molar is condensed with propylene glycol 70, having an IOB of 0.40, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 4,000.
上述聚氧化C2~C6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚,又可藉由使鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇與C2~C6環氧烷在習知條件下進行加成而製造。 The above-mentioned polyoxy C 2 -C 6 alkanediol and an ether of a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol can be further obtained by chain hydrocarbon tetraol, chain hydrocarbon triol, Alternatively, the chain hydrocarbon diol is added to a C 2 -C 6 alkylene oxide under conventional conditions.
上述鏈狀烴,因上述無機性值為0,IOB為0.00、而水溶解度為約0g,故熔點為約45℃以下者,可含於上述 血液改質劑。上述鏈狀烴,可舉例如(f1)鏈狀烷烴,例如直鏈烷烴及分支鏈烷烴,例如直鏈烷烴之場合,若考量熔點為約45℃以下,大抵含有碳數為22以下者。又,若考量蒸氣壓,大抵含有碳數為13以上者。分枝鏈烷烴之場合,因比直鏈烷烴在同一碳數中,有熔點低之情形,故亦可包含碳數為22以上者。 The chain hydrocarbon may be contained in the blood modifying agent because the inorganic value is 0, the IOB is 0.00, and the water solubility is about 0 g. Therefore, the melting point is about 45 ° C or lower. The chain hydrocarbon may, for example, be a (f 1 ) chain alkane, for example, a linear alkane or a branched alkane. For example, in the case of a linear alkane, when the melting point is about 45 ° C or less, the carbon number is preferably 22 or less. Further, when the vapor pressure is considered, it is likely to contain a carbon number of 13 or more. In the case of a branched paraffin, since the melting point is low in the same carbon number as the linear alkane, it is also possible to include a carbon number of 22 or more.
上述烴的市售品,可舉例如PARLEAM6(日油股份公司)。 A commercially available product of the above hydrocarbons may, for example, be PARLEAM 6 (Nippon Oil Co., Ltd.).
上述血液改質劑與實施例一同詳細考察,發現至少具有降低血液黏度及表面張力的作用。吸收性物品欲吸收的經血與一般的血液比較,因含子宮內膜壁等之蛋白質,彼等以血球彼此相連繋之方式作用,血球易成為連續排列的狀態。因此,吸收性物品欲吸收之經血易變得高黏度,頂部薄片為不織布或織布的場合,經血易阻塞在纖維間、著用者易感到黏膩感,而在頂部薄片的表面經血擴散、變得易滲漏。 The above blood modifying agent was examined in detail together with the examples, and it was found to have at least a function of lowering blood viscosity and surface tension. The menstrual blood to be absorbed by the absorbent article is compared with the general blood, and the blood cells are connected to each other by the proteins such as the endometrial wall, and the blood cells are easily in a state of continuous alignment. Therefore, the menstrual blood to be absorbed by the absorbent article tends to become highly viscous, and when the top sheet is non-woven or woven, the menstrual blood tends to block between the fibers, and the user tends to feel sticky, and the surface of the top sheet diffuses through the blood. It becomes easy to leak.
又,IOB為約0.00~約0.60的血液改質劑因為有機性高,易滲入血球間,故使血球安定化、血球不易形成連鏈構造。 Further, since the blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily penetrates into the blood cells, the blood cells are stabilized and the blood cells are less likely to form a linked structure.
上述改質劑藉由使血球安定化、血球不易形成連鏈構造,吸收體變得易吸收經血。例如已知在含丙烯酸系高吸收聚合物、所謂SAP的吸收性物品,吸收經血,則連鏈的血球包覆SAP表面,SAP變得不易發揮吸收性能,但藉由使血球安定化,SAP變得易發揮吸收性能。又,因為 與紅血球親和性高的血液改質劑保護紅血球膜,紅血球變得不易被破壞。 The above-mentioned modifier can make the blood cells stable, and the blood cells are less likely to form a linked structure, and the absorbent body can easily absorb menstrual blood. For example, it is known that in an absorbent article containing an acrylic high-absorbent polymer and a so-called SAP, when menstrual blood is absorbed, the linked blood cells coat the surface of the SAP, and the SAP becomes difficult to exhibit absorption performance, but by making the blood cells stable, SAP becomes Easy to play absorption performance. also because A blood modifying agent having high affinity with red blood cells protects the red blood cell membrane, and the red blood cells become difficult to be destroyed.
圖5係用以說明為了包裝而翼部6被折疊的吸收性物品1之圖。將具有以上的構成要素的吸收性物品1進行包裝之場合,如圖5所示將一對翼部6向寬方向內側折疊。 Fig. 5 is a view for explaining the absorbent article 1 in which the wings 6 are folded for packaging. When the absorbent article 1 having the above constituent elements is packaged, as shown in Fig. 5, the pair of wing portions 6 are folded inward in the width direction.
黏著部7以剝離薄片33被覆。藉此,可保護吸收性物品1的使用前的黏著部7。剝離薄片33為可由黏著部7之黏著劑剝離的薄片則不特別限定。在剝離薄片33,可使用例如塗佈剝離劑於基材者。塗佈剝離劑的基材,可舉例如聚丙烯、低密度聚乙烯、聚乙烯基醇等之薄膜、不織布、紙等,剝離劑有矽酮系、氟系、異氰酸酯等。 The adhesive portion 7 is covered with a release sheet 33. Thereby, the adhesive portion 7 before use of the absorbent article 1 can be protected. The release sheet 33 is not particularly limited as long as it can be peeled off by the adhesive of the adhesive portion 7. In the release sheet 33, for example, a release agent may be applied to the substrate. Examples of the substrate to which the release agent is applied include a film of polypropylene, low-density polyethylene, polyvinyl alcohol, a nonwoven fabric, paper, etc., and the release agent is an anthrone-based, fluorine-based or isocyanate.
圖5所示般,包裝吸收性物品1時,翼部6經折疊的吸收性物品1配置於包裝材31上。包裝材31為例如以樹脂薄膜及不織布等製作。又,在包裝材31之長度方向的其中一端設置固黏膠帶32。包裝材31上配置的吸收性物品1與包裝材31一起沿著B-B線及C-C線向長度方向(Y方向)折疊。而使用固黏膠帶32維持吸收性物品1的折疊的狀態。而使與吸收性物品1一起折疊的包裝材31的寬方向的兩側31a藉由熱壓紋加工進行接合。藉此,製作包含吸收性物品1的如圖6所示之包裝品30。圖6為包含吸收性物品的包裝品30之斜視圖。 As shown in Fig. 5, when the absorbent article 1 is packaged, the folded absorbent article 1 of the wing portion 6 is placed on the packaging material 31. The packaging material 31 is produced, for example, by a resin film, a nonwoven fabric, or the like. Further, a fixing adhesive tape 32 is provided at one end of the packaging material 31 in the longitudinal direction. The absorbent article 1 disposed on the packaging material 31 is folded along the B-B line and the C-C line in the longitudinal direction (Y direction) together with the packaging material 31. On the other hand, the state in which the absorbent article 1 is folded is maintained by the adhesive tape 32. On the other hand, the both sides 31a in the width direction of the packaging material 31 folded together with the absorbent article 1 are joined by heat embossing. Thereby, the package 30 shown in FIG. 6 containing the absorbent article 1 is produced. Figure 6 is a perspective view of a package 30 containing an absorbent article.
圖7為圖5之D-D線斷面之概略斷面圖。圖 7所示般,將翼部6折疊時的翼部6中頂部薄片2與***口接觸區域16(圖1及圖2作為參考)的頂部薄片2接觸。因為在***口接觸區域16之頂部薄片2,形成血液改質劑層24,所以翼部6中頂部薄片2與血液改質劑層24接觸。但,因第1山摺部21及/或第2山摺部22,翼部6中頂部薄片2與血液改質劑層24的接觸面積變小。又,在翼部6中之頂部薄片2未形成開口部。藉此,可抑制血液改質劑層24的血液改質劑浸透翼部6而翼部6中頂部薄片2與背部薄片3間的接合力變弱。又,可抑制血液改質劑層24的血液改質劑被轉印至翼部6之頂部薄片2而***口接觸區域16之頂部薄片2上形成的血液改質劑層24的血液改質劑的量減少。 Fig. 7 is a schematic cross-sectional view showing the line D-D of Fig. 5; Figure As shown in Fig. 7, the top sheet 2 of the wing portion 6 when the wing portion 6 is folded is brought into contact with the top sheet 2 of the drain opening contact region 16 (see Figs. 1 and 2 for reference). The top sheet 2 in the wing portion 6 is in contact with the blood modifying agent layer 24 because the top layer 2 of the excretory opening contact area 16 forms the blood modifying agent layer 24. However, the contact area between the top sheet 2 and the blood modifying agent layer 24 in the wing portion 6 is small due to the first mountain fold portion 21 and/or the second mountain fold portion 22. Further, the top sheet 2 in the wing portion 6 is not formed with an opening portion. Thereby, the blood modifying agent of the blood modifying agent layer 24 can be prevented from penetrating into the wing portion 6, and the joining force between the top sheet 2 and the back sheet 3 in the wing portion 6 can be weakened. Further, it is possible to suppress the blood modifying agent of the blood modifying agent layer 24 from being transferred to the top sheet 2 of the wing portion 6 and the blood modifying agent layer 24 of the blood modifying agent layer 24 formed on the top sheet 2 of the excretory opening contact region 16. The amount is reduced.
藉由在設置有第1山摺部21及/或第2山摺部22的翼部6之寬方向外側之緣部分形成密封部9,如圖7所示般,可使翼部6之緣62(圖1及圖2作為參考)與形成有血液改質劑層的***口接觸區域16之頂部薄片2離隔。藉此,可抑制翼部2的端62之頂部薄片2與背部薄片3間浸透血液改質劑層24的血液改質劑而翼部2中頂部薄片2與背部薄片3間的接合力變弱。 The sealing portion 9 is formed by the edge portion in the width direction outer side of the wing portion 6 in which the first mountain fold portion 21 and/or the second mountain fold portion 22 are provided, so that the edge of the wing portion 6 can be formed as shown in FIG. 62 (Figs. 1 and 2 for reference) is separated from the top sheet 2 of the drain port contact region 16 where the blood modifying agent layer is formed. Thereby, the blood modifying agent which permeates the blood modifier layer 24 between the top sheet 2 and the back sheet 3 of the end 62 of the wing portion 2 can be suppressed, and the bonding force between the top sheet 2 and the back sheet 3 in the wing portion 2 is weakened. .
進而,因為在形成有血液改質劑層的***口接觸區域16之頂部薄片2設置第1山摺部21,翼部6中頂部薄片2與血液改質劑層24的接觸面積變得更小。藉此,可更抑制血液改質劑層24的血液改質劑浸透翼部6,翼部6中頂部薄片2與背部薄片3間的接合力變弱。 又,可抑制血液改質劑層24的血液改質劑被轉印至翼部6之頂部薄片2而***口接觸區域16之頂部薄片2上形成的血液改質劑層24的血液改質劑的量減少。 Further, since the first mountain fold portion 21 is provided on the top sheet 2 of the drain opening contact region 16 in which the blood modifying agent layer is formed, the contact area of the top sheet 2 and the blood modifying agent layer 24 in the wing portion 6 becomes smaller. . Thereby, the blood modifying agent infiltration of the wing portion 6 of the blood modifying agent layer 24 can be further suppressed, and the bonding force between the top sheet 2 and the back sheet 3 in the wing portion 6 is weakened. Further, it is possible to suppress the blood modifying agent of the blood modifying agent layer 24 from being transferred to the top sheet 2 of the wing portion 6 and the blood modifying agent layer 24 of the blood modifying agent layer 24 formed on the top sheet 2 of the excretory opening contact region 16. The amount is reduced.
接著,參考圖8,說明本發明之一實施形態的吸收性物品1的製造方法。圖8為用以說明本發明之一實施形態的吸收性物品1的製造方法使用的吸收性物品製造裝置100的圖。吸收性物品1的製造方法包含形成吸收體的步驟、準備頂部薄片用薄片的步驟、在層合體形成壓縮溝的步驟、準備背部薄片用薄片的步驟、切斷吸收性物品的連續體的步驟及於吸收性物品塗佈血液改質劑的步驟。又,準備頂部薄片用薄片的步驟所使用的頂部薄片用薄片,係以包含準備樹脂薄膜薄片的步驟、於樹脂薄膜薄片形成凹部的步驟及對樹脂薄膜薄片進行齒延伸的步驟的頂部薄片用薄片的製造方法來製造。 Next, a method of manufacturing the absorbent article 1 according to an embodiment of the present invention will be described with reference to Fig. 8 . FIG. 8 is a view for explaining an absorbent article manufacturing apparatus 100 used in the method of manufacturing the absorbent article 1 according to the embodiment of the present invention. The method for producing the absorbent article 1 includes a step of forming an absorbent body, a step of preparing a sheet for top sheet, a step of forming a compressed groove in the laminate, a step of preparing a sheet for back sheet, and a step of cutting a continuous body of the absorbent article. The step of applying a blood modifying agent to the absorbent article. In addition, the sheet for the top sheet used in the step of preparing the sheet for the top sheet includes the step of preparing the resin film sheet, the step of forming the concave portion in the resin film sheet, and the sheet for the top sheet for the step of extending the resin film sheet. Manufacturing method to manufacture.
在形成吸收體的步驟,使吸收體128在輸送帶110上形成。從未圖示之粉碎紙漿供給裝置將粉碎紙漿122供給給圖案滾筒120。在圖案滾筒120之外周部,形成有作為裝填粉碎紙漿模型的凹部124。圖案滾筒120之內部被吸引126,供給至圖案滾筒120的粉碎紙漿122被吸入凹部124中被壓縮。而在凹部124中,紙漿122成形為吸收體128。吸收體128載置於輸送帶上。 In the step of forming the absorber, the absorber 128 is formed on the conveyor belt 110. The pulverized pulp 122 is supplied to the pattern cylinder 120 from a pulverized pulp supply device (not shown). A concave portion 124 as a model for loading the pulverized pulp is formed on the outer peripheral portion of the pattern cylinder 120. The inside of the pattern cylinder 120 is attracted 126, and the pulverized pulp 122 supplied to the pattern cylinder 120 is sucked into the concave portion 124 to be compressed. In the recess 124, the pulp 122 is shaped as an absorber 128. The absorbent body 128 is placed on a conveyor belt.
在準備頂部薄片用薄片的步驟,將以後述頂部薄片用薄片的製造方法製造的頂部薄片用薄片216配置於吸收體128上,使頂部薄片用薄片216與吸收體128接 著。 In the step of preparing the top sheet sheet, the top sheet sheet 216 produced by the method for producing the top sheet sheet described later is placed on the absorber 128, and the top sheet sheet 216 is attached to the absorber 128. With.
在層合體形成壓縮溝的步驟,使用壓紋加工裝置130,於頂部薄片用薄片216及吸收體128的層合體262形成壓縮溝。層合體262通過壓紋加工裝置130之上段輥131與下段輥132之間。在上段輥131的外周表面,設置對應圖1所示之吸收性物品1的壓縮溝8之形狀的凸部(未圖示)。下段輥132為外周表面平滑的平面輥。藉由於壓紋加工裝置130之上段輥131與下段輥132間,通過層合體262,層合體262中對應圖1所示之吸收性物品1的壓縮溝8之部分在厚度方向被壓縮,壓縮溝在層合體262上形成。 In the step of forming the compression groove in the laminate, the embossing device 130 is used to form the compression groove in the top sheet sheet 216 and the laminate 262 of the absorber 128. The laminate 262 passes between the upper roller 131 and the lower roller 132 of the embossing processing device 130. A convex portion (not shown) corresponding to the shape of the compression groove 8 of the absorbent article 1 shown in Fig. 1 is provided on the outer circumferential surface of the upper roller 131. The lower stage roller 132 is a flat roll having a smooth outer peripheral surface. The portion of the laminate 262 corresponding to the compression groove 8 of the absorbent article 1 shown in FIG. 1 is compressed in the thickness direction by the laminate 262 between the upper roller 131 and the lower roller 132 of the embossing processing device 130, and the compression groove is compressed. Formed on the laminate 262.
在準備背部薄片用薄片的步驟,將背部薄片用薄片輥140所供給的背部薄片用薄片142使用未圖示之塗佈裝置,塗佈接著劑後,重合接著於形成有壓縮溝的層合體134的頂部薄片用薄片側反對側之面,形成吸收性物品的連續體144。 In the step of preparing the sheet for the back sheet, the sheet for back sheet 142 supplied from the sheet roll 140 for back sheeting is applied by a coating device (not shown), and the adhesive is applied, and then laminated to the laminate 134 in which the compression groove is formed. The top sheet is formed on the side opposite the side of the sheet to form a continuous body 144 of absorbent article.
在切斷吸收性物品之連續體的步驟,使用裁切器150,使吸收性物品之連續體144切斷成吸收性物品之形狀,以製作吸收性物品。 In the step of cutting the continuous body of the absorbent article, the continuous body 144 of the absorbent article is cut into the shape of the absorbent article using the cutter 150 to produce an absorbent article.
在吸收性物品塗佈血液改質劑之步驟,使用改質劑塗佈噴霧器160,在吸收性物品之中央區域塗佈上述血液改質劑161,於頂部薄片之***口接觸區域之表面形成血液改質劑層。 In the step of applying the blood modifying agent to the absorbent article, the sprayer 160 is coated with a modifier, and the blood modifying agent 161 is applied to the central region of the absorbent article to form blood on the surface of the excretory contact area of the top sheet. Modifier layer.
在切斷吸收性物品的連續體的步驟後,塗佈 血液改質劑,但亦可在後述頂部薄片用薄片的製造步驟塗佈血液改質劑。為了防止製造吸收性物品途中,塗佈的血液改質劑從吸收性物品脫落,以在吸收性物品的製造步驟之下游階段,例如包裝吸收性物品前於吸收性物品塗佈血液改質劑為佳。 After the step of cutting the continuous body of the absorbent article, coating Although the blood modifying agent is used, the blood modifying agent may be applied in the production step of the top sheet for a sheet to be described later. In order to prevent the absorbent article from being detached from the absorbent article during the manufacture of the absorbent article, the blood modifying agent is applied to the absorbent article at a downstream stage of the manufacturing step of the absorbent article, for example, before packaging the absorbent article. good.
在吸收性物品1的製造方法,另外包含於吸收性物品的連續體144形成黏著部的步驟及於吸收性物品的連續體144形成密封部的步驟等。又,製造的吸收性物品1使用上述包裝材被包裝。 In the method of producing the absorbent article 1, the step of forming the adhesive portion in the continuous body 144 of the absorbent article and the step of forming the sealed portion in the continuous body 144 of the absorbent article are also included. Moreover, the manufactured absorbent article 1 is packaged using the above-mentioned packaging material.
接著,說明頂部薄片用薄片的製造方法。 Next, a method of manufacturing the sheet for the top sheet will be described.
在準備樹脂薄膜薄片的步驟,圖8所示般,使樹脂薄膜薄片的輥210所供給的樹脂薄膜薄片212供給至凹部形成輥220。 In the step of preparing the resin film sheet, the resin film sheet 212 supplied from the roll 210 of the resin film sheet is supplied to the concave portion forming roll 220 as shown in FIG.
在樹脂薄膜薄片形成凹部的步驟,使樹脂薄膜薄片212通過凹部形成輥220,製作形成有凹部2141的樹脂薄膜薄片214(圖10作為參考)。凹部形成輥220係由壓花輥221與具有平滑表面的預熱輥222所構成。 In the step of forming the concave portion in the resin film sheet, the resin film sheet 212 is passed through the concave portion forming roller 220, and the resin film sheet 214 in which the concave portion 2141 is formed is produced (see FIG. 10 for reference). The recess forming roller 220 is composed of an embossing roller 221 and a preheating roller 222 having a smooth surface.
圖9(a)及(b)為壓花輥221的一例的圖。圖9(a)為壓花輥221的全體之圖,圖9(b)為擴大壓花輥221的外周表面之具有凹凸的部分223的圖。圖9(c)為具有平滑表面的預熱輥222的一例的圖。在壓花輥221的表面223,設有格子狀的凸部224。藉此,壓花輥221的表面形成菱形之凹部225。又,壓花輥221的凹部225之形狀不限於菱形,可為正方形、長方形、平行四 邊形、梯形、三角形、六角形等之形狀。 9(a) and 9(b) are views showing an example of the embossing roll 221. Fig. 9(a) is a view showing the entirety of the embossing roll 221, and Fig. 9(b) is a view showing the enlarged portion 223 of the outer peripheral surface of the embossing roll 221. Fig. 9(c) is a view showing an example of the preheating roller 222 having a smooth surface. On the surface 223 of the embossing roll 221, a lattice-like convex portion 224 is provided. Thereby, the surface of the embossing roll 221 forms a rhombic recess 225. Moreover, the shape of the concave portion 225 of the embossing roller 221 is not limited to a diamond shape, and may be square, rectangular, or parallel. Shapes such as a triangle, a trapezoid, a triangle, a hexagon, and the like.
格子狀的凸部224中,平行排列的凸部224的中心線間隔,亦即格子狀的凸部224的間距,較佳為0.2mm以上、10mm以下,更佳為0.4mm以上、2mm以下。格子狀的凸部224的間距未達0.2mm、或比10mm大的場合,有不於樹脂薄膜形成凹部之情形。又,格子狀的凸部224的寬,較佳為0.01mm以上、1mm以下,更佳為0.03mm以上、0.1以下。又,菱形之凹部225之一邊之長度較佳為0.1mm以上、5mm以下,更佳為0.2mm以上、1mm以下。格子狀的凸部224的寬未達0.01mm或者比1mm大的場合、或菱形之凹部225之一邊之長度未達0.1mm或者比5mm大的場合,有不於樹脂薄膜形成凹部之情形。 In the lattice-like convex portion 224, the center line spacing of the convex portions 224 arranged in parallel, that is, the pitch of the lattice-shaped convex portions 224 is preferably 0.2 mm or more and 10 mm or less, more preferably 0.4 mm or more and 2 mm or less. When the pitch of the lattice-like convex portions 224 is less than 0.2 mm or larger than 10 mm, the concave portion may not be formed in the resin film. Further, the width of the lattice-like convex portion 224 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.03 mm or more and 0.1 or less. Further, the length of one side of the rhombic recess 225 is preferably 0.1 mm or more and 5 mm or less, more preferably 0.2 mm or more and 1 mm or less. When the width of the lattice-shaped convex portion 224 is less than 0.01 mm or larger than 1 mm, or the length of one side of the concave portion 225 of the rhombic shape is less than 0.1 mm or larger than 5 mm, the concave portion may not be formed in the resin film.
具有平滑表面的預熱輥222維持於70℃以上、100℃以下的溫度,加熱供給的樹脂薄膜薄片212。藉此,樹脂薄膜薄片212變得柔軟、容易成形。 The preheating roll 222 having a smooth surface is maintained at a temperature of 70 ° C or more and 100 ° C or less, and the supplied resin film sheet 212 is heated. Thereby, the resin film sheet 212 becomes soft and can be easily formed.
樹脂薄膜薄片212通過壓花輥221與具有平滑表面的輥222間時,在與格子狀的凸部224相接部分,樹脂薄膜薄片212在厚度方向受到強壓力。藉此,圖10所示般,在樹脂薄膜薄片214形成細的凹部2141。又,實際上,樹脂薄膜薄片212上形成的凹部2141比圖10所示小,單位面積的凹部2141的數目比圖10所示多。凹部2141僅在樹脂薄膜薄片214中對應本體部10之設置有吸收體4的區域12(圖1作為參考)的範圍2143上形成。 在此,樹脂薄膜薄片214中對應吸收性物品1的範圍為符號2142的虛線所示範圍。 When the resin film sheet 212 passes between the embossing roll 221 and the roller 222 having a smooth surface, the resin film sheet 212 receives a strong pressure in the thickness direction at a portion in contact with the lattice-like convex portion 224. Thereby, as shown in FIG. 10, a thin concave portion 2141 is formed in the resin film sheet 214. Further, actually, the concave portion 2141 formed on the resin film sheet 212 is smaller than that shown in Fig. 10, and the number of the concave portions 2141 per unit area is larger than that shown in Fig. 10 . The recess 2141 is formed only in the range 2143 of the resin film sheet 214 corresponding to the region 12 of the body portion 10 on which the absorber 4 is provided (see FIG. 1 for reference). Here, the range corresponding to the absorbent article 1 in the resin film sheet 214 is a range indicated by a broken line of the symbol 2142.
在對樹脂薄膜薄片進行齒延伸的步驟,如圖8所示,藉由使形成凹部的樹脂薄膜薄片214通過延伸齒輥230,使頂部薄片2的第1山摺部、第2山摺部及谷摺部形成於樹脂薄膜薄片214。符號216為形成有第1山摺部、第2山摺部及谷摺部的樹脂薄膜薄片。 In the step of extending the resin film sheet, as shown in FIG. 8, the resin film sheet 214 having the concave portion is passed through the extending tooth roll 230, so that the first mountain portion and the second mountain portion of the top sheet 2 are The valley fold is formed on the resin film sheet 214. Reference numeral 216 is a resin film sheet on which the first mountain fold portion, the second mountain fold portion, and the valley fold portion are formed.
延伸齒輥230,包含上段輥231與下段輥232。圖11(a)為用以說明延伸齒輥230之上段輥231的圖,圖11(b)為用以說明上段輥231的外周面上配置的齒輪齒233的圖,圖11(c)為圖11(b)的E-E線斷面圖。齒輪齒233在上段輥231的圓周方向非連續地延伸。亦即上段輥231的圓周方向延伸的齒輪齒233在途中複數處被切斷。因該齒輪齒233中途被切斷處234,於樹脂薄膜薄片214形成第2山摺部。 The extending tooth roll 230 includes an upper roll 231 and a lower roll 232. Fig. 11 (a) is a view for explaining the upper roller 231 of the extension tooth roller 230, and Fig. 11 (b) is a view for explaining the gear teeth 233 disposed on the outer circumferential surface of the upper roller 231, and Fig. 11 (c) is Fig. 11 (b) is a sectional view taken along line EE. The gear teeth 233 extend discontinuously in the circumferential direction of the upper roller 231. That is, the gear teeth 233 extending in the circumferential direction of the upper roller 231 are cut at a plurality of points in the middle. The second mountain fold portion is formed on the resin film sheet 214 by the cut portion 234 in the middle of the gear tooth 233.
齒輪齒233寬為例如0.3mm以上、0.5mm以下,相鄰的齒輪齒233之中心間的距離為例如1.0mm以上、1.2mm以下。 The gear teeth 233 are, for example, 0.3 mm or more and 0.5 mm or less in width, and the distance between the centers of the adjacent gear teeth 233 is, for example, 1.0 mm or more and 1.2 mm or less.
圖12(a)為用以說明延伸齒輥230之下段輥232之圖,圖12(b)為用以說明下段輥232的外周面上配置的齒輪齒235的圖,圖12(c)為圖12(b)的F-F線斷面圖。齒輪齒235在下段輥232的圓周方向延伸。下段輥232不若上段輥231般在途中複數處被中斷。齒輪齒235之寬,例如與上段輥231的齒輪齒233之寬相等,相 鄰的齒輪齒235之中心間的距離為例如與上段輥231的齒輪齒233之中心間的距離相等。 Fig. 12 (a) is a view for explaining the lower roller 232 of the extension roller 230, and Fig. 12 (b) is a view for explaining the gear teeth 235 disposed on the outer circumferential surface of the lower roller 232, and Fig. 12 (c) is Fig. 12 (b) is a cross-sectional view taken along the line FF. The gear teeth 235 extend in the circumferential direction of the lower roller 232. The lower roller 232 is not interrupted at the plurality of places on the way as the upper roller 231. The width of the gear teeth 235 is, for example, equal to the width of the gear teeth 233 of the upper roller 231, and the phase The distance between the centers of the adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roller 231.
上段輥231的齒輪齒233與下段輥232的齒輪齒235咬合部分之上段輥231的徑方向之長度,亦即咬合深度為例如1.25mm。上段輥231的齒輪齒233與下段輥232的齒輪齒235咬合時的上段輥231的齒輪齒233與下段輥232的齒輪齒235間的間隙為例如0.25mm以上、0.45mm以下。 The gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 engage the length of the upper roller 231 in the radial direction, that is, the nip depth is, for example, 1.25 mm. The gap between the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 when the gear teeth 233 of the upper roller 231 are engaged with the gear teeth 235 of the lower roller 232 is, for example, 0.25 mm or more and 0.45 mm or less.
如圖8所示,樹脂薄膜薄片214通過延伸齒輥230時,樹脂薄膜214折曲為略波狀,於樹脂薄膜214形成頂部薄片2的第1山摺部21、第2山摺部22及谷摺部23。又,樹脂薄膜薄片214的形成有凹部2141的區域2143(圖10作為參考)再形成頂部薄片2的開口部25(圖4作為參考)。 As shown in FIG. 8, when the resin film sheet 214 is extended by the tooth roll 230, the resin film 214 is bent into a slight wave shape, and the resin film 214 forms the first mountain fold portion 21 of the top sheet 2, the second mountain fold portion 22, and Valley folds 23. Further, the region 2143 of the resin film sheet 214 in which the concave portion 2141 is formed (see FIG. 10 as a reference) re-forms the opening portion 25 of the top sheet 2 (see FIG. 4 for reference).
接著,參考圖13,說明使樹脂薄膜薄片214通過延伸齒輥230時,於樹脂薄膜薄片214形成開口部的原理。又,該原理不限定本發明。 Next, the principle of forming the opening portion in the resin film sheet 214 when the resin film sheet 214 is passed through the extending tooth roll 230 will be described with reference to FIG. Moreover, the principle does not limit the invention.
樹脂薄膜薄片214在上段輥231的齒輪齒233與下段輥232的齒輪齒235咬合部分236,大幅被延伸。在上述凹部形成步驟,形成凹部2141(圖10作為參考)的部分為樹脂薄膜薄片214變薄、再藉由壓花輥221的格子狀的凸部224而賦予損傷的部分,因此強度弱,樹脂薄膜薄片214的凹部2141受到延伸則破裂。因此,樹脂薄膜薄片214的受到延伸的部分236,樹脂薄膜薄片214的 凹部2141破裂,樹脂薄膜薄片214的破裂部分擴大,在樹脂薄膜薄片214的破裂部分形成開口部。 The resin film sheet 214 is largely extended by the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232. In the concave portion forming step, the portion where the concave portion 2141 (see FIG. 10 is referred to as a reference) is formed so that the resin film sheet 214 is thinned and the damage is imparted by the lattice-like convex portion 224 of the embossing roll 221, so that the strength is weak, and the resin is weak. The concave portion 2141 of the film sheet 214 is broken to be extended. Therefore, the extended portion 236 of the resin film sheet 214, the resin film sheet 214 The concave portion 2141 is broken, and the broken portion of the resin film sheet 214 is enlarged, and an opening portion is formed in the broken portion of the resin film sheet 214.
樹脂薄膜薄片214,在上段輥231之齒輪齒233與下段輥232的齒輪齒235未咬合的部分237,238不太被延伸。因此,在樹脂薄膜薄片241中上段輥231之齒輪齒233與下段輥232的齒輪齒235未咬合的部分237,238,即使樹脂薄膜薄片214通過延伸齒輥230,在上述凹部形成步驟形成的凹部2141不破裂,不成為開口部。 The resin film sheet 214 is not extended in the portions 237, 238 where the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 are not engaged. Therefore, in the resin film sheet 241, the gear teeth 233 of the upper roller 231 and the portions 237, 238 where the gear teeth 235 of the lower roller 232 are not engaged, even if the resin film sheet 214 passes through the extending tooth roller 230, the concave portion formed in the above-described concave portion forming step 2141 does not break and does not become an opening.
在樹脂薄膜薄片214的未形成凹部2141的區域,在上段輥231的齒輪齒233與下段輥232的齒輪齒235咬合部分236,樹脂薄膜薄片214即使被大幅延伸,樹脂薄膜薄片214不破裂。因此,樹脂薄膜薄片214中在各自對應本體部10之吸收體4的寬方向的兩側面41的外側之區域14及翼部6的區域,不形成開口部。 In the region where the concave portion 2141 is not formed in the resin film sheet 214, the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 are engaged with the portion 236, and even if the resin film sheet 214 is largely extended, the resin film sheet 214 is not broken. Therefore, in the resin film sheet 214, the opening portion is not formed in the region 14 and the region of the wing portion 6 which are located outside the both side faces 41 of the absorbent body 4 in the width direction of the main body portion 10.
可將以上的本發明之一實施形態的吸收性物品1如下進行變更。 The absorbent article 1 according to the embodiment of the present invention described above can be modified as follows.
(1)若可降低本體部10之頂部薄片2所設置的血液改質劑層24與翼部6之頂部薄片2間的接觸面積,則翼部6之頂部薄片上形成的突部不限於第1山摺部及第2山摺部。例如亦可於翼部6之頂部薄片設置於寬方向(X方向)延伸存在的山摺部。又,亦可於翼部6之頂部薄片設置以波狀之形態於長度方向(Y方向)或寬方向(X方向)延伸存在的山摺部。進而,亦可於翼部6之頂部薄片 設置圓柱、方柱、半球等之形狀的突部。 (1) If the contact area between the blood modifying agent layer 24 provided on the top sheet 2 of the main body portion 10 and the top sheet 2 of the wing portion 6 can be reduced, the protrusion formed on the top sheet of the wing portion 6 is not limited to the first 1 mountain fold and 2nd mountain fold. For example, the top sheet of the wing portion 6 may be provided with a mountain fold extending in the width direction (X direction). Further, a mountain fold portion extending in the longitudinal direction (Y direction) or the width direction (X direction) in a wave shape may be provided on the top sheet of the wing portion 6. Furthermore, it can also be on the top of the wing 6 A protrusion having a shape of a cylinder, a square column, a hemisphere, or the like is provided.
(2)如圖14所示之吸收性物品1A般,可在頂部薄片2A的兩側設置側邊薄片18A。該場合,翼部6具備側邊薄片18A與背部薄片。該場合,側邊薄片18A為樹脂薄膜,側邊薄片18A在翼部6中不具有開口部,同時具備第1山摺部21及第2山摺部等之突部。藉此,可抑制因本體部10之頂部薄片2所塗佈的血液改質劑浸透翼部6,而構成翼部6的側邊薄片18A從背部薄片剝離。 (2) As in the absorbent article 1A shown in Fig. 14, the side sheets 18A may be provided on both sides of the top sheet 2A. In this case, the wing portion 6 is provided with a side sheet 18A and a back sheet. In this case, the side sheet 18A is a resin film, and the side sheet 18A does not have an opening in the wing portion 6, and includes a protrusion such as the first mountain fold portion 21 and the second mountain fold portion. Thereby, the blood modifying agent applied to the top sheet 2 of the main body portion 10 can be prevented from penetrating the wing portion 6, and the side sheet 18A constituting the wing portion 6 can be peeled off from the back sheet.
於側邊薄片18A,設置第1山摺部21、第2山摺部22及谷摺部23,在頂部薄片2A,可不設置第1山摺部21、第2山摺部22及谷摺部23。又,頂部薄片2A可使用不織布。此等之場合亦可抑制因本體部10之頂部薄片2所塗佈的血液改質劑浸透翼部6,而構成翼部6的側邊薄片18A從背部薄片剝離。 The first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 are provided on the side sheet 18A, and the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion are not provided in the top sheet 2A. twenty three. Further, a non-woven fabric can be used for the top sheet 2A. In such a case, the blood modifying agent applied to the top sheet 2 of the main body portion 10 can be prevented from penetrating the wing portion 6, and the side sheet 18A constituting the wing portion 6 can be peeled off from the back sheet.
於頂部薄片2A使用不織布場合,頂部薄片2A使用的不織布可為天然纖維或化學纖維。頂部薄片2A使用的天然纖維,可舉例如粉碎紙漿、棉等之纖維素。頂部薄片2A使用的化學纖維,可舉例如人造絲、原纖化人造絲等之再生纖維素、乙酸酯、三乙酸酯等之半合成纖維素、熱可塑性疏水性化學纖維、及施以親水化處理的熱可塑性疏水性化學纖維等。頂部薄片2A使用的熱可塑性疏水性化學纖維,可舉例如聚乙烯(PE)、聚丙烯(PP)、聚乙烯對苯二甲酸酯(PET)等之單纖維、使聚乙烯與聚丙烯接枝聚合而成的纖維及芯鞘構造等之複合纖 維。 In the case where the top sheet 2A is a non-woven fabric, the nonwoven fabric used for the top sheet 2A may be a natural fiber or a chemical fiber. The natural fiber used for the top sheet 2A may, for example, be pulverized cellulose such as pulp or cotton. The chemical fiber used for the top sheet 2A may, for example, be regenerated cellulose such as rayon or fibrillated rayon, semi-synthetic cellulose such as acetate or triacetate, or thermoplastic hydrophobic chemical fiber, and A hydrophilized thermoplastic thermoplastic fiber or the like. The thermoplastic plastic chemical fiber used for the top sheet 2A may, for example, be a single fiber such as polyethylene (PE), polypropylene (PP) or polyethylene terephthalate (PET), and the polyethylene and polypropylene may be connected. Composite fiber such as fiber and core sheath structure dimension.
又,在頂部薄片2A的兩側設置側邊薄片18A的場合亦可設置第1山摺部21、第2山摺部22及谷摺部23於頂部薄片2A。 Moreover, when the side sheet 18A is provided on both sides of the top sheet 2A, the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 may be provided on the top sheet 2A.
(3)若可降低本體部10之頂部薄片2所設置的血液改質劑層24與翼部6之頂部薄片2間的接觸面積,則形成有血液改質劑層的排出口對向區域16之頂部薄片2上形成的突部不限於第1突條部。例如可於形成有血液改質劑層的排出口對向區域16之頂部薄片設置於寬方向(X方向)延伸存在的突條部。又,亦可於形成有血液改質劑層的排出口對向區域16之頂部薄片設置以波狀之形態於長度方向(Y方向)或於寬方向(X方向)延伸存在的突條部。進而,亦可於形成有血液改質劑層的排出口對向區域16之頂部薄片設置圓柱、方柱、半球等之形狀的突部。此等之場合,亦可抑制血液改質劑層的血液改質劑浸透翼部,而翼部之頂部薄片與背部薄片間的接合力變弱。又,可抑制血液改質劑層的血液改質劑被轉印至翼部之頂部薄片,排出口對向區域的頂部薄片上形成的血液改質劑層的血液改質劑的量減少。 (3) If the contact area between the blood modifying agent layer 24 provided on the top sheet 2 of the main body portion 10 and the top sheet 2 of the wing portion 6 can be lowered, the discharge outlet facing region 16 in which the blood modifying agent layer is formed is formed. The protrusion formed on the top sheet 2 is not limited to the first ridge portion. For example, a ridge portion extending in the width direction (X direction) may be provided on the top sheet of the discharge port facing region 16 in which the blood modifying agent layer is formed. Further, a ridge portion extending in the longitudinal direction (Y direction) or the width direction (X direction) in a wave shape may be provided in the top sheet of the discharge port opposing region 16 in which the blood modifying agent layer is formed. Further, a protrusion of a shape such as a column, a square column, or a hemisphere may be provided on the top sheet of the discharge port facing region 16 in which the blood modifying agent layer is formed. In such a case, it is also possible to suppress the blood modifying agent of the blood modifying agent layer from penetrating into the wing portion, and the joining force between the top sheet of the wing portion and the back sheet is weak. Further, the blood modifying agent of the blood modifying agent layer can be prevented from being transferred to the top sheet of the wing portion, and the amount of the blood modifying agent of the blood modifying agent layer formed on the top sheet of the discharge port facing region can be reduced.
(4)頂部薄片的肌膚側之面的至少接觸著用者的***口的***接觸區域上形成的層,為塗佈有特定組成物的組成物塗佈層,則不限於血液改質劑層。例如頂部薄片的肌膚側之面的至少接觸著用者的***口的***口接觸區域可設置塗佈有防止肌膚乾燥的乳液之乳液塗佈層。 (4) The layer formed on the skin side surface of the top sheet at least in contact with the excretion contact area of the user's excretory opening is a coating layer coated with a specific composition, and is not limited to the blood modifying agent layer. . For example, an emulsion coating layer coated with an emulsion for preventing dryness of the skin may be provided in at least the surface of the skin side of the top sheet which is in contact with the excretory opening of the user.
在本發明,因血液改質劑具有使血液的黏度及表面張力下降的機轉,體液藉由血液改質劑層24而可不殘留於頂部薄片2,移動至吸收體4被吸收體4吸收。藉由以下的實施例,確認血液改質劑具有使血液的黏度及表面張力下降的機轉。該確認使用與樹脂薄膜相比,體液易殘留的不織布進行。 In the present invention, the blood modifying agent has a function of lowering the viscosity and surface tension of the blood, and the body fluid does not remain in the top sheet 2 by the blood modifying agent layer 24, and moves to the absorber 4 to be absorbed by the absorber 4. According to the following examples, it was confirmed that the blood modifying agent has a mechanism for lowering the viscosity and surface tension of blood. This confirmation was carried out using a non-woven fabric in which body fluid easily remained as compared with the resin film.
準備市售生理用衛生棉。該生理用衛生棉係由以親水劑處理的熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構成的複合纖維、基重:35 g/m2)所形成的頂部薄片、熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構成的複合纖維、基重:30 g/m2)所形成的第二薄片、紙漿(基重:150~450 g/m2、中央部較多)、丙烯酸系高吸收聚合物(基重:15 g/m2)及含有作為核心包層之織物的吸收體、經撥水劑處理的側邊薄片、與聚乙烯薄膜所構成的背部薄片所形成。 Prepare commercially available sanitary napkins. The sanitary tampon is a top sheet formed by a hot air non-woven fabric treated with a hydrophilic agent (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m 2 ), and a hot air non-woven fabric ( The second sheet formed by the composite fiber composed of polyester and polyethylene terephthalate, basis weight: 30 g/m 2 ), pulp (basis weight: 150-450 g/m 2 , more central portion) ), acrylic high-absorbent polymer (basis weight: 15 g/m 2 ) and an absorbent body containing a fabric as a core cladding, a water-repellent-treated side sheet, and a back sheet composed of a polyethylene film form.
以下列舉實驗所使用的血液改質劑。 The blood modifying agents used in the experiments are listed below.
‧UNISTAR H-408BRS,日油股份公司製 ‧UNISTAR H-408BRS, manufactured by Nippon Oil Co., Ltd.
四2-乙基己烷酸季戊四醇,重量平均分子量:約640 Tetrakilyl tetraethyl 4-hexyl carboxylate, weight average molecular weight: about 640
‧UNISTAR H-2408BRS-22,日油股份公司製 ‧UNISTAR H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.
四2-乙基己烷酸季戊四醇與二2-乙基己烷酸新戊基二醇之混合物(58:42,重量比),重量平均分子量:約520 Mixture of pentaerythritol tetrakis(2-ethyl)hexane acid and neopentyl glycol di-2-ethylhexaneate (58:42, weight ratio), weight average molecular weight: about 520
‧Cetiol SB45DEO,Cognis Japan Ltd.製 ‧Cetiol SB45DEO, manufactured by Cognis Japan Ltd.
脂肪酸為油酸或硬脂酸的甘油與脂肪酸之三酯 Fatty acid is glycerol and fatty acid triester of oleic acid or stearic acid
‧SOY42,日油股份公司製 ‧SOY42, made by Nippon Oil Co., Ltd.
C14之脂肪酸:C16之脂肪酸:C18之脂肪酸:C20之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為0.2:11:88:0.8重量比的甘油與脂肪酸之三酯,重量平均分子量:880 C 14 fatty acids: C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated and unsaturated fatty acids) contain approximately 0.2:11:88:0.8 by weight of glycerol and fatty acid triesters , weight average molecular weight: 880
‧三C2L油脂肪酸甘油酯,日油股份公司製 ‧Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.
C8之脂肪酸:C10之脂肪酸:C12之脂肪酸含有大約為37:7:56重量比的甘油與脂肪酸之三酯,重量平均分子量:約570 C 8 fatty acid: C 10 fatty acid: C 12 fatty acid contains about 37:7:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570
‧三CL油脂肪酸甘油酯,日油股份公司製 ‧Three CL oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.
C8之脂肪酸:C12之脂肪酸含有大約為44:56重量比的甘油與脂肪酸之三酯,重量平均分子量:約570 C 8 fatty acid: C 12 fatty acid contains about 44:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570
‧Panasate 810s,日油股份公司製 ‧Panasate 810s, manufactured by Nippon Oil Corporation
C8之脂肪酸:C10之脂肪酸含有大約為85:15重量 比的甘油與脂肪酸之三酯,重量平均分子量:約480 C 8 fatty acid: C 10 fatty acid contains about 85:15 by weight of glycerol and fatty acid triester, weight average molecular weight: about 480
‧Panasate 800,日油股份公司製 ‧Panasate 800, made by Nippon Oil Co., Ltd.
脂肪酸全為辛烷酸(C8)的甘油與脂肪酸之三酯,重量平均分子量:約470 Fatty acid is all octane acid (C 8 ) glycerol and fatty acid triester, weight average molecular weight: about 470
‧Panasate 800B,日油股份公司製 ‧Panasate 800B, made by Nippon Oil Co., Ltd.
脂肪酸全為2-乙基己烷酸(C8)的甘油與脂肪酸之三酯,重量平均分子量:約470 The fatty acid is all 2-ethyl hexane acid (C 8 ) glycerol and fatty acid triester, weight average molecular weight: about 470
‧NA36,日油股份公司製 ‧NA36, made by Nippon Oil Co., Ltd.
C16之脂肪酸:C18之脂肪酸:C20之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為5:92:3重量比的甘油與脂肪酸之三酯,重量平均分子量:約880 C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated and unsaturated fatty acids) contain about 5:92:3 by weight of glycerol and fatty acid triesters, weight average molecular weight: about 880
‧三椰子油脂肪酸甘油酯,日油股份公司製 ‧Three coconut oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.
C8之脂肪酸:C10之脂肪酸:C12之脂肪酸:C14之脂肪酸:C16之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為4:8:60:25:3重量比的甘油與脂肪酸之三酯,重量平均分子量:670 C 8 fatty acids: C 10 fatty acids: C 12 fatty acids: C 14 fatty acids: C 16 fatty acids (including both saturated and unsaturated fatty acids) contain a weight ratio of about 4:8:60:25:3 Glycerol and fatty acid triester, weight average molecular weight: 670
‧辛酸二甘油酯,日油股份公司製 ‧ Caprylic diglyceride, manufactured by Nippon Oil Co., Ltd.
脂肪酸為辛烷酸的甘油與脂肪酸之二酯,重量平均分子量:340 Fatty acid is a diester of glycerol and fatty acid of octanoic acid, weight average molecular weight: 340
‧科母波魯BL,日油股份公司製 ‧Komubolu BL, made by Nippon Oil Co., Ltd.
丁二醇的十二烷酸(C12)單酯,重量平均分子量:約270 Butyric acid (C 12 ) monoester of butanediol, weight average molecular weight: about 270
‧科母波魯BS,日油股份公司製 ‧Komu Bolu BS, made by Nippon Oil Co., Ltd.
丁二醇的十八烷酸(C18)單酯,重量平均分子量:約350 Octadecanoic acid (C 18 ) monoester of butanediol, weight average molecular weight: about 350
‧UNISTAR H-208BRS,日油股份公司製 ‧UNISTAR H-208BRS, manufactured by Nippon Oil Co., Ltd.
二2-乙基己烷酸新戊基二醇,重量平均分子量:約360 Diethyl 2-ethylhexane acid neopentyl glycol, weight average molecular weight: about 360
‧O-乙醯基檸檬酸三丁酯,東京化成工業股份公司製 ‧O-Ethyl tributyl tributyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.
重量平均分子量:約400 Weight average molecular weight: about 400
‧己二酸二辛基酯,和光純藥工業製 ‧Dioctyl adipate, manufactured by Wako Pure Chemical Industries
重量平均分子量:約380 Weight average molecular weight: about 380
‧愛雷特魯WE20,日油股份公司製 ‧Eliteru WE20, manufactured by Nippon Oil Co., Ltd.
十二烷酸(C12)與十二醇(C12)之酯,重量平均分 子量:約360 Ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), weight average molecular weight: about 360
‧愛雷特魯WE40,日油股份公司製 ‧Eliteru WE40, made by Nippon Oil Co., Ltd.
十四烷酸(C14)與十二醇(C12)之酯,重量平均分子量:約390 Ester of tetradecanoic acid (C 14 ) and dodecyl alcohol (C 12 ), weight average molecular weight: about 390
‧UNIOL D-1000,日油股份公司製 ‧UNIOL D-1000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇,重量平均分子量:約1,000 Polypropylene glycol, weight average molecular weight: about 1,000
‧UNIOL D-1200,日油股份公司製 ‧UNIOL D-1200, manufactured by Nippon Oil Co., Ltd.
聚丙二醇,重量平均分子量:約1,200 Polypropylene glycol, weight average molecular weight: about 1,200
‧UNIOL D-3000,日油股份公司製 ‧UNIOL D-3000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇,重量平均分子量:約3,000 Polypropylene glycol, weight average molecular weight: about 3,000
‧UNIOL D-4000,日油股份公司製 ‧UNIOL D-4000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇,重量平均分子量:約4,000 Polypropylene glycol, weight average molecular weight: about 4,000
‧UNIOL PB500,日油股份公司製 ‧UNIOL PB500, manufactured by Nippon Oil Co., Ltd.
聚丁二醇,重量平均分子量:約500 Polytetramethylene glycol, weight average molecular weight: about 500
‧UNIOL PB700,日油股份公司製 ‧UNIOL PB700, manufactured by Nippon Oil Corporation
聚氧化丁烯 聚氧化丙二醇,重量平均分子量:約700 Polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700
‧UNIOL PB1000R,日油股份公司製 ‧UNIOL PB1000R, manufactured by Nippon Oil Co., Ltd.
聚丁二醇,重量平均分子量:約1000 Polytetramethylene glycol, weight average molecular weight: about 1000
‧WILBRIDE cp9,日油股份公司製 ‧WILBRIDE cp9, made by Nippon Oil Co., Ltd.
聚丁二醇的兩末端的OH基被十六烷酸(C16)所酯化的化合物,重量平均分子量:約1,150 a compound in which an OH group at both ends of polytetramethylene glycol is esterified with palmitic acid (C 16 ), weight average molecular weight: about 1,150
‧UNILUBE MS-70K,日油股份公司製 ‧UNILUBE MS-70K, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的硬脂醯基醚,約15之重複單位,重量平均分子量:約1,140 Stearic acid decyl ether of polypropylene glycol, about 15 repeating units, weight average molecular weight: about 1,140
‧UNILUBE 5TP-300KB ‧UNILUBE 5TP-300KB
藉由於季戊四醇1莫耳加成環氧乙烷5莫耳與環氧丙烷65莫耳所生成的聚氧化乙烯聚氧化丙烯季戊四醇醚,重量平均分子量:4,130 Polyoxyethylene polyoxypropylene pentaerythritol ether formed by pentaerythritol 1 molar addition of ethylene oxide 5 moles and propylene oxide 65 moles, weight average molecular weight: 4,130
‧UNIOL TG-3000,日油股份公司製 ‧UNIOL TG-3000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的甘油基醚,約16之重複單位,重量平均分子量:約3,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 3,000
‧UNIOL TG-4000,日油股份公司製 ‧UNIOL TG-4000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的甘油基醚,約16之重複單位,重量平均分子量:約4,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 4,000
‧PARLEAM6,日油股份公司製 ‧PARLEAM6, made by Nippon Oil Co., Ltd.
藉由使流動異石蠟、異丁烯及n-丁烯共聚合,接著加成氫而生成的分枝鏈烴、聚合度:約5~約10,重量平均分子量:約330 a branched chain hydrocarbon formed by copolymerizing a flowing isoparaffin, isobutylene and n-butene, followed by addition of hydrogen, a degree of polymerization: about 5 to about 10, and a weight average molecular weight of about 330
‧NA50,日油股份公司製 ‧NA50, made by Nippon Oil Co., Ltd.
使NA36加成氫,降低來自原料之不飽和脂肪酸的雙鍵比率的甘油與脂肪酸之三酯,重量平均分子量:約880 Adding hydrogen to NA36, reducing the double bond ratio of glycerol and fatty acid from the unsaturated fatty acid of the raw material, weight average molecular weight: about 880
‧(辛酸/癸酸)單甘油酯,日油股份公司製 ‧(octanoic acid/tannic acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.
辛烷酸(C8)及癸烷酸(C10)含有大約為85:15重量比的甘油與脂肪酸之單酯,重量平均分子量:約220 Octanoic acid (C 8 ) and decanoic acid (C 10 ) contain a monoester of glycerol and fatty acid in a weight ratio of about 85:15, weight average molecular weight: about 220
‧Monomuls 90-L2月桂酸單甘油酯,Cognis Japan Ltd.製 ‧Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Ltd.
‧檸檬酸異丙酯,東京化成工業股份公司製 ‧Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.
重量平均分子量:約230 Weight average molecular weight: about 230
‧蘋果酸二異硬脂醯基酯 ‧ Malate diisostearyl methacrylate
重量平均分子量:約640 Weight average molecular weight: about 640
‧UNIOL D-400,日油股份公司製 ‧UNIOL D-400, manufactured by Nippon Oil Co., Ltd.
聚丙二醇,重量平均分子量:約400 Polypropylene glycol, weight average molecular weight: about 400
‧PEG1500,日油股份公司製 ‧PEG1500, made by Nippon Oil Co., Ltd.
聚乙二醇,重量平均分子量:約1,500~約1,600 Polyethylene glycol, weight average molecular weight: about 1,500 ~ about 1,600
‧NONION S-6,日油股份公司製 ‧NONION S-6, made by Nippon Oil Co., Ltd.
聚氧化乙烯單硬脂酸酯、約7之重複單位、重量平均分子量:約880 Polyoxyethylene monostearate, about 7 repeat units, weight average molecular weight: about 880
‧WILBRIDE s753,日油股份公司製 ‧WILBRIDE s753, manufactured by Nippon Oil Co., Ltd.
聚氧化乙烯聚氧化丙烯聚氧化丁烯 甘油,重量平均分子量:約960 Polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
‧UNIOL TG-330,日油股份公司製 ‧UNIOL TG-330, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的甘油基醚,約6之重複單位,重量平均分子量:約330 Glyceryl ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330
‧UNIOL TG-1000,日油股份公司製 ‧UNIOL TG-1000, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的甘油基醚,約16之重複單位,重量平均分子量:約1,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 1,000
‧UNILUBE DGP-700,日油股份公司製 ‧UNILUBE DGP-700, manufactured by Nippon Oil Co., Ltd.
聚丙二醇的二甘油基醚,約9之重複單位,重量平均分子量:約700 Diglyceryl ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700
‧UNIOX HC60,日油股份公司製 ‧UNIOX HC60, manufactured by Nippon Oil Co., Ltd.
聚氧化乙烯硬化蓖麻油,重量平均分子量:約3,570 Polyoxyethylene hardened castor oil, weight average molecular weight: about 3,570
‧凡士林,Cognis Japan Ltd.製 ‧Vaseline, made by Cognis Japan Ltd.
來自石油的烴、半固形 Hydrocarbon, semi-solid from petroleum
上述試料的IOB,熔點及水溶解度如下述表2。又,水溶解度為依據上述方法而測定,於100g之脫鹽 水中添加20.0g,24小時後溶解的試料評估為「20g<」、而在100g之脫鹽水中、溶解0.05g但不溶解1.00g的試料評估為0.05~1.00g。又,關於熔點,「<45」為熔點未達45℃。 The IOB, melting point and water solubility of the above samples are shown in Table 2 below. Further, the water solubility is measured according to the above method, and desalination at 100 g 20.0 g of water was added, and the sample dissolved after 24 hours was evaluated as "20 g <", and in 100 g of demineralized water, the sample dissolved in 0.05 g but not dissolved in 1.00 g was evaluated to be 0.05 to 1.00 g. Further, regarding the melting point, "<45" has a melting point of less than 45 °C.
將上述生理用衛生棉的頂部薄片的肌膚接觸面以上述血液改質劑塗佈。將各血液改質劑,血液改質劑在室溫為液體之場合直接、而血液改質劑在室溫為固體之場合加熱至熔點+20℃,接著,使用控制接縫HMA槍,使各血液改質劑微粒化,在頂部薄片的肌膚接觸面的全體,以基重約成為5 g/m2之方式塗佈。 The skin contact surface of the top sheet of the above sanitary napkin is coated with the above blood modifying agent. Each blood modifying agent and blood modifying agent are directly used at room temperature, and the blood modifying agent is heated to a melting point of +20 ° C when the room temperature is solid, and then, using a control seam HMA gun, each The blood modifying agent was micronized, and the entire skin contact surface of the top sheet was applied so as to have a basis weight of about 5 g/m 2 .
圖15為頂部薄片含有三C2L油脂肪酸甘油酯的生理用衛生棉(No.2-5)中頂部薄片的肌膚接觸面之電子顯微鏡照片。由圖15可得知,三C2L油脂肪酸甘油酯以微粒子狀附著於纖維的表面。 Fig. 15 is an electron micrograph of the skin contact surface of the top sheet in the physiological sanitary napkin (No. 2-5) containing the top C 3L oil fatty acid glyceride. As can be seen from Fig. 15, the tri-C2L oil fatty acid glyceride adhered to the surface of the fiber in the form of fine particles.
依照上述方法,測定回滲率與吸收體移動速度。結果如下述表2所示。 The rewet rate and the moving speed of the absorbent body were measured in accordance with the above method. The results are shown in Table 2 below.
在含各血液改質劑之頂部薄片上,放置開孔的丙烯酸板(200mm×100mm,125g,在中央開有40mm×10mm之穴),由上述穴使37±1℃之馬EDTA血(馬之血液中,為了防止凝結,添加有乙二胺四乙酸(以下、稱「EDTA」)者)3g,使用吸量管滴下(第1次),1分鐘後,使37±1℃之馬EDTA血3g從丙烯酸板之穴,以吸 量管再度滴下(第2次)。 On the top sheet containing each blood modifying agent, an open acrylic plate (200 mm × 100 mm, 125 g, with a hole of 40 mm × 10 mm in the center) was placed, and the horse was EDTA blood (37 ± 1 ° C) from the above hole. In order to prevent coagulation, 3 g of ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA") was added to the blood, and the mixture was dropped using a pipette (first time). After 1 minute, the horse was EDTA at 37±1 °C. Blood 3g from the hole of the acrylic plate to suck The measuring tube was dropped again (the second time).
在第2次的血液的滴下後,即刻除去上述丙烯酸板,於滴下血液的場所,放置濾紙(ADVANTEC東洋股份公司 定性濾紙No.2,50mm×35mm)10枚,從其上使壓力成為30 g/cm2之方式放置重物。1分鐘後,將上述濾紙取出,用以下的式算出「回滲率」。 Immediately after the dropping of the second blood, the acrylic plate was removed, and 10 pieces of filter paper (ADVANTEC Toyo Co., Ltd. qualitative filter paper No. 2, 50 mm × 35 mm) were placed in the place where the blood was dropped, and the pressure was 30 g from the top. Place the weight in /cm 2 way. After 1 minute, the filter paper was taken out, and the "reverse bleed rate" was calculated by the following formula.
回滲率(%)=100×(試驗後之濾紙質量-當初的濾紙質量)/6 Infiltration rate (%) = 100 × (quality of filter paper after test - original filter paper quality) / 6
進而、在回滲率評估外,測定第2次的血液的滴下後,血液從頂部薄片移動至吸收體的時間亦即「吸收體移動速度」。上述吸收體移動速度係指於吸收體投入血液後至頂部薄片的表面及內部看不見血液的紅色為止的時間。 Further, in addition to the evaluation of the rewet rate, the time during which the blood is moved from the top sheet to the absorber after the second blood drop is measured is the "absorbent moving speed". The moving speed of the absorbent body refers to the time from when the absorbent body is put into the blood until the red color of the blood is not visible on the surface of the top sheet and inside.
回滲率與吸收體移動速度的結果如以下的表2。 The results of the rewet ratio and the moving speed of the absorbent body are shown in Table 2 below.
接著,吸收體移動速度的試驗後之頂部薄片的肌膚接觸面的潔白度,依據以下的基準以目視評估。 Next, the whiteness of the skin contact surface of the top sheet after the test of the moving speed of the absorbent body was visually evaluated based on the following criteria.
◎:血液之紅色幾乎不殘留,無法區分血液存在的場所與不存在的場所 ◎: The red color of the blood hardly remains, and it is impossible to distinguish between the place where the blood exists and the place where it does not exist.
○:血液之紅色雖有若干殘留,不易區分血液存在的場所與不存在的場所 ○: Although there are some residues in the red color of the blood, it is difficult to distinguish between the place where the blood exists and the place where it does not exist.
△:血液之紅色有若干殘留,可知血液存在的場所 △: There are some residues in the red color of the blood, and the place where the blood exists is known.
×:血液之紅色直接殘留 ×: The red color of the blood directly remains
結果一併如下述表2。 The results are shown in Table 2 below.
在不具有血液改質劑的場合,回滲率為22.7%、而吸收體移動速度雖超過60秒,但因甘油與脂肪酸之三酯皆回滲率在7.0%以下、而吸收體移動速度在8秒以下,故可知吸收性能被大幅改善。但是,甘油與脂肪酸之三酯中,在熔點超過45℃的NA50,未見到吸收性能大幅改善。 When there is no blood modifying agent, the re-infiltration rate is 22.7%, and the moving speed of the absorbent body is more than 60 seconds, but the osmotic rate of the glycerol and the fatty acid triester is less than 7.0%, and the moving speed of the absorbent body is at After 8 seconds or less, it is known that the absorption performance is greatly improved. However, in the triester of glycerin and fatty acid, at the NA50 having a melting point exceeding 45 ° C, no significant improvement in the absorption performance was observed.
同樣地,可知在具有約0.00~約0.60之IOB、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g之水溶解度的血液改質劑,吸收性能大幅被改善。 Similarly, it is understood that the absorption performance is greatly improved in a blood modifying agent having a water solubility of from about 0.00 to about 0.60 IOB, a melting point of about 45 ° C or less, and a water solubility of about 0.00 to about 0.05 g to 100 g of water at 25 ° C.
接著,No.2-1~2-47之生理用衛生棉給複數的自願受試者著用,在含No.2-1~2-32的血液改質劑之生理用衛生棉,得到即使吸收經血後頂部薄片無黏膩感、頂部薄片為清爽之回答。 Next, the sanitary napkins of No. 2-1 to 2-47 are used by a plurality of voluntary subjects, and even in the sanitary napkin containing the blood modifying agent of No. 2-1 to 2-32, After absorbing the menstrual blood, the top sheet is not sticky, and the top sheet is refreshing.
又,在No.2-1~No.2-32的生理用衛生棉,而尤其在含No.2-1~11,15~19及32的血液改質劑的生理用衛生棉,得到吸收經血後之頂部薄片的肌膚接觸面未被血液染紅,不快感少的回答。 In addition, in the sanitary napkins of No. 2-1 to No. 2-32, the sanitary napkins containing the blood modifying agents No. 2-1 to 11, 15 to 19 and 32 are absorbed. The skin contact surface of the top sheet after menstrual blood is not stained with blood, and the answer is less unpleasant.
關於動物之各種血液,依照上述方法,評估回滲率。實驗中可使用的血液如以下。 Regarding the various blood of animals, the rate of rewet was evaluated in accordance with the above method. The blood that can be used in the experiment is as follows.
(1)人 (1 person
(2)馬 (2) Horse
(3)羊 (3) sheep
‧脫纖維血:採取血液後,與玻璃珠一起在三角燒瓶內攪拌約5分鐘者 ‧Defibration: After taking blood, stir it in a conical flask with glass beads for about 5 minutes.
‧EDTA血:靜脈血65mL中添加12%EDTA‧2K生理食鹽液0.5mL者 ‧EDTA blood: Add 12% EDTA‧2K physiological saline solution 0.5mL to venous blood 65mL
血清或血漿:各自使脫纖維血或EDTA血在室溫下以約1900G進行10分鐘離心分離後之上清 Serum or plasma: each defibrinated blood or EDTA blood was centrifuged at room temperature for about 10 minutes at room temperature for 10 minutes.
血球:從血液將血清除去,使殘渣以磷酸緩衝生理食鹽液(PBS)進行2次洗淨,接著加入除去血清分的磷酸緩衝生理食鹽液者 Blood cells: The serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline (PBS), followed by phosphate buffered physiological saline solution containing serum.
三C2L油脂肪酸甘油酯以基重約成為5 g/m2之方式塗佈以外,與例2同樣地製造吸收性物品,對上述各種血液,評估回滲率。對各血液進行測定3次,採用其平均值。 An absorbent article was produced in the same manner as in Example 2 except that the trisodium C2L oil fatty acid glyceride was applied so that the basis weight was about 5 g/m 2 , and the rewet ratio was evaluated for each of the above blood. Each blood was measured three times, and the average value was used.
結果如下述表3。 The results are shown in Table 3 below.
與在例2得到的馬EDTA血同樣之傾向在人及羊之血液亦可得到。又,脫纖維血及EDTA血中亦觀察到同樣傾向。 The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in the blood of humans and sheep. Also, the same tendency was observed in defibrinated blood and EDTA blood.
評估含血液改質劑的頂部薄片與不含血液改質劑的頂部薄片中的血液保留性。 The blood retention in the top sheet containing the blood modifying agent and the top sheet containing no blood modifying agent was evaluated.
(1)熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構 成的複合纖維、基重:35 g/m2)所形成的頂部薄片的肌膚接觸面,將三C2L油脂肪酸甘油酯使用控制接縫HMA槍進行微粒化,以基重成為約5 g/m2之方式進行塗佈。又,為了比較,亦準備不塗佈三C2L油脂肪酸甘油酯者。接著,將塗佈有三C2L油脂肪酸甘油酯的頂部薄片與未塗佈的頂部薄片兩者,切為0.2g之大小,正確測定無菌細胞過濾蓋管+頂部薄片的質量(a)。 (1) The skin contact surface of the top sheet formed by hot air non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m 2 ), using three C2L oil fatty acid glycerides The control joint HMA gun was micronized and applied in such a manner that the basis weight became about 5 g/m 2 . Further, for comparison, those who do not apply the tri-C2L oil fatty acid glyceride are also prepared. Next, both the top sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated top sheet were cut to a size of 0.2 g, and the mass (a) of the sterile cell filtration cap tube + top sheet was correctly determined.
(2)使馬EDTA血約2mL由皮膚接觸面側添加,靜置1分鐘。 (2) About 2 mL of horse EDTA blood was added from the skin contact surface side, and allowed to stand for 1 minute.
(3)將無菌細胞過濾蓋管設置於離心管,進行低速離心,將多餘的馬EDTA血除去。 (3) The sterile cell filtration cap tube was placed in a centrifuge tube, and subjected to low-speed centrifugation to remove excess horse EDTA blood.
(4)測定含有無菌細胞過濾蓋管+馬EDTA血之頂部薄片的重量(b)。 (4) Determine the weight (b) of the top sheet containing the sterile cell filter cap + horse EDTA blood.
(5)依據下式,算出頂部薄片每1g之當初吸收量(g)。 (5) The initial absorption amount (g) per 1 g of the top sheet was calculated according to the following formula.
當初吸收量=[重量(b)-重量(a)]/0.2 Initial absorption = [weight (b) - weight (a)] / 0.2
(6)將無菌細胞過濾蓋管再設置於離心管,室溫下以約1200G進行1分鐘離心分離。 (6) The sterile cell filtration cap tube was further placed in a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.
(7)測定含有無菌細胞過濾蓋管+馬EDTA血之頂部薄片的重量(c)。 (7) The weight (c) of the top sheet containing the sterile cell filter cap + horse EDTA blood was measured.
(8)依據下式,算出頂部薄片每1g之試驗後吸收量(g)。 (8) The amount of absorption (g) per 1 g of the top sheet after the test was calculated according to the following formula.
試驗後吸收量=[重量(c)-重量(a)]/0.2 Absorption after test = [weight (c) - weight (a)] / 0.2
(9)依據下式算出血液保留率(%)。 (9) The blood retention rate (%) was calculated according to the following formula.
血液保留率(%)=100×試驗後吸收量/當初吸收量 Blood retention rate (%) = 100 × absorption after test / initial absorption
又,測定進行3次,採用其平均值。結果如下述表4。 Further, the measurement was carried out three times, and the average value thereof was used. The results are shown in Table 4 below.
暗示含有血液改質劑的頂部薄片血液保留性低、吸收血液後,可迅速移動至吸收體。 It is suggested that the top sheet containing the blood modifying agent has low blood retention and can quickly move to the absorber after absorbing blood.
將含有血液改質劑的血液的黏性使用Rheometric Expansion System ARES(Rheometric Scientific,Inc)測定。在馬脫纖維血中添加Panasate810s 2質量%,輕輕地攪拌形成試料,於直徑50mm之平行板放置試料,間隙為100μm,在37±0.5℃測定黏度。因為平行板,雖未對試料施加均勻剪斷速度,機器表示的平均剪斷速度為10s-1。 The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). To the horsetail fiber, 2% by mass of Panasate 810s was added, and the sample was gently stirred to form a sample, and the sample was placed in a parallel plate having a diameter of 50 mm, and the gap was 100 μm, and the viscosity was measured at 37 ± 0.5 °C. Because of the parallel plate, although the uniform shear rate was not applied to the sample, the average shear rate indicated by the machine was 10 s -1 .
含有2質量% Panasate 810s之馬脫纖維血之黏度為5.9 mPa‧s、另一方面,不含血液改質劑的馬脫纖維血之黏度為50.4 mPa‧s。因此,可知含2質量% Panasate 810s之馬脫纖維血,與不含血液改質劑場合比 較,下降約90%黏度。血液已知含有血球等之成分,且具有搖變性之性質,但認為本發明的血液改質劑在低黏度域可使血液的黏度下降。認為藉由使血液的黏度下降,可使吸收的經血快速由頂部薄片移動至吸收體。 The viscosity of the horse-defibrinated blood containing 2% by mass of Panasate 810s was 5.9 mPa·s, and on the other hand, the viscosity of the horse-depleted blood containing no blood modifying agent was 50.4 mPa·s. Therefore, it can be seen that the horse defibrinated blood containing 2% by mass of Panasate 810s is compared with the case where no blood modifying agent is contained. Compared, it drops about 90% viscosity. The blood is known to contain components such as blood cells and has a property of shaking, but it is considered that the blood modifying agent of the present invention lowers the viscosity of blood in a low viscosity domain. It is believed that by reducing the viscosity of the blood, the absorbed menstrual blood can be quickly moved from the top sheet to the absorber.
將健康自願者的經血採集於Saran Wrap(商標)上,於其一部份添加分散於10倍質量的磷酸緩衝生理食鹽水中的Panasate 810s以使Panasate 810s之濃度成為1質量%。使經血滴下於載玻片,蓋上蓋玻片,以光學顯微鏡觀察紅血球狀態。不含血液改質劑的經血之顯微鏡照片如圖16(a),而含Panasate 810s的經血之顯微鏡照片如圖16(b)所示。 The menstrual blood of the healthy volunteers was collected on Saran Wrap (trademark), and Panastate 810s dispersed in 10 times by mass of phosphate buffered physiological saline was added to a part thereof to make the concentration of Panasee 810s 1% by mass. The menstrual blood was dropped on a glass slide, covered with a cover glass, and the red blood cell state was observed with an optical microscope. A photomicrograph of menstrual blood without a blood modifying agent is shown in Fig. 16(a), and a photomicrograph of a menstrual blood containing Panasate 810s is shown in Fig. 16(b).
由圖16,可知在不含血液改質劑的經血,紅血球形成連鏈等之集合塊,但在含Panasate 810s的經血,紅血球各自安定地分散。因此,暗示血液改質劑在血液之中扮演使紅血球安定化的角色。 Fig. 16 shows that in the menstrual blood containing no blood modifying agent, the red blood cells form a collecting block such as a chain, but in the menstrual blood containing Panasate 810s, the red blood cells are stably dispersed. Therefore, it is suggested that the blood modifying agent plays a role in the blood to stabilize the red blood cells.
含有血液改質劑的血液的表面張力使用協和界面科學公司製接觸角計Drop Master500,以垂滴法測定。表面張力係在羊脫纖維血中添加特定量的血液改質劑,充分振 動後進行測定。測定雖以機器自動進行,密度γ使用下式求出(圖17作為參考)。 The surface tension of the blood containing the blood modifying agent was measured by a drip drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. Surface tension is added to the sheep defibration blood by adding a specific amount of blood modifier, fully vibrating The measurement was carried out after the action. The measurement was automatically performed by a machine, and the density γ was obtained by the following equation (see Fig. 17 for reference).
γ=g×ρ×(de)2×1/H γ=g×ρ×(de) 2 ×1/H
g:重力常數 g: gravity constant
1/H:由ds/de所求出的修正項 1/H: correction term determined by ds/de
ρ:密度 ρ: density
de:最大直徑 De: maximum diameter
ds:由滴下端僅上升de的位置之直徑 Ds: the diameter of the position where only the de is raised by the drop end
密度ρ係依據JIS K 2249-1995之「密度試驗方法及密度‧質量‧容量換算表」之5.振動式密度試驗方法,用下述表5所示之溫度進行測定。於測定,係使用京都電子工業股份公司之DA-505。結果如表5。 The density ρ is measured by the vibration density test method according to JIS K 2249-1995, "Density Test Method and Density ‧ Mass ‧ Capacity Conversion Table", using the temperature shown in Table 5 below. For the measurement, the DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 5.
表5可知,血液改質劑具有對25℃之水100g為約0.00~約0.05g之水溶解度亦可明白,雖對水之溶解 性非常低但可使血液之表面張力降低。認為藉由使血液的表面張力下降,吸收的血液不保留於頂部薄片的纖維間,而可快速移動至吸收體。 As can be seen from Table 5, the blood modifying agent has a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C, although it is also known to dissolve in water. Very low in sex but can reduce the surface tension of blood. It is considered that by lowering the surface tension of blood, the absorbed blood does not remain between the fibers of the top sheet, and can be quickly moved to the absorber.
可組合實施形態與變形例的一個、或者複數個。變形例彼此亦可組合。 One or a plurality of embodiments and modifications may be combined. Modifications can also be combined with each other.
以上的說明僅為一例、發明不限於上述實施形態。 The above description is only an example, and the invention is not limited to the above embodiment.
Claims (9)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012082334A JP5769655B2 (en) | 2012-03-30 | 2012-03-30 | Absorbent articles |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201402086A TW201402086A (en) | 2014-01-16 |
TWI581775B true TWI581775B (en) | 2017-05-11 |
Family
ID=49259936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102111515A TWI581775B (en) | 2012-03-30 | 2013-03-29 | Absorbent items |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5769655B2 (en) |
AR (1) | AR090519A1 (en) |
TW (1) | TWI581775B (en) |
WO (1) | WO2013146685A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5539601B1 (en) * | 2014-02-25 | 2014-07-02 | ユニ・チャーム株式会社 | Urine collection pad and urine collection pad |
JP6457780B2 (en) * | 2014-10-28 | 2019-01-23 | 大王製紙株式会社 | Absorbent articles |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2262235A (en) * | 1991-12-09 | 1993-06-16 | Kao Corp | Sanitary napkin |
US20090221978A1 (en) * | 2008-02-15 | 2009-09-03 | Joseph Anthony Gatto | Absorbent article with lotion comprising a polypropylene glycol material |
TW201023839A (en) * | 2008-11-13 | 2010-07-01 | Kao Corp | Individual package of absorbent article |
TW201200508A (en) * | 2004-03-12 | 2012-01-01 | Vertex Pharma | Processes and intermediates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2528661Y2 (en) * | 1990-06-08 | 1997-03-12 | 花王株式会社 | Absorbent articles |
KR100266494B1 (en) * | 1995-10-06 | 2000-09-15 | 데이비드 엠 모이어 | Absorbent article having flaps with a deformed hinge and zones of extensibility |
JP5372484B2 (en) * | 2008-12-17 | 2013-12-18 | 花王株式会社 | Absorbent articles |
-
2012
- 2012-03-30 JP JP2012082334A patent/JP5769655B2/en not_active Expired - Fee Related
-
2013
- 2013-03-25 WO PCT/JP2013/058590 patent/WO2013146685A1/en active Application Filing
- 2013-03-27 AR ARP130100999A patent/AR090519A1/en unknown
- 2013-03-29 TW TW102111515A patent/TWI581775B/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2262235A (en) * | 1991-12-09 | 1993-06-16 | Kao Corp | Sanitary napkin |
TW201200508A (en) * | 2004-03-12 | 2012-01-01 | Vertex Pharma | Processes and intermediates |
US20090221978A1 (en) * | 2008-02-15 | 2009-09-03 | Joseph Anthony Gatto | Absorbent article with lotion comprising a polypropylene glycol material |
TW201023839A (en) * | 2008-11-13 | 2010-07-01 | Kao Corp | Individual package of absorbent article |
Also Published As
Publication number | Publication date |
---|---|
JP5769655B2 (en) | 2015-08-26 |
JP2013208387A (en) | 2013-10-10 |
AR090519A1 (en) | 2014-11-19 |
TW201402086A (en) | 2014-01-16 |
WO2013146685A1 (en) | 2013-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI577350B (en) | Absorbent items | |
TWI573575B (en) | Absorbent items | |
TWI573570B (en) | Absorbent items | |
TWI577353B (en) | Absorbent items | |
TWI629976B (en) | Absorbent article | |
TWI572343B (en) | Absorbent items | |
TWI577351B (en) | Absorbent items | |
TWI597054B (en) | Absorbent article | |
TWI589280B (en) | Absorbent article | |
TWI581773B (en) | An absorbent article, a surface sheet of an absorbent article, and a method for producing the same | |
TWI619477B (en) | Absorbent article | |
TWI581775B (en) | Absorbent items | |
TWI572345B (en) | An absorbent article, a topsheet of an absorbent article, and a method for producing the same | |
TWI573573B (en) | Absorbent items |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |